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1. ABSTRACT 
 
Stroke in general but especially in the postoperative period is a serious clinical 
problem that warrants new therapeutic approaches. Here neuroprotective 
strategies and especially preconditioning have recently emerged as promising. 
Preconditioning was originally demonstrated in the heart but was subsequently 
also found in other organs. Classically it describes a phenomenon where short 
periods of ischaemia render tissues less vulnerable to major infarcts. In addition to 
ischaemia neuronal preconditioning can be achieved pharmacologically as well as 
through inhalational anaesthetics or drugs that open ATP-sensitive K+(KATP) 
channels. However, the mechanisms through which anaesthetics produce 
protection remain elusive and the use of K+ channel openers is hampered by their 
inability to cross the blood-brain-barrier.  
This study was conducted to investigate the effects of inhalational anaesthetics on 
KATP channels and to explore whether their neuronal preconditioning properties 
were dependent on KATP channel opening. First, in whole-cell and excised patch-
clamp experiments the effects of inhalational anaesthetics on recombinant wild 
type neuronal (Kir6.2/SUR1) KATP and related as well as modified channels were 
evaluated. Secondly, the KATP channel dependence of anaesthetic preconditioning 
was tested in neuronal-glial co-cultures. 
Recombinant KATP channels were activated by xenon, but inhibited by 
halogenated volatiles. Moreover, it was shown that xenon acted directly on the 
Kir6.2 pore-forming subunit, reduced the ability of ATP to inhibit the channel and 
had no effect on the ATP-regulated Kir1.1 channel. Functionally both sevoflurane 
and xenon preconditioned neurons at clinically used concentrations but only the 
effect of xenon was dependent on KATP channel activation. 
Thus this study established xenon as a novel KATP channel opener. It interacts 
with the pore-forming Kir6.2 rather than the regulatory sulphonylurea receptor 
subunit and disinhibits the channel from the blocking actions of ATP. As a 
consequence xenon but not sevoflurane is able to precondition neurons in a KATP 
channel-dependent manner. 
Word count: 297 
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5. INTRODUCTION 
 
Pharmacological preconditioning has recently attracted attention as a therapeutic 
alternative for the treatment of stroke in general and perioperative stroke in 
particular. This is based on the recognition that current therapies of 
cerebrovascular accidents are either insufficient or carry their own significant risk 
profile. 
In the following based on the existing literature the significance of stroke for the 
general population as well as for surgical patients is explained. This account is 
followed by a review of the current knowledge of causes and pathophysiology of 
stroke as well as currently available treatment options. In this context then the 
concepts of neuroprotection and preconditioning are introduced and their major 
pathways described. 
Because the present study is mostly concerned with ATP-sensitive K+ (KATP) 
channels in the final part of the introduction their potential critical involvement in 
pharmacological neuronal preconditioning is summarised and the reasoning 
explained that led to the conduct of this study. 
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5.1 Stroke: Defining the Problem 
 
Stroke is defined as a rapidly developing focal neurological deficit, which lasts for 
more than 24 hours (Riley, 2003). It is the functional result of an acute injury to 
the brain secondary to either reduction of cerebral blood flow in the territory of a 
major artery (ischaemic stroke) or intracranial bleeding (haemorrhagic stroke) 
(Dirnagl et al., 1999; Rosamond et al., 2008). 
Because of its frequent adverse outcome with death or disability, its associated 
high costs and its risk profile that is not restricted to any age, gender, race or 
social group, stroke is one of the most important medical conditions of our times. 
With a mortality of 10-20% for ischaemic and 35-45% for haemorrhagic stroke, 
cerebrovascular accidents are the third commonest cause of death in the 
developed world (Kolominsky-Rabas et al., 1998; Thrift et al., 2001; Rosamond et 
al., 2008). Alone in the USA stroke contributes 6.3% of people to the annual death 
register whilst heart diseases and cancer do this with 27.2% and 23.1% 
respectively (SEER, 2008) 
It is not only the high mortality rate that is staggering, it is also the impact stroke 
frequently has on its survivors. Recent studies found that stroke is commonly 
associated with neurological complications (seizures, recurrent strokes), infections 
(urinary, chest), immobility, thrombembolism, pain and psychological disorders 
(cognitive impairment, depression, anxiety) (Langhorne et al., 2000; Rabadi et al., 
2008). Even minor strokes have been found to reduce quality of life of patients 
significantly despite a high degree of daily independence (Edwards et al., 2006). 
The financial burden of stroke and therefore the burden for society as a whole is 
mostly dependent on the length of hospitalisation, degree of rehabilitation and 
ability of patients to return to work. The average length of hospital stay after 
stroke is between 10 and 44 days with 14 to 73% of patients being able to fully 
reintegrate into their previous working environments (Claesson et al., 2000; 
Yoneda et al., 2003; Luengo-Fernandez et al., 2006; Treger et al., 2007). This 
variability in stroke victim recovery is also reflected in the wide range of costs 
which studies were able to uncover. These costs that are normally calculated as 
“costs per case in the first year after stroke” are worldwide between $6887 and 
$49,403 (Taylor et al., 1996; Claesson et al., 2000; Dewey et al., 2001; Yoneda et 
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al., 2003; Luengo-Fernandez et al., 2006). However, strokes that occur in patients 
already in hospital for other reasons increase costs by $21,096 - $40,192 per case 
in the first year and are generally more expensive (Tung et al., 1999; Luengo-
Fernandez et al., 2006). Therefore, the overall lifetime costs per stroke case have 
been estimated as $11,787 to $3,035,671 (Taylor et al., 1996; Palmer et al., 2005). 
Related to the spending of a single country these sums mean that the USA for 
example spent nearly $50 billion on stroke in 2008. In comparison, the US 
spending for cancer and HIV was estimated to be $70 billion and $20 billion, 
respectively (Kaiser-Family, 2007; National-Cancer-Institute, 2007). 
 
 
5.2 Stroke: The General Risk 
 
The incidence of a disease describes the number of new cases within a specific 
period of time. The incidence rate however expresses the number of new cases per 
unit of population per year. Both define the risk with which any given person of a 
population could contract that condition. 
The overall annual incidence of stroke worldwide has been found to be between 
149 and 174 cases per 100,000 people with a proportion of 13% haemorrhagic and 
87% ischaemic strokes (Kolominsky-Rabas et al., 1998; Thrift et al., 2001; 
Rosamond et al., 2008). For the USA this means about 780,000 stroke cases each 
year and for the UK 110,000 of which approximately two thirds are first time and 
one-third recurrent attacks (Rosamond et al., 2008; NHS-Direct, 2009). 
For comparison, cancer has an incidence of 470 per 100,000 in the USA and in 
Europe each year about 8000 new HIV cases are registered (Semaille et al., 2002; 
SEER, 2008). 
The incidence of stroke doubles with every decade increase in age. Therefore the 
incidence of stroke beyond the age of 75 is 992 per 100,000 people, which leaves 
more than 50% of all stroke victims at an age older than 75 years (Kolominsky-
Rabas et al., 1998; Thrift et al., 2001). 
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5.3 Stroke: The Perioperative Risk 
 
Wong and colleagues (Wong et al., 2000) found an increased incidence for stroke 
within the first month after routine general operations and they determined the 
combination of surgery with anaesthesia as an independent risk factor for the 
development of cerebrovascular accidents. Despite this finding, the overall 
incidence for stroke during and after non-high risk surgery is low. It has been 
estimated that only 0.08-0.7% of patients develop a neurological sequel. The risk 
to contract a stroke after non-cardiovascular surgery is therefore approximately 
the same as the risk for the public in general (Kikura et al., 2004; Selim, 2007). 
Nevertheless, the risk is dependent on advanced age, co-morbidities and the 
surgical procedure (see section 5.4). Especially cardiac, aortic and carotid 
operations with an incidence of 1.4 to 9.7% carry an about 20fold increased 
chance for stroke (see Table 5.1) (Selim, 2007). Stroke is therefore still the most 
feared complication of cardiovascular operations despite changes in surgical 
techniques and patient pre-optimisation (McKhann et al., 2006). 
The specific risk for cerebrovascular accidents associated with heart surgery is 
also emphasized by the fact that the time frame of stroke development is different 
in cardiac compared to non-cardiac surgery. Limburg and colleagues as well as 
Kikura and colleagues found the median time interval of surgery to stroke after 
non-cardiac operations to be between 2 and 11 days (Limburg et al., 1998; Kikura 
et al., 2004). In contrast, after cardiac procedures a significant number of strokes 
occur within 24 hours of surgery (“early strokes”). Moreover, patients contracting 
early strokes are considerably more likely to suffer from severe neurological 
complications than patients with delayed strokes (Lisle et al., 2008). This 
increased complication rate is also reflected by a significantly increased short- and 
long -term mortality rate (Toumpoulis et al., 2008).  
Therefore, cardiovascular surgical patients not only face a large risk of developing 
stroke in the early postoperative period they are also more likely to suffer the 
gravest consequences. Considering the fact that in the UK alone each year more 
than 30,000 patient have heart surgery, early postoperative cerebrovascular 
accidents are a real clinical problem warranting new treatment and preventative 
strategies (The-Care-Quality-Commission, 2006). 
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Table 5.1: Incidence of Stroke after Surgical Procedures 
 
Procedure 
General Surgery 
Peripheral Vascular Surgery 
Head and Neck Tumor Resection 
Carotid Endarterectomy 
Isolated Coronary Artery Bypass Graft (CABG) 
Combined CABG and Valve Surgery 
Isolated Valve Surgery 
Multiple Valve Surgery 
Aortic Repair 
 
Risk of Stroke (%) 
0.08-0.7 
0.8-3.0 
4.8 
5.5-6.1 
1.4-3.8 
7.4 
4.8-8.8 
9.7 
8.7 
 
Modified after Selim (2007)  
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5.4 Perioperative Stroke: Risk Determining Factors 
 
Selim (Selim, 2007) classified the factors that determine the risk for the 
development of perioperative stroke into three groups: 1) preoperative patient-
related factors; 2) intraoperative procedure-related factors and 3) postoperative 
factors. 
In general, patient-related risk factors are advanced age (>70 years) and 
significant co-morbidities. Among diseases, which have been found to be stroke 
predictors are hypertension, diabetes mellitus, renal failure, chronic obstructive 
pulmonary disease, heart failure, arrhythmias, prior stroke and atherosclerotic 
vascular diseases (peripheral vascular, coronary, ascending aorta, carotid, 
cerebrovascular) (Kikura et al., 2004; Selim, 2007). 
In addition, Toumpoulis and colleagues determined specific predictors for the 
development of early and delayed stroke after cardiac surgery: Predictors of early 
strokes were age, recent myocardial infarction, smoking, femoral vascular disease 
and obesity whereas predictors for delayed stroke were female gender, white race 
and preoperative renal failure (Toumpoulis et al., 2008). 
Intraoperative predictors for stroke overall are type, nature and duration of 
anaesthesia and surgery as well as the development of arrhythmias, 
hyperglycaemia as well as hypo- and hypertension. Specific cardio-surgery related 
risks were the duration of cardiopulmonary bypass, aortic cross-clamp time and 
manipulations of an atherosclerotic aorta (Kikura et al., 2004; Selim, 2007). 
Postoperative predictors for early stroke according to Toumpoulis and colleagues 
are reoperation for bleeding, sepsis and respiratory failure. Risk factors for 
delayed stroke are respiratory and renal failure (Toumpoulis et al., 2008). But it is 
principally intrinsic cardiogenic factors that place the patients at risk in the 
postoperative period. Heart failure, infarction and atrial fibrillation in particular, 
which occurs in up to 50% of patients after cardiac surgery, have been strongly 
associated with postoperative cerebrovascular accidents (Selim, 2007). 
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5.5 Perioperative Ischaemic Stroke: Pathophysiology  
 
5.5.1 The Cause 
 
As discussed in the previous sections early postoperative stroke after cardiac 
surgery has a high incidence and is associated with an elevated disability and 
mortality rate.  
Perioperative stroke is mostly caused by thrombembolic events (Selim, 2007). 
The risk to contract such a cerebrovascular accident has therefore been linked to 
conditions that carry an increased chance for the development of thrombi. Atrial 
fibrillation for instance, that predisposes the heart for thrombus formation, occurs 
in more than 30% of heart surgical patients in the early postoperative period. 
Conversely, 36% to 75% of patients with stroke after cardiac procedures had at 
least one episode of atrial fibrillation, which has therefore been identified as a 
predictor for the development of postoperative stroke (McKhann et al., 2006). 
Also manipulation of an atherosclerotic aorta during surgery has been strongly 
correlated to the development of stroke (McKhann et al., 2006). Emboli for that 
reason have long been suspected to be the main cause of brain infarction 
(McKhann et al., 2006). Their composition can be of air or lipid but is most likely 
of platelet-fibrin aggregates or atheromatous debris that can emerge principally 
from the heart, the ascending aorta or any cervicocranial artery (Caplan and 
Hennerici, 1998). Indeed their formation has been confirmed in Doppler 
ultrasound studies during and after cardiac surgery in both aorta and cerebral 
circulation, but especially in the middle cerebral artery (Caplan and Hennerici, 
1998).  
In addition to embolisation cerebral hypoperfusion during heart surgery is now 
suspected to contribute to stroke development in the perioperative period as well. 
This is based on the fact that reduced tissue perfusion per se deprives organs from 
provision with nutrients and oxygen. Such deprived organs might either become 
directly injured or more vulnerable to the impact of an acute, even partial, arterial 
occlusion. Also, diminished perfusion is suspected to impair the washout and 
clearance of emboli deposited in the cerebral circulation or even predispose to 
thrombus formation at sites of stenotic lesions (Caplan and Hennerici, 1998). 
However, the probably most important consequence of cerebral hypoperfusion is 
5. Introduction 
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the unmasking of a normally subcritical arterial stenosis, which under such 
circumstances might become clinical relevant. McKhann and colleagues argue 
that subcritical vascular lesions can be assumed in a considerable proportion of 
patients especially in those with co-existing atherosclerotic disease in peripheral 
vascular systems (McKhann et al., 2006). Indirect evidence for the presence and 
unmasking of a subcritical cerebro-vascular stenosis as a cause for stroke comes 
from the POISE trial (Devereaux et al., 2008). Here the perioperative 
administration of the beta-blocker metoprolol significantly increased the risk of 
stroke compared to placebo. This increased risk of stroke in the treatment group 
was attributed to the frequent occurrence of bradycardia and hypotension in this 
group and hence cerebral hypoperfusion (Sear et al., 2008). Consequently 
perioperative stroke can be regarded as a multifactorial process, which does not 
only include vascular occlusion but also cerebral perfusion abnormalities. Surgery 
and anaesthesia as well as concomitant therapies can therefore be expected to each 
contribute to the mechanism of stroke. 
 
 
5.5.2 The Penumbra Concept 
 
Thrombembolic occlusion of a blood vessel in the brain leads to a reduction in 
cerebral blood flow (CBF), a condition called cerebrovascular ischaemia. Should 
this ischaemia persist oxygen supply to the affected brain area will become 
significantly impaired, and the partial pressure of oxygen in the affected cells will 
subsequently fall to or below a critical level (tissue hypoxia). The consequence of 
such a focal hypoxic- process will ultimately be brain injury or stroke.  
The occlusion is hardly ever total and some residual perfusion almost always 
persists, for instance through facilitation of collateral blood vessels (Moustafa and 
Baron, 2008). Consequently, the degree of blood flow reduction and associated 
hypoxia determines the severity of injury. Mild ischaemia leads only to functional 
impairment, moderate ischaemia additionally suppresses metabolic activity but 
severe and ongoing malperfusion will finally destroy the structural integrity of the 
affected brain area (Hossmann, 2006). Therefore hypoxia-ischaemia will unmask 
the hierarchy of energy dependent cellular functions with each function being 
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reliant on a certain minimal blood flow (Back, 1998). In other words the impact of 
stroke can be expressed in terms of CBF thresholds (Figure 5.1). Two thresholds 
are of particular interest in this regard since they not only describe the degree of 
damage that has been inflicted upon the brain but also determine the fate of the 
affected neurons. The upper threshold describes the degree of CBF reduction 
(usually mild) that is sufficient to induce electrical impairment in neurons. The 
lower threshold in contrast is only reached when flow is severely affected and is 
defined as the threshold for cellular energy failure (Astrup et al., 1981). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Cerebral blood flow reduction and physiological consequences 
Remaining cerebral blood flow (CBF) in % from normal and biochemical and 
physiological consequences of CBF reduction. The figure associates also the 
remaining blood flow with the core and penumbral region of an ischaemic brain 
infarct. Figure modified after Symon (1977) and Hossmann (1994). 
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Tissue perfused at or below the lower threshold is termed the (infarct) “core” 
(Figure 5.1). Cells in the core are irreversibly damaged and frequently display the 
features of necrotic cell death (Moustafa and Baron, 2008). Because of the 
depletion of energy metabolites and the subsequent failure of ion pumps that lead 
to a breakdown of physiological gradients across the cell membranes (membrane 
failure) the core has further been characterised through the generation of anoxic 
depolarisations (Hossmann, 2006). 
 
In contrast to the core, tissue with maintained energy metabolism despite exposure 
to hypoperfusion has been termed “penumbra” (Figure 5.2). In stroke the 
penumbra surrounds the infarct core and despite the selective loss of neurons its 
texture and morphological integrity are preserved as well as its fate remains 
largely undetermined for a prolonged period of time (Astrup et al., 1981; Back, 
1998). The penumbra is the tissue between the upper threshold of electrical and 
the lower threshold of energy failure. In absolute terms, that refers to tissue 
exposed to CBF between 0.12 and 0.22ml/g/min as a guide (Fiehler et al., 2002). 
Since CBF is age-dependent (higher in the young) penumbral blood flow 
thresholds are better defined in relation to the normal flow of the population of 
interest (Obrist et al., 1975). Therefore, a penumbral area can be assumed if 
cerebral blood flow is between to 20% to 70% of normal. 
Furthermore, it has been found that neurons in the penumbra experience graded 
functional loss as blood flow is more impaired and the more severe hypoxia 
becomes (Figure 5.1). As a result, thresholds for metabolic and electrical cellular 
functions have been determined: Protein synthesis is abolished prior to glucose 
utilisation followed by lactic acidosis development. Electrophysiologically, 30% 
reduction in perfusion leads to the generation of peri-infarct depolarisations and 
50-70% flow impairment to reduced EEG signals and evoked potential responses. 
Finally, in the core a flow less than 20% of normal will lead to anoxic 
depolarisations (Back, 1998; Hossmann, 2006). 
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Figure 5.2: The brain after ischaemic stroke – defining the core and 
penumbra 
Spatial pattern of cerebral blood flow (CBF) reduction following middle cerebral 
artery (MCA) occlusion in a baboon model of stroke. Red denotes the core; blue 
the penumbra and grey normally perfused brain tissue. Numbers represent CBF 
in ml/100g tissue/minute. CBF values greater 50ml/100g/min are assumed 
normal. Figure modified after Moustafa and Baron (2008). 
 
 
 
5.5.3 The Pathways 
 
As described above, brain tissue affected by ischaemia and subsequent hypoxia 
can be divided into a core and the penumbra. In the core the fate of the affected 
neurons is clear from the beginning of the blood vessel occlusion: Fulminant 
intra- and extra-cellular pathway activation will lead to rapid cell death. In the 
penumbra, in contrast, cells are injured but the signalling cascades that are 
activated are not instantaneously lethal. If neuronal death develops this process 
will take up days to build up rather than hours in the core. The penumbra has 
therefore been regarded as potentially salvageable since it is currently understood 
that the damaging pathways remain reversible (Weinberger, 2006). 
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Figure 5.3: Time course of events contributing to the ischaemic cascade 
This figure depicts the impact and time course of the four main 
pathophysiological principles causing neuronal damage and death after stroke 
(‘ischaemic cascade’).  
Figure modified after Dirnagl (1999). 
Minutes            Hours                                        Days
Time
Im
pa
ct
 o
f M
ec
ha
ni
sm
Excitotoxicity
Per-infarct Depolarisations Inflammation
ApoptosisIm
pa
ct
 o
f M
ec
ha
ni
sm
5. Introduction 
 22
Over recent years some of those pathways have emerged to be particularly 
important for the development of neuronal injury and subsequent death. They are 
distinct in their temporal profile after the insult as well as in their complex signal 
transduction. Because these cascades are initiated by ischaemia they have been 
summarised under the term ‘ischaemic cascade’ (Figure 5.3) (Dirnagl et al., 1999; 
Weinberger, 2006).  
Dirnagl and colleagues (Dirnagl et al., 1999) reviewed events leading to early and 
delayed cell death during stroke and identified four main mechanisms (Figure 
5.4): 1) Excitotoxicity; 2) peri-infarct depolarisation; 3) inflammation and 4) 
apoptosis. Mergenthaler and colleagues added free oxygen radicals (ROS) and 
tissue acidosis (Mergenthaler et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Time course of damaging mechanisms and involved mediators 
Cerebral ischaemia induces a cascade of events that damage brain cells. The 
figure shows the involved major mechanisms and their mediators in relation to the 
time course of injury.  
Figure modified after Dirnagl (2003). 
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5.5.3.1 Peri-infarct depolarisation 
 
Peri-infarct depolarisation develops within minutes after a severe insult to the 
brain (Dirnagl et al., 1999). The neurons of the core depolarise because of a 
shortage of energy. The associated failure of ion pumps prevents re-uptake of 
potassium into the cells, which then accumulates in the extracellular space. 
Moreover, as another consequence of the depolarisation large amounts of 
glutamate are released into the synaptic cleft (Mergenthaler et al., 2004). 
Glutamate then accumulates outside the cells particularly since the shortage of 
ATP impairs glutamate re-uptake transporters. The surplus of glutamate and K+ 
subsequently spreads from the core into the penumbra. There it induces more 
excitation and therefore propagation and spreading of the depolarisation 
(Mergenthaler et al., 2004). The repetitive depolarisations in the infarcted region 
as cause and consequence of neuronal damaging events are called “peri-infarct 
depolarisations” (Dirnagl et al., 1999; Mergenthaler et al., 2004). 
In contrast to the neurons in the core, which cannot repolarise after anoxic 
depolarisation, the penumbra maintains its capability of repolarisation (Dirnagl et 
al., 1999; Bramlett and Dietrich, 2004). This presents an additional threat to the 
penumbral cells because of the energy consuming nature of the processes 
involved that might further aggravate the injury. 
 
 
5.5.3.2 Excitotoxicity 
 
Excitotoxicity is strongly linked to the action of extracellular glutamate and 
resulting cellular Ca2+ overload.  
Hypoxia-triggered membrane depolarisation activates voltage gated Ca2+ 
channels. This process in turn increases the concentration of intracellular Ca2+, 
which subsequently induces glutamate release (Small et al., 1999). The release 
together with the impaired re-uptake leads to an accumulation of glutamate in the 
extracellular space within minutes after hypoxic-ischaemic brain injury (Dirnagl 
et al., 1999). The extracellular glutamate then stimulates glutamate receptors in 
the neuronal cell membrane and consequently intracellular damaging pathways.  
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Glutamate receptors can principally be divided into metabotropic (G-protein 
coupled) and ionotropic receptors (Small et al., 1999). Especially the role of 
ionotropic receptors has been suggested to play a key role in glutamate mediated 
excitotoxicity. Ionotropic glutamate receptors are ion channels and three main 
classes have been identified so far: 1) N-methyl-D-aspartate (NMDA) receptors, 
2) α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors and 3) 
kainate (KA) receptors (Small et al., 1999; Weinberger, 2006).  
NMDA receptors are highly permeable to Ca2+, Na+ and K+. Na+ influx through 
NMDA receptors primarily depolarises the cell but has also been associated with 
altered neuronal osmotic homeostasis leading to cellular swelling (Small et al., 
1999). 
An increase of intracellular free Ca2+ through glutamate induced NMDA receptor 
opening is suggested to significantly contribute to neuronal Ca2+ overload, which 
has been identified as an important mechanism of rapid neuronal death (Won et 
al., 2002). 
The role of AMPA and KA receptors however is less clear, but they are suggested 
to contribute to cascades mediating delayed cellular death (Won et al., 2002). 
Neuronal free calcium overload triggers a plethora of pathways that all lead to 
cellular damage or even death within minutes to hours after the initiating event. 
Here the interaction of calcium with either protein expression or protein function 
has been suggested to play a key role. For instance, increasing nuclear [Ca2+] 
affects gene expression via the cAMP-response element (CRE) and CRE-binding 
protein (CREP) whereas increased cytoplasmic [Ca2+] activates protein 
transcription through the serum-response element (SRE) (Hardingham et al., 
1998). 
In addition, an increase of intracellular free calcium also affects protein 
homeostasis from a different angle by activating various proteases such as 
calpains (family of cysteine proteases), phospholipase A2, protein kinases and 
endonucleases (Small et al., 1999; Won et al., 2002). 
Cells aim to mitigate the effects of the increased intracellular Ca2+ concentration. 
One of those mechanisms is the activation of the Ca2+/Na+ antiporter. But instead 
of alleviating the Ca2+ effect the increase of [Na+]i aggravates the injury. Na+ 
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influx - as explained above - is accompanied by water inflow. This will cause 
cellular swelling and subsequently structural damage to the affected neurons. 
The attempt of neurons to buffer increased intracellular Ca2+ through uptake into 
mitochondria is only sufficient if the free cellular calcium concentration does not 
exceed a certain limit. Above that threshold further mitochondrial calcium uptake 
will lead to an overload of mitochondria with calcium and a subsequent increase 
in the permeability of the inner mitochondrial membrane. This mechanism then 
triggers the release of cytochrome c and the initiation of an apoptotic cascade 
(Small et al., 1999).  
Apart from having consequences for mitochondrial membrane integrity, Ca2+ 
overload also influences the electro-chemical gradient of mitochondria. Increased 
Ca2+ will lead to mitochondrial depolarisation with subsequent inhibition of 
oxidative phosphorylation and ATP production. This in turn aggravates the energy 
deficit of the cell and reduces its chance of survival (Small et al., 1999).  
 
 
5.5.3.3 Reactive Oxygen Species (ROS) 
 
Reactive oxygen species (ROS) or free radicals are generated by several 
physiologic reactions in the body. Because of their unpaired free electron they are 
highly reactive and therefore capable of rapidly altering structure proteins, 
enzymes, channels, membranes and DNA. This makes them potentially harmful to 
the cell and therefore mandates tight regulation of their intracellular concentration 
by means of radical scavengers like superoxide dismutase (SOD) or vitamins C 
and E (Dwenger et al., 1994). However, radicals apart from being potentially 
damaging to cells are also vital for many cellular mechanisms. For instance ROS 
are key effectors in defence pathways protecting cells against intruders. In 
addition they have also been found to have a role in intracellular signal 
transduction cascades (Genestra, 2007). 
During the process of hypoxic-ischaemia in the brain ROS accumulate in cells and 
exhaust intrinsic scavenging capabilities, which subsequently leads to cellular 
damage (Won et al., 2002). 
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Radical production during stroke is reliant on three main pathways: The first 
pathway is calcium-dependent and therefore activated in response to calcium 
overload during excitotoxicity. In the second pathway ROS are generated as 
products of chemical reactions critically involving transition metals such as Fe2+ 
and Zn2+. Finally ROS are also produced in mitochondria. Under aerobic 
conditions most oxygen is used for energy production via the electron transport 
chain in the inner mitochondrial membrane. However, even under physiological 
conditions a proportion of the intracellular oxygen is also metabolised in reactions 
that generate oxygen free radicals. This mechanism is aggravated under 
circumstances of hypoxic-ischaemia because of the then disrupted electron 
transport chain. Hence in situations of metabolic stress the remaining O2 is 
increasingly used for ROS production. The radicals subsequently leak into the 
cytoplasm to cause structural damage (Won et al., 2002).  
But it is not only ROS potentially harming cells during ischaemia, nitrogen 
radicals are also suggested to play a major role. Neuronal nitric oxide synthase 
(nNOS) is activated by increased intracellular calcium concentrations. The 
subsequent excess of nitric oxide (NO) is believed to contribute directly to 
excitotoxic neuronal damage via reaction with superoxide (O2-). The resulting 
peroxynitrate (ONOO-) has been suggested to be directly cytotoxic (Radi et al., 
1991). 
 
 
5.5.3.4 Tissue acidosis 
 
To maintain some basic level of ATP neurons switch their metabolism during 
hypoxia from aerobic to anaerobic. As a side-product of this process lactate is 
generated which accumulates in the compromised cell and induces acidosis once 
it exceeds the buffering capability of the cell (Mergenthaler et al., 2004). The 
precise consequences of acidosis are currently not fully understood but is has been 
suggested that it might lead to oxygen radical (ROS) production. There is also 
some evidence that acidosis interferes with protein synthesis and function 
(Mergenthaler et al., 2004). 
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5.5.3.5 Inflammation  
 
In addition to their role in reconstruction and remodelling of the brain after injury, 
inflammatory pathways are currently believed to contribute significantly to 
cellular damage and death during stroke (Dirnagl et al., 1999). Inflammation 
usually develops within minutes after the hypoxic-ischaemic insult but reaches its 
peak only several hours afterwards (Figure 5.3) (Dirnagl et al., 1999). Triggers of 
the inflammatory response are, amongst others, increased intracellular Ca2+ 
concentrations, ROS and hypoxia itself. These triggers lead to an expression of 
pro-inflammatory genes with the subsequent production of mediators such as 
tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and platelet-activating 
factor (PAF). Furthermore vascular endothelial cells of the affected brain area will 
produce adhesion molecules, which are complementary to receptors on 
neutrophils. This will facilitate leukocyte adherence to the vessel walls and 
subsequent migration into the brain parenchyma (Dirnagl et al., 1999; 
Mergenthaler et al., 2004). The journey of the cells is guided by the release of 
chemotaxins from injured neuronal cells. The chemotaxins not only attract 
migrating cells but also activate resident astrocytes and microglia to release 
further pro-inflammatory mediators (Dirnagl et al., 1999; Mergenthaler et al., 
2004). This leads to a spread of the inflammatory response throughout the injured 
brain area, predominantly the penumbra. There is now growing evidence that 
cellular activation during this process critically involves stimulation and up 
regulation of inducible nitric oxide synthesis (iNOS) with subsequent increased 
NO production as well as induction of cyclooxygenase-2 (COX-2) activity (Small 
et al., 1999; Mergenthaler et al., 2004).  
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5.5.3.6 Apoptosis 
 
Apoptosis or programmed cell death is classically regarded as a late event in 
hypoxic-ischaemic stroke with gradual onset after hours and days (Figure 5.3). In 
contrast to necrosis, which traditionally has been viewed as the major form of 
accidental or pathological cell death and hence as the predominant type of death 
in the core, apoptosis was seen as the endpoint of death pathways in the penumbra 
(Small et al., 1999; Bramlett and Dietrich, 2004). However, this strict distinction 
of necrosis and apoptosis based on histopathological characteristics and spatial 
distribution has recently been challenged. Necrosis and apoptosis are now 
increasingly regarded as two poles of a continuous mechanism leading to cellular 
death after stroke (Small et al., 1999; Schaller, 2007). Whether a cell dies from 
necrosis or apoptosis in this process is probably dependent on the nature, and most 
of all intensity, of the damaging stimulus (Dirnagl et al., 1999).  
Classically necrosis and apoptosis have been morphologically characterized 
according to criteria listed in Table 5.2. 
Programmed cell death is the result of an activation of a cascade of specific 
enzymes, the caspases. Caspases are a family of cysteine proteases that cleave 
proteins next to aspartic acid residues (Boatright and Salvesen, 2003). According 
to their function and place in the apoptotic cascade caspases can be classified as 
‘initiator’ or ‘executioner’ caspases (Boatright and Salvesen, 2003). 
For the activation of initiator caspases an intrinsic pathway has been described 
which is distinct from an extrinsic pathway. The extrinsic pathway involves 
caspase-8 and is under physiological conditions responsible for the elimination of 
unwanted cells during development and immune system maturation. The extrinsic 
pathway is started by the activation of a transmembrane death receptor of the 
tumor necrosis factor receptor family (FAS), which is located on the outer cell 
membrane. FAS in turn activates caspase-8 which stimulates pro-caspases-3 and –
7 to form caspases-3 and –7, respectively (Sugawara et al., 2004). 
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Table 5.2: Morphological Characteristics of Apoptotic and Necrotic Cell 
Death 
 
 
Apoptosis 
 
Necrosis 
 
Usually individual cells 
 
Several cells involved 
 
Early stage: 
 
Cell shrinkage 
Chromatin condensation against nuclear 
membrane 
DNA fragmentation and degradation 
DNA digestion produces small double- 
stranded fragments 
    > fragments show distinct ladder pattern 
       on electrophoresis gels 
Cytoplasmic organelles remain largely 
intact 
 
 
 
Early stage: 
 
Cell swelling 
Modest chromatin condensation 
 
 
 
 
 
 
Cytoplasmic vacuolisation 
Breakdown of organelles 
Rupture cell membrane 
Release of cellular contents 
 
Late stage: 
 
Disintegration of nucleus and cytoplasm 
into apoptotic bodies 
Phagocytosis of apoptotic bodies through 
immune and surrounding cells 
Mild inflammatory response 
 
 
Late stage: 
 
Shrinkage and loss of nuclear chromatin 
Random single-strand DNA breaks 
 
 
Strong inflammatory response with 
immune cell invasion 
 
 
Modified after Oppenheim (1999). 
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The intrinsic pathway has been demonstrated to eliminate cells in the body in 
response to ionising radiation, chemotherapy or mitochondrial damage. The 
initiating stimuli, for example Ca2+ or ROS, alter the permeability of 
mitochondrial membranes, which subsequently leads to the release of cytochrome 
c into the cytoplasm (Mergenthaler et al., 2004; Sugawara et al., 2004). Cytosolic 
cytochrome c than forms a complex with the protein ‘Apaf-1’ to form an 
apoptosome. This apotosome is the activator for caspase-9, which as caspase-8 is 
capable of converting pro-aspases-3 and –7 into their active forms (Boatright and 
Salvesen, 2003; Sugawara et al., 2004). 
Caspases-3 and -7 are currently the most extensively examined executioner 
caspases. Their proposed role in the apoptotic pathway is the direct interference 
with the transcription of genetic information for instance via inactivation of DNA 
repair enzymes (Mergenthaler et al., 2004).  
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5.6 Therapy of Ischaemic Stroke  
 
The current management of stroke follows two main strategic paradigms: 1) 
prevention of stroke by modifying its risks and 2) treatment of the acute event. 
 
 
5.6.1 Risk Management 
 
The overall risks for stroke are the same regardless as to whether a patient is at 
home, in hospital or has been subjected to surgery (see also sections 5.2 and 5.3) 
(Szeder and Torbey, 2008).  
Clinicians divide these risks into factors that are not modifiable (age, male sex, 
non-white ethnicity, family history, previous stroke) and those that are (Dahlof, 
2007). The main modifiable factors are hypertension, diabetes mellitus, atrial 
fibrillation, carotid artery disease, hyperlipidaemia, cigarette smoking, obesity and 
high alcohol consumption (Alberts, 2003; Dahlof, 2007). Successful management 
of those risks has been found to significantly reduce the individual chance of 
contracting cerebrovascular accidents. In this regard management of high blood 
pressure (>140/90 mmHg) has become the single most important factor in risk 
management since studies have shown untreated hypertension to be associated 
with the highest incidence of stroke (Dahlof, 2007).  
The use of anti-platelet agents like aspirin and clopidogrel has also been 
advocated to improve blood rheology. These drugs are especially recommended to 
prevent recurrent strokes (Alberts, 2003; Klijn and Hankey, 2003).  
 
 
5.6.2 Treatment of Acute Stroke 
 
Since acute vascular occlusion is the underlying cause for hypoxic-ischaemic 
stroke (see section 5.5), revascularisation of the affected brain area is considered 
the conditio sine qua non of any stroke therapy. Consequently strategies to re-
open obstructed blood vessels have been explored and especially thrombolytic 
agents have been found to be effective. Intravenous treatment with tissue 
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plasminogen activator (tPA, alteplase) within 3 hours of stroke onset reduced 
death and disability by 44% in a placebo controlled study (Klijn and Hankey, 
2003). Therefore administration of tPA is currently the only approved therapy for 
acute cerebrovascular accidents (Alberts, 2003). However, this treatment concept 
is not without problems: The main concerns about thrombolytic agents are the 
induction of bleeding complications like intracranial haemorrhage which has been 
found to occur in 6-7% of treated patients (Alberts, 2003; Moustafa and Baron, 
2008). For this reason, costly diagnostic procedures like computed tomography 
(CT) or magnetic resonance imaging (MRI) are currently warranted in patients 
with suspected stroke. They are intended not only to confirm the diagnosis of 
stroke but also to exclude a haemorrhagic event. This is important because 
application of lysis therapy during an acute haemorrhage may have disastrous 
consequences for the patient. 
The diagnostic requirements together with an often delayed time to hospital 
admission frequently result in a breach of the three-hour threshold for 
thrombolytic therapy. This precludes most stroke patients in daily clinical practice 
from an effective therapy. Studies have estimated that in the USA only 2-3% of 
patients with stroke are currently treated with tPA (Alberts, 2003). The usefulness 
of the three-hour cut-off for tPA application has recently been questioned on the 
basis of studies showing beneficial effects of alteplase up to six hours after stroke 
onset (Moustafa and Baron, 2008). Nevertheless, even if new guidelines would 
recommend a more liberal use of lysis therapy, it is unlikely that substantially 
more patients would receive it.  
Moreover, patients suffering from stroke in the perioperative period are altogether 
excluded from thrombolysis due to concerns of severe bleeding complications 
(Szeder and Torbey, 2008). This leaves a significant patient population without 
the option of the currently most effective therapy. Outcome in these patients 
therefore relies completely on their intrinsic ability to dissolve obstructive blood 
clots or to open collateral blood vessels (Kidwell et al., 2003). They would most 
likely benefit from a therapeutic concept that could strengthen the resistance of 
neurons against hypoxia. The aim of such a therapy would be to allow brain tissue 
to withstand the effects of stroke until re-opening of affected blood vessels has 
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occurred. Such a concept is pursued with the introduction of the idea of 
neuroprotection into the search for treatments of stroke. 
 
 
5.6.3 Neuroprotection  
 
Neuroprotection is a therapeutic concept that aims to limit the deleterious effects 
of ischaemia on neurons in the affected brain area (see section 5.5.3) (Green and 
Shuaib, 2006). Since the core of the brain tissue subjected to a cerebrovascular 
accident is regarded as unsalvageable the target of neuroprotective treatments is 
the penumbra with its undecided fate (Back, 1998; Weinberger, 2006; Moustafa 
and Baron, 2008).  
Neuroprotection in its strictest definition is a generic term for different strategies 
that are distinct for their time of application in relation to the onset of stroke 
(Figure 5.5). Treatments can be given either before (preemptive) or immediately 
after the start of ischaemia (neuroresuscitation) as well as in the reperfusion 
period (Fukuda and Warner, 2007). Preemptive therapy is now known as 
preconditioning, whilst treatment administered during reperfusion is termed 
postconditioning (Ferdinandy et al., 2007; Zhao, 2007). However, currently in 
most of the literature neuroprotection is being used as synonym for 
neuroresuscitation (Fukuda and Warner, 2007). 
Neuroprotection, especially pharmacologically induced, can either be direct or 
indirect. Whilst neurons are the targets of direct treatments, indirect therapies alter 
the conditions brain cells are exposed to. Drugs that alter cerebral blood flow and 
therefore help to maintain cellular oxygen supply are examples for indirect 
protection. Since the focus of the current study is on direct neuroprotection only 
mechanisms concerned with this principle will be discussed here. 
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Index Ischaemia
PoCIndex Ischaemia
A
B
C
PC Index Ischaemia
neuroresuscitation
< 120 min: “classic”
24 –72 hours: “late”
 
 
Figure 5.5: Neuroprotective strategies  
This figure depicts the possible application of neuroprotective strategies in 
relation to the damaging ischaemic insult (index ischaemia; InI).  
A) Neuroresuscitation: Application of neuroprotective treatments during the 
damaging period. B) Preconditioning (PC): Brief exposure to a sublethal insult 
(preconditioning stimulus; PCS) increases tissue resistance to a subsequent 
ischaemic (InI) event. Early (classical) PC: short time interval (hours) between 
PCS and InI. Delayed or late PC: Prolonged time interval (days) between PCS 
and InI. C) Postconditioning (PoC): Brief cycles of a sublethal insult in the period 
immediately after InI. 
Figure modified after Ferdinandy (2007). 
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5.6.3.1 Preconditioning  
 
Preconditioning describes the principle of applying subthreshold damaging stimuli 
to tissues with the aim to induce resistance against a subsequent more severe 
insult (Dirnagl et al., 2003; Steiger and Hanggi, 2007). Classically ischaemic 
preconditioning was evoked by temporarily interrupting the blood supply to the 
organ of interest, e.g. the heart (Murry et al., 1986). However, recent research has 
also found that the heart can be protected against the consequences of coronary 
occlusion by means of remote preconditioning. Here myocardial protection is 
induced by exposing a remote organ such as gut or kidney to brief episodes of 
ischaemia and reperfusion (Gho et al., 1996). In addition there is now evidence 
indicating that remote preconditioning might also be applicable to the brain (Dave 
et al., 2006).  
A detailed account on preconditioning will be given in the next chapter of this 
introduction (chapter 5.7). 
 
 
5.6.3.2 Neuroresuscitation 
 
The inevitable prerequisite of all neuroresuscitation is the reinstitution of 
sufficient blood flow to the infarcted brain area. However, since the damaging 
pathways of the ‘ischaemic cascade’ might be active until well after reperfusion 
has been achieved and are not terminated by mere tissue reoxygenation, 
treatments have long been sought to reduce the impact of these mechanisms 
(Fukuda and Warner, 2007). Therefore so far all drugs used with potential 
neuroprotective properties were aimed against specific targets to interrupt the 
injury-mediating signal transduction cascade (Figure 5.4 and 5.6) (Ferriero, 2005). 
Amongst compounds that were successful in animal models and subsequently 
tested in clinical trials were NMDA receptor antagonists, calcium channel 
blockers, anti-inflammatory agents, γ-aminobutyric acid (GABA) agonists, 
growth factors and antioxidants (Green and Shuaib, 2006; Savitz and Fisher, 
2007). Unfortunately, all but the ROS scavenger NXY-059 showed disappointing 
results in those trials (Lees et al., 2006). However, in a follow-up trial also NXY 
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failed (Shuaib et al., 2007). In response to this failure researchers determined 
some reasons why neuroprotection might fail when given after the onset of stroke 
in man: It was suggested that the patient selection for the trials was too broad-
based and disregarded the fact that different circumstances might involve different 
signalling pathways (Savitz and Fisher, 2007; Hussain and Shuaib, 2008). Also, 
achieving the same and therefore sufficient drug concentration in the human brain 
as in test animals was found to be difficult. This was not only because of drug 
toxicity but also because of a lack of ability to monitor effective brain 
concentrations (Savitz and Fisher, 2007; Hussain and Shuaib, 2008). Moreover, it 
was appreciated that the achievement of effective concentrations of 
neuroprotectants in the brain was dependent on the level of reperfusion 
established. Finally, timing of treatment implementation was regarded as another 
key factor to success since too late an application might have missed the window 
of opportunity with the penumbra already converted to core tissue (Hussain and 
Shuaib, 2008). The preemptive treatment (preconditioning) in high-risk patients, 
for instance in patients prior to cardiovascular surgery, might offer an alternative 
since cerebral perfusion can then be expected to be still grossly intact. 
Preconditioning should preferably be done with compounds that readily cross the 
blood brain barrier and whose brain concentrations could be monitored (see 
below).  
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Figure 5.6: Main principles of endogenous neuronal protective and repair 
mechanisms  
The mechanisms are depicted in relation to their suggested time of involvement in 
cellular defensive strategies and repair mechanisms.  
Figure modified after Dirnagl (2003) 
 
 
 
5.6.3.3 Postconditioning  
 
Postconditioning is a novel concept that has been developed only recently (Zhao 
et al., 2003). It consists of short bursts of perfusion impairments in the reperfusion 
period after a lethal event (Zhao, 2007). It was first described by Zhao and 
colleagues in 2003. These authors found in dogs that short periods of coronary 
artery re-occlusion in the reperfusion phase after myocardial infarction 
significantly reduced myocardial damage (Zhao et al., 2003). In their experiments 
postconditioning was nearly as effective as myocardial preconditioning.  
Subsequent research has demonstrated myocardial postconditioning also in other 
species such as rats (Obal et al., 2005), mice (Kin et al., 2005), rabbits 
5. Introduction 
 38
(Krolikowski et al., 2006), pigs (Iliodromitis et al., 2006) and even man (Staat et 
al., 2005). 
In 2006 Zhao and colleagues (Zhao et al., 2006) demonstrated a beneficial effect 
of postconditioning also on rat brains subjected to focal ischaemia. However, data 
about effectiveness and the involved pathways are so far are only limited and the 
clinical usefulness of this principle elusive (Zhao, 2007).  
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5.7 Preconditioning  
 
Preconditioning is the concept of achieving organ tolerance against critical 
ischaemia through brief subcritical or pharmacological challenges (Dirnagl et al., 
2003; Steiger and Hanggi, 2007). 
It started to gain widespread attention in 1986 after Murry and colleagues found a 
reduction of myocardial infarct size in dog hearts that had been pre-treated with 
short periods of ischaemia prior to prolonged coronary artery occlusion (Murry et 
al., 1986). Despite the fact that reports of experimentally-induced tolerance had 
been published before, the Murry paper marked the beginning of a new era of 
research (Dirnagl et al., 2003). Although originally a cardiac domain the potential 
of preconditioning for tissue protection was quickly realised also by scientists 
from other fields. However, most of the groundbreaking work was still done in 
cardiology laboratories.  
In their experiments Murry and colleagues had used four sequences of five-minute 
coronary occlusion followed by five-minute reperfusion immediately before a 
forty-minute myocardial ischaemia to induce cardioprotection (Murry et al., 
1986). From these experiments it became obvious that myocardial cells were able 
to adapt swiftly to acute changes in blood supply. Subsequent work not only 
confirmed Murry’s data but also found this response being a transient 
phenomenon lasting only a few hours (Kuzuya et al., 1993). However, in their 
study Kuzuya and colleagues also demonstrated a recurrence of tolerance twenty-
four hours after the preconditioning stimulus, hence the presence of a second 
phase of protection (Kuzuya et al., 1993).  
It is now established that in the heart tolerance towards ischaemia induced by 
preconditioning follows a distinct pattern: There is an early phase of protection 
termed in reference to Murry’s description ‘classic’ or ‘early’ preconditioning and 
a late phase that is present between twenty-four and seventy-two hours after pre-
treatment. For the late phase the terms ‘second window of protection’, ‘delayed 
preconditioning’ or ‘late phase preconditioning’ are in use in the literature 
(Ferdinandy et al., 2007). The protection conferred to cardiomyocytes in the 
second window is usually less pronounced than that from the early phase and an 
involvement of different pathways in both phases has been suggested (Zaugg et 
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al., 2003). In contrast to the early phase, the second window of protection has 
been associated for instance with substantial de novo synthesis of proteins (Zaugg 
et al., 2003).  
Soon after the discovery of preconditioning in preclinical studies scientists started 
to explore whether this phenomenon could be observed under clinical 
circumstances as well. Up to now there have been several studies reporting 
preconditioning in cardiac patients (Rezkalla and Kloner, 2007). For instance 
there is evidence that the severity of myocardial damage is attenuated and the 
outcome of patients improved when they had experienced pre-infarct angina 
(Kloner et al., 1995; Kloner et al., 1998). Moreover, data from patients after 
coronary balloon angioplasty as well as off-pump coronary bypass surgery 
suggests, that short periods of coronary occlusion during these procedures reduces 
the deleterious effects of prolonged ischaemia in man (Argaud et al., 2004; 
Karthik et al., 2004). 
 
Because of the limited therapeutic options for stroke and encouraged by the 
promising results from cardiac laboratories, neuroscientists in the early 1990s 
started to systematically explore preconditioning as a means of brain protection. 
Kitagawa and colleagues were the first who demonstrated preconditioning in 
hippocampal neurons (Kitagawa et al., 1990). They had subjected gerbils to 
cerebral ischaemia for five minutes and measured the number of dead cells in the 
CA1 hippocampal region. Hippocampi from animals that had received a short 
period of non-damaging ischaemia twenty-four hours earlier presented a reduced 
number of dead cells compared to control. In a subsequent study using the same 
model the authors demonstrated significant protection not only in other 
hippocampal regions but also in the cerebral cortex, the caudoputamen and the 
thalamus (Kitagawa et al., 1991). The phenomenon of tolerance in the brain 
induced by preconditioning was later confirmed in other animal models of global 
and focal ischaemia (Kirino, 2002). These studies largely corroborated the results 
of research in the field of cardioprotection and many similarities between hearts 
and brains in their responses to ischaemia have subsequently been reported 
(Kirino, 2002; Zaugg et al., 2003). However, apart from these similarities, it 
became also clear that some mechanisms were distinct in the brain. For instance, 
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Kato as well as Barone and colleagues found the time course of cerebral 
protection after preconditioning in whole animal experiments different from that 
described in heart (Kato et al., 1991; Barone et al., 1998). They were unable to 
find evidence for an early window of protection but rather showed that protective 
mechanisms started to become effective one day after the preconditioning 
stimulus. Furthermore compared to cardiac tissue they were able to demonstrate 
more sustained protection that could last for as long as seven days (Kato et al., 
1991; Barone et al., 1998). This finding has important consequences for clinical 
practice especially for patients with an increased risk of contracting a stroke (see 
5.2 to 5.4). It suggests for example, that cardiovascular surgical patients would be 
unprotected in the early perioperative phase, a period associated with highest risk 
of thrombembolic events. 
 
Shortly after the demonstration of the phenomenon of preconditioning in animal 
brains neuroscientists started to search for evidence of its occurrence in man as 
well. Although limited there are some data now indicating that neuronal 
preconditioning might exist in patients (Johnston, 2004). However, all studies in 
man are hampered by the fact that experimental temporary cerebral blood flow 
interruptions similar to intermittent coronary artery occlusions in hearts are not 
possible due to ethical considerations. Brain tissue is exceptionally sensitive to 
hypoxic-ischaemia so that the risk for volunteers even under controlled conditions 
in a laboratory would be unforeseeable (Kirino, 2002). Therefore most 
information so far is gained from clinical studies comparing the outcome of stroke 
victims with and without subcritical transient ischaemic attacks (TIAs). TIA prior 
to stroke could alleviate neurological symptoms as well as improve outcome and 
possibly reduce infarct volume (Johnston, 2004). Moreover, some additional data 
suggested an even better outcome if TIA and stroke were separated by some time, 
usually days (Johnston, 2004), again arguing against an early protective phase.  
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5.7.1 Pharmacological (Anaesthetic) Preconditioning 
 
Although ischaemic preconditioning is regarded as the archetypical form of 
preconditioning and suggested to be an evolutionary conserved strategy of 
organisms to cope with restricted substrate delivery, recent research has shown, 
that preconditioning is also possible by the application of other stimuli (Dirnagl et 
al., 2003; Gidday, 2006). Gidday stated that every mechanism with the potential 
of causing brain injury could also induce protection when applied at right (lower) 
concentrations (Gidday, 2006). Therefore physical stimuli (hyperthermia), 
exogenously applied substances (inflammatory mediators, glutamate, ROS), 
changes of endogenous conditions (hypoglycaemia, spreading depressions, 
epilepsy) as well as chemically available drugs have been shown to induce 
neuroprotection via preconditioning (Kirino, 2002; Gidday, 2006; Steiger and 
Hanggi, 2007). 
The application of drugs for induction of cerebral tolerance has been termed 
‘pharmacological preconditioning’ (De Hert, 2004). Here inhalational anaesthetics 
have been regarded as a particularly interesting class of compounds because of the 
long-term experience clinicians have in their use as well as their favourable safety 
profile. They are capable of rapidly inducing a variety of clinically important 
effects, which they normally achieve in a dose-dependent and reversible manner 
(Campagna et al., 2003). Moreover, since the target of preconditioning is the brain 
one concern associated with other classes of drugs namely the ability to cross the 
blood-brain barrier (BBB) in sufficient concentrations can be neglected with 
anaesthetics. It is even possible to assess brain concentrations of anaesthetics by 
relatively simple means in daily practice. For instance, the degree of sedation or 
depth of anaesthesia a person experiences after inhalation of an anaesthetic gas is 
directly correlated to the achieved cerebral concentration. This concentration is 
determined by the partial pressure of the anaesthetic in the brain. However the 
cerebral partial pressure of an anaesthetic is directly proportional to its partial 
pressure in the blood, which itself is a function of the partial pressure of the agent 
in the alveoli (PA). It follows that the achieved brain concentration is directly 
proportional to PA and hence to the alveolar concentration (Peck and Williams, 
2000 ). Measuring the end-tidal concentration of an anaesthetic provides therefore 
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a good estimate for the achieved brain concentration of that anaesthetic (Sice, 
2005). 
The most commonly used inhalational anaesthetics worldwide today are the 
nitrate derivative nitrous oxide (N2O) as well as the ethers isoflurane, desflurane 
and sevoflurane. The latter group had largely replaced the hydrocarbon halothane 
as the leading volatile by the turn of the millennium (Campagna et al., 2003). As 
with the recognition of potential problems with N2O such as pollution (green 
house gas) and neurotoxicity in developing brains clinicians have sought for 
alternatives (Soriano and Anand, 2005). Consequently, the noble gas xenon, 
which anaesthetic and analgesic properties are known for some time, has gained 
much attention recently. Although burdened with high production costs mandating 
a special delivery system, xenon has a favourable pharmacokinetic and -dynamic 
profile that is in contrast to the properties of other inhalational anaesthetics 
(Sanders et al., 2003).  
 
There is now a growing body of evidence that the anaesthetics desflurane, 
halothane, isoflurane, sevoflurane and xenon all possess the ability to precondition 
neuronal tissues either in vivo or in vitro or both. Tables 5.3 and 5.4 give a 
comprehensive overview about studies investigating the preconditioning effects of 
those anaesthetics. 
In whole animals isoflurane so far is the most extensively studied agent and has 
been shown to be an efficient preconditioner. It has been found effective in 
different species as well as in different models of cerebral ischaemia (Table 5.3). 
However to this point preconditioning with isoflurane could only be shown in 
males and seems therefore gender specific (Clarkson, 2007; Kitano et al., 2007; 
Wang et al., 2008a). In addition there is growing evidence that isoflurane is 
neurotoxic in neonates and infants (Mellon et al., 2007; Sanders et al., 2009). 
In contrast to isoflurane, data on the preconditioning effect of sevoflurane in 
neurons is limited but evidence suggests that it is capable of inducing tolerance 
against the damaging effect of global ischaemia in rats (Payne et al., 2005). 
Halothane on the other hand has mostly been studied under conditions of focal 
ischaemia and demonstrated to be protective there (Clarkson, 2007; Wang et al., 
2008a).  
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In addition to in vivo studies, recent in vitro experiments established halothane, 
isoflurane, desflurane and sevoflurane as preconditioners of brain slices and 
neuronal cultures against the deleterious effects of several neuronal injury-
inducing stimuli (Table 5.4). 
Also, there is mounting evidence now that the noble gas xenon has organo-
protective properties and is capable of preconditioning neuronal tissues. A study 
by Ma and colleagues (Ma et al., 2006) for instance explored the preconditioning 
effect of xenon on cell injury induced by oxygen-glucose deprivation in neuronal-
glial cell co-cultures. They found that two-hours of xenon exposure twenty-four 
hours prior to the damaging stimulus reduced cell injury in a concentration-
dependent manner. Moreover, in the same study the authors were able to show 
that xenon preconditioning reduced the size of a hypoxic- iachaemic infarct in 
seven-day old rats significantly (Ma et al., 2006). 
These data indicate that pharmacological (anaesthetic) preconditioning is as 
effective in neuronal tissue as it is in hearts, although with a different time-course. 
However, the cellular mechanisms involved in anaesthetic-induced neuronal 
preconditioning remain highly elusive. 
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Table 5.3: Anaesthetic Preconditioning - in vivo  
 
Agent Species Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
Isoflurane 
(fixed dose) 
 
 
 
Dog 
 
 
 
GI 
 
 
yes 
 
 
n/d 
 
 
↓ neurological 
deficit 
preservation of 
CaMKII 
 
Blanck 
2000 
 
 
Isoflurane 
(fixed dose) 
 
Rat 
 
 
FI 
 
 
n/d 
 
 
yes 
 
 
↑ iNOS 
 
Kapinya 
2002 
 
Isoflurane 
(dose-effect) 
 
Rat 
 
 
FI 
 
 
n/d 
 
 
yes 
 
 
↓ neurological 
deficit 
↓ infarct volume 
KATP-dependent 
 
Xiong  
2003 
 
Isoflurane 
(fixed dose) 
 
 
Rat 
(male) 
 
FI 
 
 
n/d 
 
 
yes 
 
 
MAPK dependent 
↓ neurological 
deficit 
↓ infarct volume 
 
Zheng  
2004 
 
Isoflurane 
(fixed dose) 
 
 
Rat  
(neonatal) 
 
FI 
 
 
n/d 
 
 
yes 
 
 
↔ mortality rate 
↓ infarct volume 
iNOS dependent 
 
Zhao 
2004 
 
Isoflurane 
(fixed dose) 
 
 
Rat 
 
 
FI 
 
 
yes 
 
n/d 
 
↓ neurological 
deficit 
↓ infarct volume 
adenosine A1-
receptor 
dependent 
 
Liu  
2006 
 
Isoflurane 
(dose-effect) 
 
Rat 
 
 
FI 
 
 
yes 
 
n/d 
 
↓ cortical cell 
death 
↑ neuromotor 
score 
doses < 1.5 MAC 
more beneficial 
 
 
Nasu 
2006 
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Table 5.3 (cont.): Anaesthetic Preconditioning - in vivo  
 
Agent Species Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
Isoflurane 
(fixed dose) 
 
 
Mice 
(neonatal) 
 
FI 
 
 
n/d 
 
yes 
 
↓ Mortality rate 
↓ striatal function 
↔ spatial 
memory 
 
 
McAuliffe 
2007 
 
Isoflurane 
(fixed dose) 
 
 
Rat 
(neonatal) 
 
FI 
 
 
n/d 
 
yes 
 
↔ Mortality rate 
↓ neuronal death 
↑ motor 
coordination 
↔ learning and 
memory 
↑ Bcl-2 
iNOS dependent 
 
 
Zhao  
2007 
 
Isoflurane 
(fixed dose) 
 
 
Mice 
(male  
& 
female) 
 
FI 
 
 
n/d 
 
yes 
 
↓ Infarct volume 
in males 
↑ Infarct volume 
in females 
↑ Akt in males 
 
 
Kitano 
2007 
 
Isoflurane 
(fixed dose) 
 
 
Rat 
(male) 
 
 
FI 
 
 
n/d 
 
yes 
 
↓ Infarct volume 
↓ Neurological 
deficit 
↑ Bcl-2 
↓ caspase 3 
↓ cytochrome c 
release 
 
Li 
2008 
 
Isoflurane 
(fixed dose) 
 
Mice 
(female) 
 
FI 
 
 
n/d 
 
yes 
 
↓ Infarct volume 
PC effect 
reversed with 
estradiol 
 
Wang 
2008 
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Table 5.3 (cont.): Anaesthetic Preconditioning - in vivo 
 
Agent Species Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
Isoflurane 
(fixed dose) 
 
Rat 
(neonatal) 
 
FI 
 
 
yes 
 
n/d 
 
↓ neuronal death 
 
Sasaoka 
2009 
       
 
Halothane 
(fixed dose) 
 
Rat 
 
 
FI 
 
 
n/d 
 
 
yes 
 
 
 
↑ iNOS 
 
Kapinya 
2002 
 
       
 
Sevoflurane 
(fixed dose) 
 
Rat 
 
 
GI 
 
yes 
 
 
yes 
 
 
preserved 
neuronal 
morphology and 
function 
 
Payne 
2005 
 
Sevoflurane 
(fixed dose) 
 
Rat 
 
GI 
 
yes 
 
 
n/d 
 
↓ neuronal death 
 
Wang 
2007 
 
Sevoflurane 
(fixed dose) 
 
Rat 
(neonatal) 
 
GI 
 
yes 
 
 
n/d 
 
↑ neuromotor 
function 
↓ infarct size 
 
Luo  
2008 
 
Sevoflurane + 
Xenon 
coadministration 
(fixed dose) 
 
Rat 
(neonatal) 
 
GI 
 
yes 
 
 
n/d 
 
↑ neuromotor 
function 
↓ infarct size 
 
Luo  
2008 
       
 
Xenon 
 
Rat 
(neonatal) 
 
GI 
 
n/d 
 
yes 
 
↓ neurological 
deficit 
↑ pCREB, ↑ Bcl-
2, ↑ BDNF 
 
Ma  
2006 
 
Xenon 
(fixed dose) 
 
Rat 
(neonatal) 
 
GI 
 
yes 
 
 
n/d 
 
↑ neuromotor 
function 
↓ infarct size 
 
Luo  
2008 
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Table 5.4: Anaesthetic Preconditioning - in vitro 
Agent Models Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
Isoflurane 
 
PNC 
 
 
OGD 
 
 
n/d 
 
yes 
 
 
↓ LDH release 
 
(Kapinya 
2002) 
 
Isoflurane 
(concentration-
effect) 
 
Rat 
Cerebellar 
slices 
 
OGD 
 
yes 
EC50: 
1.17% 
 
n/d 
 
Glutamate 
transporter 
dependent 
Not KATP-
dependent 
 
(Zheng and 
Zuo, 2003) 
 
Isoflurane 
(fixed dose) 
 
PNC 
 
OGD 
 
n/d 
 
yes 
 
 
↓ LDH release 
MKATP-
dependent 
 
(Kaneko 
2005) 
 
Isoflurane 
(concentration-
effect) 
 
Rat 
Hippo-
campal 
cultures 
 
OGD 
 
n/d 
 
yes 
 
 
↓ neuronal death 
↑ intracellular 
Ca2+ 
↑ MAP kinase 
↑ Akt 
 
(Bickler 
2005) 
 
Isoflurane 
(fixed dose) 
 
Rat 
Brain 
slice 
 
Glutamate 
toxicity 
 
yes 
 
 
n/d 
 
↓ neuronal death 
PKC and iNOS 
dependent 
 
(Zheng and 
Zuo, 2005) 
 
Isoflurane 
 
Human 
Neuro-
blastoma 
SH-SY5Y 
cells 
 
OGD 
 
 
n/d 
 
yes 
 
 
ERK activation 
↑ Bcl-2, ↑Egr-1 
 
(Zuo 2006) 
 
Isoflurane 
(concentration-
effect) 
 
Rat 
Cerebellar 
slices 
 
OGD 
 
 
yes 
EC50 
221μM 
 
n/d 
 
Glutamate 
transporter 
dependent 
 
(Wang 
2007a) 
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Table 5.4 (cont.): Anaesthetic Preconditioning - in vitro 
Agent Models Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
Isoflurane 
(concentration-
effect) 
 
PNC 
PC12 
cells 
 
Isoflurane 
induced 
damage 
 
yes 
 
 
n/d 
 
↓ cell death 
 
(Wei 2007) 
 
Isoflurane 
(concentration-
effect) 
 
Mouse 
Microglial 
cells 
 
LPS 
+ 
IFNγ 
 
yes 
 
 
n/d 
 
↓ glutamate 
release, 
PKC dependent, 
↓ iNOS 
expression 
 
(Xu 2008) 
 
Isoflurane 
 
 
Hippo-
campal 
neurons 
 
OGD 
 
n/d 
 
yes 
 
 
↑ cell viability, 
↑ HO-1 
expression 
 
(Li 2008a) 
 
Isoflurane 
(concentration-
effect) 
 
Hippo-
campal 
neurons 
 
OGD 
 
n/d 
 
yes 
 
 
↓ cell injury, 
HIF-1α 
activation, 
ERK1/2 
activation. 
↑ iNOS 
expression 
 
(Li 2008b) 
 
Isoflurane 
(fixed dose) 
 
 
NGCC 
 
OGD 
 
n/d 
 
yes 
 
 
PC MT-I/II 
dependent 
 
(Edmands 
and Hall, 
2009) 
       
 
Halothane 
(fixed dose) 
 
PNC 
PC12 
cells 
 
Isoflurane 
induced 
damage 
 
yes 
 
 
n/d 
 
↓ cell death 
 
(Wei 2007) 
 
Halothane 
(concentration-
effect) 
 
Rat 
Cerebellar 
slices 
 
OGD 
 
 
yes 
EC50 
173μM 
 
n/d 
 
Glutamate 
transporter 
dependent 
 
(Wang 
2007a) 
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Table 5.4 (cont.): Anaesthetic Preconditioning - in vitro 
Agent Models Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
Sevoflurane 
(concentration-
effect) 
 
Rat 
Hippo-
campal 
slices, 
cellular 
recording 
 
hypoxia 
 
yes 
 
 
n/d 
 
↑ neuronal 
function, 
MKATP-
dependent 
 
(Kehl 
2004) 
 
Sevoflurane 
(fixed dose) 
 
Rat 
Hippo-
campal 
slices, 
cellular 
recording 
 
OGD 
 
 
yes 
 
 
n/d 
 
MKATP-
dependent, 
↓ morphologic 
changes 
 
(Wang 
2006) 
 
Sevoflurane 
(high fixed 
dose) 
 
PNC 
PC12 
cells 
 
Isoflurane 
induced 
damage 
 
yes 
 
 
n/d 
 
no effect 
 
(Wei 2007) 
 
Sevoflurane 
(concentration-
effect) 
 
Rat 
Cerebellar 
slices 
 
OGD 
 
 
yes 
EC50 
184μM 
 
n/d 
 
Glutamate 
transporter 
dependent 
 
(Wang 
2007a) 
 
Sevoflurane 
(concentration-
effect) 
 
Rat 
Hippo-
campal 
slices 
 
Hypoxia, 
Intra-
cellular 
recordings 
 
yes 
 
 
n/d 
 
↑ repolarisations 
↓ depolarisations 
PKC dependence 
 
(Wang 
2007b) 
 
Sevoflurane 
(concentration-
effect) 
 
PNC, 
NGCC 
 
OGD 
 
n/d 
 
yes 
 
 
↑ cellular 
viability 
 
(Luo 2008) 
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Table 5.4 (cont.): Anaesthetic Preconditioning - in vitro 
Agent Models Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
Sevoflurane 
& 
Xenon 
coadmini-
stration 
(fixed dose) 
 
 
PNC, 
NGCC 
 
OGD 
 
n/d 
 
yes 
 
 
↑ cellular 
viability, 
P3K dependent 
 
(Luo 2008) 
 
Sevoflurane 
(concentration-
effect) 
 
NGCC 
 
OGD 
 
 
yes 
 
 
n/d 
 
↓ LDH release, 
KATP and ROS 
dependent 
 
(Velly 
2009) 
 
Sevoflurane 
(fixed dose) 
 
 
Rat 
Hippo-
campal 
slices, 
 
OGD 
 
 
yes 
 
 
n/d 
 
↑ FAK 
↓caspase 3 
 
(Sigaut 
2009) 
       
 
Desflurane 
(concentration-
effect) 
 
Rat 
Cerebellar 
slices 
 
OGD 
 
 
yes 
EC50 
929μM 
 
n/d 
 
Glutamate 
transporter 
dependent 
 
(Wang 
2007a) 
       
 
Xenon 
(concentration-
effect) 
 
NGCC, 
Hippo-
campal 
slice 
culture 
 
OGD 
 
 
n/d 
 
yes 
 
↓ LDH release, 
↓ cell death 
 
(Ma 2006) 
 
Xenon 
(concentration-
effect) 
 
PNC, 
NGCC 
 
OGD 
 
n/d 
 
yes 
 
 
↑ cellular 
viability, 
P3K dependent 
 
(Luo 2008) 
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 Akt Protein kinase LPS lipopolysccharide 
 Bcl-2 B-cell lymphoma-2 protein MAC minimum alveolar 
concentration 
 BDNF brain-derived neurotrophic 
factor 
MAPK p38 mitogen-activated protein 
kinase 
 CaMKII Ca2+/calmodulin-dependent 
protein kinase 
MT-I/II Metal-regulatory genes, 
metallothioneins-I/II 
 DP delayed preconditioning  NGCC Neuronal-glial cell 
coculture 
 Erg-1 early growth response gene 1 n/d not determined 
 EP early preconditioning OGD oxygen-glucose deprivation 
 ERK extracellular signal-regulated 
kinase 
PC preconditioning 
 FAK focal adhesion kinase PC12 cells phaeochromocytoma 
neurosecretory cells 
 FI focal ischaemia pCREB phosphorylated cAMP 
response element 
 GI global iscaemia PKC protein kinase C 
 HIF-1α hypoxia inducible factor-
1alpha 
PNC primary neuronal cultures 
 HO-1 heme oxygenase isoenzyme 1 P3K phosphoinositol-3-kinase 
 IFNγ interferon gamma ROS reactive oxygen species 
 INOS inducible notric oxide 
synthase 
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5.7.2 Preconditioning Pathways 
 
5.7.2.1 Overview 
 
In his comprehensive review Sapolsky (Sapolsky, 2001) identified six main 
intrinsic principles of how neurons defend themselves against excitotoxic insults. 
Since excitotoxicity is a main contributor for the development of cerebral injury 
(see section 5.5.3.2) after hypoxic-ischaemia these mechanisms can be expected 
to be crucial for endogenous and drug-induced neuroprotective and 
preconditioning pathways as well. 
The first defence mechanism Sapolsky (Sapolsky, 2001) describes is a decrease in 
neuronal excitability via opening of potassium channels. Indeed over the past 10 
years various classes of K+ channels have been shown to be involved in neuronal 
protective mechanisms. Tanabe and colleagues (Tanabe et al., 1999b) for instance 
showed hypoxia-induced activation of Ca2+-dependent K+ conductance in 
hippocampal neurons, which was viewed as a positive adaptive process. 
Heurteaux and colleagues (Heurteaux et al., 2004) demonstrated an increased 
sensitivity of two-pore K+ channel (TREK-1) knock-out mice to ischaemia and 
epilepsy. Misonou and colleagues (Misonou et al., 2005) found delayed rectifier 
voltage-dependent K+ channels to contribute to a reduction in neuronal 
excitability during periods of hypoxia and suggested a role of these channels in 
intrinsic neuronal protection. Also, an increasing body of evidence suggests an 
involvement of ATP-sensitive K+ (KATP) channels in neuroprotective and 
preconditioning pathways. Trapp and Ballanyi demonstrated in 1995 that KATP 
channels in rat dorsal vagal neurons open in response to anoxia (Trapp and 
Ballanyi, 1995). These data were in agreement with studies by Heurteaux and 
colleagues indicating a critical participation of KATP channels in basic neuronal 
protective as well as preconditioning pathways (Heurteaux et al., 1993; Heurteaux 
et al., 1995). 
The second principle Sapolsky (Sapolsky, 2001) lists is a mechanism through 
which neurons limit the accumulation of glutamate in the synaptic cleft. This can 
be achieved by either up regulation of glutamate reuptake or decreased release of 
glutamate from cells. Increased glutamate transporter expression has in fact been 
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demonstrated in experimental preconditioning paradigms (Zhang et al., 2007). 
Also glutamate release can be reduced for example through opening of KATP 
channels (Lee et al., 1996) or activation of adenosine A1 receptors (Li and 
Eisenach, 2005). In addition, scientists have also tried to diminish the effects of 
the released glutamate on NMDA receptors, which are suggested to mediate 
glutamate’s deleterious action on neurons. Although successful in vitro (Kaku et 
al., 1991) and in vivo (Park et al., 1988) models, NMDA receptor antagonists have 
failed to show any benfit in stroke outcome in clinical trials (Clark et al., 2000; 
Albers et al., 2001; Warach et al., 2006). 
The third and fourth principle Sapolsky (Sapolsky, 2001) describes are concerned 
with neuronal calcium homeostasis (see section 5.5.3). To prevent possible 
harmful effects of increased intracellular calcium concentrations, neurons have 
adopted mechanisms to limit its rise and to abolish its consequences. For example 
an increase of [Ca2+]i via opening of voltage gated Ca2+ channels is partially offset 
by a negative feedback on Ca2+ influx through NMDA receptors (Vyklicky, 1993; 
Lieberman and Mody, 1994). This negative feedback of Ca2+ on NMDA receptors 
might be mediated via the activation of the calcium-dependent phosphatase 
calcineurin (Vyklicky, 1993; Lieberman and Mody, 1994). Also to reduce the 
damaging effects increased [Ca2+]i has on cellular proteins, neurons facilitate heat-
shock proteins for protection (Sharp et al., 1994).  
In an attempt to reduce calcium influx under situations of hypoxia, L-type Ca2+ 
channels inhibitors have been trailed in pre-clinical and clinical settings. 
However, similar to the results with NMDA receptor antagonists this concept 
failed to show a benefit in clinical trials (Mandir et al., 2000; Fogelholm et al., 
2004). 
Sapolsky’s fifth defence principle is concerned with mechanisms by which 
neurons preserve energy or increase the availability of substrates for energy 
metabolism. This principle, compared to all others, is the only one directly dealing 
with energy depletion as the cause of cellular distress under conditions of 
hypoxic-ischaemia. 
Up regulation of glucose transporters and hence cellular glucose uptake represents 
one example of such a mechanism (Lee and Bondy, 1993). An additional one is 
glycogenolysis in glial cells with subsequent lactate production and release 
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(Wiesinger et al., 1997). This lactate then becomes the preferred source of energy 
for neurons under conditions of glucose depletion (Bliss and Sapolsky, 2001). To 
preserve energy in vivo it is now also the possible to expose the brain to mild 
hypothermia (33°C). This has been shown in a rat model of focal ischaemia to 
reduce the development of stroke and neurological deficit (Yanamoto et al., 
2001). 
The sixth and final defences mechanism of cells is the up regulation of anti-
apoptotic proteins like bcl-2 and the subsequent cleavage of pro-apoptotic 
caspases (Clark et al., 1999). In addition, the proteolytic degradation of glutamate 
(AMPA) receptors, which reduce the neuronal vulnerability to the excitotoxic 
stimulus has been described (Glazner et al., 2000). 
However, one of the most important intrinsic cellular defence mechanisms that 
contribute to energy preservation is the down regulation of neuronal excitability 
as mentioned above. Here KATP channels are suggested to play a crucial role since 
their activity has been directly linked to cellular metabolism (Ashcroft and Trapp, 
2001). These channels will be discussed in more detail in the next section. 
 
As discussed above there is evidence that all six principles might play a role in 
neuroprotection and possibly also in preconditioning. However, apart from 
determining the cascades involved in tolerance, scientists are also interested to 
uncover the hierarchy of the events. Therefore, Dirnagl and colleagues as well as 
Gidday distinguished between triggers, sensors, transducers and effectors (Table 
5.5), with the triggers being the process-initiating stimuli. The sensors pick up the 
initiating signal and transfer it to the transducers. These integrate and transmit it to 
the end-effectors, which finally confer protection to the cells (Dirnagl et al., 2003; 
Gidday, 2006). Triggers for instance are hypoxia, ischaemia or drugs. Sensors are 
adenosine and adenosine A1 receptors. Interestingly, KATP channels have been 
categorized amongst transducers as well as effectors (Schulz et al., 2001; Dirnagl 
et al., 2003; Zaugg et al., 2003; Gidday, 2006). For these channels there is an 
increasing body of evidence indicating a pivotal role in neuronal preconditioning 
(for overview see Tables 5.6 and 5.7). 
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Table 5.5: Triggers and Effectors of Preconditioning 
 
Triggers 
 
Sensors 
 
Transducers 
 
Effectors 
 
Hypoxia; 
Ischaemia; 
Inflammation; 
Chemicals 
 
 
 
 
 
Adenosine A1 receptors; 
Hypoxia inducible factor 
(HIF); 
Reactive oxygen species 
(ROS); 
Excitatory amino acid 
transporter 
 
 
ATP-sensitive K+ 
(KATP) channels; 
Nitric oxide (NO); 
Erythropoetin; 
Protein kinase C; 
Tumor necrosis factor; 
Immediate early genes 
 
ATP-sensitive K+ 
(KATP) channels; 
Heat shock protein; 
Radical scavengers; 
Brain-derived 
neurotrophic factor 
 
The table gives an overview over suggested main triggers, sensors, transducers and effectors 
of preconditioning. As can be seen KATP channels might play a key role in preconditioning. 
Table modified after Dirnagl (2003). 
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5.7.2.2 ATP-sensitive K+ (KATP) channels  
 
Potassium channels can be classified according to the International Union of 
Pharmacology XLI Compendium into four main classes depending on 
architectural similarities as well as phylogenetic relationships. These defined 
classes are voltage-gated (KV); calcium-activated (KCa); two-pore (K2P) and 
inward rectifier (Kir) potassium channels (Gutman et al., 2003). 
Adenosine 5’-triphosphate sensitive potassium (KATP) channels have been defined 
as a subfamily of potassium channels because of their hallmark feature of 
inhibition through intracellular ATP. They have been found to be an integral part 
of several cellular membranes but functional the most important subgroups are 
plasmalemmal and mitochondrial KATP channels (Ashcroft and Trapp, 2001). 
 
 
5.7.2.3 Mitochondrial KATP (mKATP) channels  
 
First evidence for the presence of mitochondrial KATP channels (mKATP) was 
provided in 1991 by Inoue and colleagues who identified a small conductance 
channel highly selective for K+ in the inner membrane of fused giant mitoplasts 
prepared from rat liver mitochondria (Inoue et al., 1991). They further observed 
that ATP, 4-aminopyridine and glybenclamide applied to the matrix side in inside-
out patch-clamp experiments could reversibly inactivate this channel. A year later 
Paucek and colleagues reported the reconstruction of a purified inner 
mitochondrial membrane potassium channel protein from rat liver and beef heart 
that was inhibited by ATP and glybenclamide (Paucek et al., 1992). Evidence for 
the existence of neuronal mKATP channels came from a study published in 2001: 
Here Bajgar and colleagues stated that they had partially purified and 
reconstituted mKATP channels from brain mitochondria (Bajgar et al., 2001). 
Although some data suggest mKATP channels to be identical with Kir6.1 this 
notion has been subsequently challenged leaving the molecular identity of these 
channels still elusive (Suzuki et al., 1997; Hanley and Daut, 2005). 
Since these initial reports numerous studies have been published investigating the 
role of mKATP channels in organ protection and preconditioning. The attention 
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mKATP channels have attracted over the recent years is likely due to the fact that 
they are suggested to a) be involved in the regulation of mitochondrial volume 
(Szewczyk and Marban, 1999), b) be a limiting factor for the increase of the 
mitochondrial membrane potential during respiratory H+ transport (Ashcroft and 
Trapp, 2001) and most importantly c) reduce ATP synthesis via mitochondrial 
membrane depolarisation (Holmuhamedov et al., 1998). This reduction of ATP 
synthesis, which resembles situations of hypoxia and ischaemia, might in turn also 
induce adaptive protective processes (O'Rourke, 2000b).  
Channel opening is believed to be the initiating step of mKATP channel-
dependent protective pathways. These pathways might involve reactive oxygen 
species (ROS) and protein kinase C (PKC) as messengers, which have been 
shown to be important for organ protection (Carroll et al., 2001; Schulz et al., 
2001; Costa and Garlid, 2008).  
However, the evidence for the existence of mKATP channels is met with some 
reservations among the scientific community concerned with KATP channels as 
nicely laid out in a recent comprehensive review by Henley and Daut (Hanley and 
Daut, 2005). In this very detailed article the authors critically appraise the 
currently available results, methods and techniques that build the basis for the 
mKATP channel hypothesis. They come to the conclusion that at this time data 
supporting the presence of mKATP channels are incomplete and that therefore 
conclusions drawn from studies based on their existence should be handled with 
caution. 
 
 
 
 
 
 
 
 
 
 
 
5. Introduction 
 59
 
Table 5.6: KATP Channel-Dependent Preconditioning - in vivo 
Preconditioning Species Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
KATP opening 
(diazoxide) 
 
Rabbit 
 
Spinal 
cord 
ischaemia 
 
yes 
 
yes 
 
Improvement of 
neurological 
symptoms 
 
(Caparrelli 
2002) 
 
Ischaemia 
 
Gerbil 
 
Cerebral 
ischaemia 
 
yes 
 
n/d 
 
KATP channels 
and adenosine 
A1 receptors 
not involved in 
early phase 
preconditioning 
 
(Sorimachi 
and 
Nowak, 
2004) 
 
Ischaemia 
 
Rat 
 
Focal 
cerebral 
ischaemia 
 
n/d 
 
yes 
 
KATP channels 
and adenosine 
A1 receptors 
involved in  
preconditioning 
 
(Yoshida 
2004) 
 
KATP opening 
(diazoxide) 
 
Rat 
 
Focal 
cerebral 
ischaemia 
 
yes 
 
n/d 
 
Reduction of 
proteolysis and 
immediate early 
gene expression 
 
(Jiang 
2005) 
 
Remote 
Ischaemia 
 
Mouse 
 
Cerebral 
ischaemia 
 
yes 
 
n/d 
 
KATP channels 
and adenosine 
A1 receptors 
involved in  
preconditioning 
 
(Rehni 
2007) 
 
KATP opening 
(diazoxide) 
 
Rat 
 
Focal 
cerebral 
ischaemia 
 
n/d 
 
yes 
 
KATP channels 
involved in 
delayed  
preconditioning 
 
(Mayanagi 
2007) 
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Table 5.7: KATP Channel-Dependent Preconditioning - in vitro 
Agent Models Injury Preconditioning Outcome / Reference 
   early delayed Mechanism  
 
Chemical 
(3-NP) 
 
Hippo- 
campal 
slices 
 
Chemical 
 
yes 
 
n/d 
 
KATP-
dependent 
 
(Riepe 
1996) 
 
 
Chemical 
(3-NP) 
 
Hippo- 
campal 
slices 
 
Hypoxia 
 
yes 
 
n/d 
 
KATP and ROS 
dependent 
 
(Riepe 
1997) 
 
KATP 
opening 
(diazoxide) 
 
Primary 
neuronal 
cultures 
 
OGD 
 
n/d 
 
yes 
 
ROS and PKC 
dependent 
 
(Kis 2003) 
 
Hypothermia 
 
Cerebellar 
slices 
 
OGD 
 
yes 
 
n/d 
 
KATP-
dependent 
 
(Yuan 2004) 
 
Ischaemia, 
PKC, KATP 
opening 
(diazoxide, 
pinacidil) 
 
Hippo- 
campal 
slices 
 
OGD 
 
n/d 
 
yes 
 
 and PKC 
preconditioning  
are KATP-
dependent 
 
(Raval 
2007) 
 
 
 n/d not determined PKC protein kinase C 
 3-NP 3 -nitropropionic acid ROS reactive oxygen species 
 OGD oxygen-glucose deprivation   
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5.7.2.4 Plasmalemmal KATP (pKATP) channels  
 
Plasmalemmal KATP channels are located in the outer membrane of cells. They 
were first described by Noma in 1983 in cardiomyocytes but soon afterwards 
evidence for their presence was found in other tissues as well (Noma, 1983; 
Jenkinson, 2006). In 1984 Ashcroft and colleagues were the first to link KATP 
channels to a specific function; they showed their involvement in insulin secretion 
from pancreatic β-cells (Ashcroft et al., 1984).  
Both Noma’s and Ashcroft’s work set the stage for the future research into the 
properties and functions of pKATP channels. Since their initial work has been with 
cardiac and pancreatic tissues it is not surprising that pKATP channels have been 
subsequently best characterised in those two tissues. However, evidence for the 
existence of pKATP channels in brains is early as well and comes from radioligand 
binding experiments performed in 1985 (Geisen et al., 1985).  
 
In the cell membrane the assembly of two subunits is necessary to form a 
plasmalemmal KATP channel: An inwardly rectifying pore forming unit (Kir6) is 
combined with a regulator unit, the sulphonylurea receptor (SUR) in a 
stoichiometry of 4:4. Since it is known that four Kir6 subunits are needed to form 
the functional channel pore, four sulphonylurea receptors are also required, which 
makes the wild type pKATP channel an octameric complex (Figure 5.8 and 5.9) 
(Clement et al., 1997). 
1995 marked a decisive year for the research of plasmalemmal KATP channels. For 
the first time cDNA of both a ubiquitously expressed Kir (Kir6.1) subunit and a 
pancreas-specific unit (Kir6.2) was cloned and reconstituted successfully into cells 
(Inagaki et al., 1995a; Inagaki et al., 1995c; Sakura et al., 1995). In the same year, 
the sulphonylurea receptor (SUR) of pancreatic β-cells was also cloned (Aguilar-
Bryan et al., 1995). This gave scientists not only new insights into the 
composition of pKATP channels but provided also new opportunities for functional 
studies. 
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As stated above the Kir6 subunit of pKATP channels belongs to the class of inward 
rectifier potassium channels of which to date seven different subclasses are 
known. These are the strong rectifiers Kir2 and Kir3, the weak inward rectifiers 
Kir1, Kir4, Kir5 and Kir6 as well as Kir7 (Isomoto et al., 1997; Nichols and Lopatin, 
1997; Partiseti et al., 1998). 
Kir2 is the classical inwardly rectifier K+ channel, whereas Kir3 comprises G 
protein-activated channels. All ATP-sensitive potassium channels are subsumed 
under Kir6. They are structurally related to Kir1, which also contain a binding 
domain for ATP (Isomoto et al., 1997; Nichols and Lopatin, 1997). However, 
ATP-binding to Kir6 occurs with an about thousand-times greater affinity than to 
Kir1 (Wu et al., 2004). Kir6 have therefore been termed ATP-sensitive whereas 
Kir1 are regarded as ATP-dependent. 
Two isoforms of the pore forming subunits of pKATP channels are known to date, 
Kir6.1 and Kir6.2 (Ashcroft and Trapp, 2001). Kir6.2 is the predominant pore-
forming unit in most tissues although Kir6.1 might have a physiological role in 
some types of smooth muscles. Despite 71% molecular identity, the two forms 
display distinct characteristics (Yamada et al., 1997). Single channel conductances 
of Kir6.1/SUR2B for instance are with 30pS considerably smaller than for 
Kir6.2/SUR2B (70pS) (Repunte et al., 1999). Also, there is some evidence that 
ATP inhibits Kir6.1 with lower affinity than Kir6.2 (Yamada et al., 1997). 
The general structure of Kir6.2 demonstrates the prototypic topology of Kir 
channels. It has two hydrophobic membrane-spanning domains, M1 and M2, one 
pore-forming loop and cytoplasmic hydrophilic N- as well as C-terminal domains 
(Figure 5.9) (Isomoto et al., 1997; Baukrowitz and Fakler, 2000). 
 
Inward rectification means that a current of positive charge can pass more easily 
into than out of a cell. This flux is dependent on the extracellular K+ concentration 
in a way that potassium conductance increases with increased external K+ and 
decreases with falling extracellular K+ levels (Lopatin and Nichols, 1996). 
Although potassium influx into the cell is always possible, potassium outflow 
becomes increasingly reduced the more positive the membrane potential becomes 
in relation to the K+ equilibrium potential. This has physiologic consequences for 
the generation of action potentials: A potassium current that is equally possible in 
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both directions through the channel would immediately offset any sodium influx 
during depolarisation and hence significantly reduce cellular excitability (Nichols 
and Lopatin, 1997; Lopatin and Nichols, 2001; Lu, 2004). Therefore inward 
rectifiers stabilise the resting membrane potential near the K+ equilibrium 
potential without impairing the cells’ general excitable actions.  
The property of inward rectification is caused by the effects of intracellular Mg2+ 
and polyamines on the channel. These substances act from the inside of the pore 
to obstruct potassium flow in an unidirectional manner (Figure 5.7) (Horie et al., 
1987; Ciani and Ribalet, 1988; Fakler et al., 1994; Fakler et al., 1995). An 
additional mechanism contributing to rectification has been described as intrinsic 
gating. This means that the current flow through a channel is dependent on the 
state of that channel and therefore on its regulation. Opening or closing of Kir6.2 
is facilitated via cytoplasmic variations of the [ADP]/[ATP] ratio (see below) 
(Isomoto et al., 1997). 
 
 
5. Introduction 
 64
 
 
 
 
Figure 5.7: Inward rectifier K+ channels 
Figure exemplifies inward rectification. Rectification is elicited from Kir1.1 
through polyamine block. The major polyamines in cells are spermine and 
spermidine. A similar type of block is usually achieved under physiological 
conditions by the action of Mg2+. Hence polyamines and Mg2+ represent the two 
main rectifying principles. Figure modified from Glowatzki (1995). 
 
0                    50       [mV]
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0.25
-0.25
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Kir6.2 needs to combine with SUR in a 1:1 ratio to form the functional octameric 
pKATP channel. As demonstrated in figures 5.8 and 5.9 the four pore-forming 
Kir6.2 subunits are located in the centre of the channel complex whereas SUR 
subunits surround them peripherally (Antcliff et al., 2005). Binding of SUR to 
Kir6 has been suggested to fulfil two purposes. The first is that the assembly of the 
two subunits allows the translocation of the channel from the endoplasmatic 
reticulum (ER) to the cell membrane. Conversely, a lack of building these 
complexes would lead to retention of channel proteins in the ER (Burke et al., 
2008). Most importantly, the combination Kir6/SUR is also a suggested part of 
channel regulatory mechanisms (Burke et al., 2008).  
The name sulphonylurea receptor for the regulator subunit of pKATP channels was 
derived after binding studies showed a high affinity of the anti-hyperglycaemic 
sulphonylurea glibenclamide to that subunit (Babenko et al., 1998).  
The sulphonylurea receptor SUR1 had been cloned in 1995 and its molecular 
structure subsequently resolved (Aguilar-Bryan et al., 1995). It is a large 
transmembrane protein that belongs to the ATP-binding cassette (ABC) family, 
which function as transporters, ion channels and channel regulators. Together with 
the cystic fibrosis regulator protein (CFTR) and the multidrug-resistance-related 
protein 1 (MRP1) SUR is part of the ABC-C subfamily (Campbell et al., 2003; 
Gribble and Reimann, 2003a).  
ABC proteins in general are composed of four structural parts, two 
transmembrane domains (TMD1, TMD2) and two cytosolic nucleotide-binding 
domains (NBD1, NBD2). SUR1 grossly follows this blueprint with TMD1 and 
TMD2, which contain 6 helices each. However, SUR is also somewhat atypical 
since it has an additional 5-helix transmembrane domain, TMD0 that most likely 
links the pore forming Kir6.2 to the rest of SUR (Campbell et al., 2003; Neagoe 
and Schwappach, 2005; Burke et al., 2008). Therefore sulphonylurea receptors are 
made of a total of 17 transmembrane helices (Figure 5.9) (Babenko et al., 1998; 
Campbell et al., 2003; Burke et al., 2008). 
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Figure 5.8: The Kir6.2 pore forming unit 
(A) Side view of Kir6.2 with the ATP binding site. ATP (yellow) is shown attached 
to the binding pocket. (B) Kir6.2 tetramer viewed from above with the 
transmembrane domains removed for clarity. ATP (yellow) is attached to its 
binding sites. The N domain is shown in ribbon whereas the C domain is shown in 
backbone format. 
Figure modified after Antcliff (2005).  
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Figure 5.9: Principle structure of Kir6.2/SUR1 K+ channel 
The upper part of the figure depicts the hypothetical organisation of a 
plasmalemmal KATP channel. Four inwardly rectifying Kir6.2 and four 
sulphonylurea subunits (SUR1) form a functional channel octamer. Kir6.2 has two 
transmembrane helices (M1, M2) and a large cytoplasmic domain containg an 
inhibitory ATP binding site. SUR is made of three transmembrane domains 
(TMD) and two cytoplasmic nucleotide binding domains (NBD). The bottom part 
of the figure shows a schematic view of the channel complex from above. 
‘Ext’: external side of the membrane; figure modified after Moreau (2005). 
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The nucleotide-binding domains of SUR are highly conserved structures. Each 
NBD contains a Walker A (WA) and a Walker B (WB) motif, a linker motif and a 
histidine as well as glutamine residue (Ashcroft and Trapp, 2001; Campbell et al., 
2003). All of these structures are likely involved in nucleotide binding and 
hydrolysis. ATP for instance when bound to SUR lies in a sandwich-like pocket 
formed by the WA and WB motifs (Campbell et al., 2003). 
Two sulphonylurea receptor genes have been cloned so far, SUR1 and SUR2, 
from which additional splice variants are also known. Of those splice variants 
SUR2A and SUR2B are the most important (Burke et al., 2008). Therefore six 
different combinations of subunits are theoretically possible to form the main 
types of plasmalemmal ATP-sensitive potassium channels in tissues. This 
generates the possibility that pKATP channels are tissue-specific. Indeed a 
preponderance of some combinations could be demonstrated in various organs 
(Table 5.8). For instance Kir6.2/SUR1 is the predominant KATP channel in neurons 
and pancreatic β-cells whereas Kir6.2/SUR2A has been demonstrated to be the 
main channel in the heart. Kir6.2/SUR2B and Kir6.1/SUR2B can be found mainly 
in smooth muscle cells. Kir6.1/SUR2A is most likely physiologically not relevant 
(Babenko et al., 1998; Matsuo et al., 2005; Burke et al., 2008). 
 
 
Table 5.8: Subunit Composition of KATP channel Subtypes 
 
KATP channel subtype 
 
Composition 
 
Pancreatic and neuronal type 
 
SUR1 + Kir6.2 
 
Cardiac type 
 
SUR2A + Kir6.2 
 
Vascular smooth muscle type  
 
SUR2B + Kir6.1 
 
Smooth muscle type 
 
SUR2B + Kir6.2 
 
Modified after Matsuo (2005)  
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There is now consensus that the Kir6.2 subunit regulates the transport of 
potassium and contains the principal ATP binding site whereas SUR1 modulates 
channel activity (Burke et al., 2008). This is also supported by the fact that the 
clinically available pKATP channel openers as well as inhibitors exert their effect 
via interaction with SUR (Moreau et al., 2005). However, normally the channel 
activity is regulated by the ratio of intracellular ATP to ADP concentrations 
(Ashcroft and Trapp, 2001). This interaction most likely represents a complex 
interplay of nucleotide effects at the Kir and SUR subunits. This notion is 
supported by experiments from Tucker and colleagues who examined the 
inhibitory potency of adenine nucleotides on truncated channels, i.e. channels 
which do not need SUR to form a functional molecule. The results showed that 
both ATP and ADP potently inhibited Kir6.2 with nearly equal Ki’s of 115μM and 
260μM, respectively. AMP in contrast only displayed a low affinity effect (Ki 
9.2mM) (Tucker et al., 1998). The inhibitory effect of ATP and ADP is Mg2+ 
independent and does not require channel phosphorylation (Ashcroft and Trapp, 
2001). 
In addition to the inhibitory effect of magnesium-free ATP and ADP on Kir6.2, 
Gribble and colleagues found that Mg-ATP and Mg-ADP opened pKATP channels. 
However, the potency of this stimulatory effect was less compared to the potency 
of inhibition displayed by these compounds (Gribble et al., 1998a). The channel 
opening is suggested to be mediated via nucleotide interaction with SUR1 rather 
than Kir6.2 (Gribble et al., 1997b). This is supported by evidence that shows high 
affinity binding of ATP and ADP to NBD1 of SUR1 as well as low affinity 
binding to NBD2 (Matsuo et al., 2000). It is has been proposed that ATP binds 
only to NBD1 and NBD2 when pKATP channels are closed. However, this 
nucleotide binding requires the presence of Mg2+. Mg-ATP is subsequently 
hydrolysed to Mg-ADP, which is believed to induce such conformational changes 
at SUR1 that ATP inhibition of Kir is overridden and the channel is opened 
(Matsuo et al., 1999; Ashcroft and Trapp, 2001). 
 
In cardiomyocytes as well as in neurons pKATP channels are likely to be closed 
under physiological conditions. However, they are suggested to open during 
phases of ischaemia and hypoxia when the cell is exposed to metabolic stress and 
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intracellular ATP concentrations are diminished. The opening of pKATP channels 
facilitates an outward K+ current that shifts the membrane potential towards the 
potassium equilibrium potential of –80 mV (Babenko et al., 1998). This in turn 
limits cellular excitability and influences action potential duration and frequency. 
Therefore, KATP channels are suggested to couple cell metabolism to electrical 
activity and K+ flux. Moreover, by stabilising the resting membrane potential they 
help to reduce the influx of Ca2+ and its possible deleterious consequences 
(Babenko et al., 1998; Ashcroft and Trapp, 2001). 
 
 
5.7.2.5 Effects of anaesthetics on KATP channels 
 
First evidence suggesting a possible contribution of KATP channels to the effects 
of the volatile anaesthetics halothane, isoflurane and sevoflurane were published 
in the early 1990s and started with the observation that the airway relaxing effect 
of halothane was dependent on opening of KATP channels (Mehr and Lindeman, 
1993). Subsequent studies confirmed this initial result and it was established that 
halothane and isoflurane dilated blood vessels most likely via pKATP channel 
(Kir6.2/SUR2B) dependent smooth muscle relaxation (Cason et al., 1994; Crystal 
et al., 1997; Crystal et al., 2000). 
Since the knowledge about the effects of volatile anaesthetics on vascular smooth 
muscles was largely gained through investigations of the coronary system it is not 
surprising that scientists tried to characterise also the nature of the interaction of 
volatile anaesthetics with cardiomyocytes directly. In functional essays they not 
only found that the cardio-protective effect of isoflurane and sevoflurane is 
partially dependent on KATP channel opening they also showed in patch-clamp 
experiments with cardiac muscle cells that isoflurane could directly participate in 
pKATP channel opening (Kersten et al., 1996; Nakayama et al., 1997; Kwok et al., 
2002; Mullenheim et al., 2003). In contrast, the effects of halothane on the cardiac 
type pKATP channel (Kir6.2/SUR2A) in electrophysiological experiments were less 
clear but suggested a possible channel inhibition by halothane (Kwok et al., 
2002). 
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So far data of volatile anaesthetic actions on KATP channels in the brain exists only 
for sevoflurane and only for its effect on mKATP channels. Kehl and colleagues 
as well as Wang and colleagues found that sevoflurane concentration-dependently 
preconditioned rat hippocampal slices against global hypoxia and that this effect 
was dependent upon activation of mitochondrial KATP channels (Kehl et al., 
2004; Wang et al., 2006). Therefore, it is still elusive if and how the volatile 
anaesthetics halothane, isoflurane and sevoflurane interact with the predominant 
neuronal type pKATP channel Kir6.2/SUR1. 
One problem so far with most studies investigating the effects of anaesthetics on 
pKATP channels is that they lack a clear pharmacological distinction between the 
different pKATP channel subtypes. Cardiac type pKATP channels have a different 
composition compared to neuronal type channels (Table 5.8) and hence display a 
different pharmacology. Table 5.9 gives an overview about commonly used KATP 
channel agonists and antagonists and their differential actions on KATP channel 
subtypes. 
Evidence that xenon might exert an effect on potassium channels is also scarce. 
So far only one study has addressed this question: In 2004 Gruss, Bushell and 
colleagues found that xenon has differential actions on two-pore potassium 
channels. Whilst they could demonstrate an activation of a member of the TREK 
subfamily of two-pore potassium channels (TREK-1) in response to 80% xenon, 
they found no effect of xenon on a channel of a different subfamily (TASK-3) 
(Gruss et al., 2004). However, the effect of xenon on KATP channels had not yet 
been investigated.  
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Table 5.9: Pharmacology of KATP Channel Subtypes 
 
 
Agonist 
Diazoxide 
Pinacidil 
 
Antagonist 
Tolbutamide 
Glibenclamide 
5-HD 
 
Neuronal 
(Kir6.2/SUR1) 
Yes 
No 
 
 
Yes 
Yes 
(Yes) 
 
Cardiac 
(Kir6.2/SUR2A) 
No 
Yes 
 
 
No 
Yes 
No 
 
Mitochondrial 
KATP channels 
Yes 
Yes 
 
 
No 
Yes 
Yes 
 
Yes or No describe whether the drug has an effect on the channel subtype.  
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5.8 Hypothesis 
 
There is a growing body of evidence suggesting an involvement of KATP channels 
in pharmacological preconditioning. However, it still remains undetermined 
whether pKATP channels are involved in anaesthetic induced tolerance to 
ischaemia in neurons. The present study was conducted to address this question. 
 
If Kir6.2/SUR1 were to mediate preconditioning by modern inhalational 
anaesthetics it would be expected that those anaesthetics open KATP channels. 
Therefore the first part of this study examined electrophysiologically whether the 
anaesthetics halothane, isoflurane, sevoflurane and xenon open KATP channels in a 
heterologous expression system. For those compounds that were found to be 
pKATP channel openers it was further determined which channel subunit was 
targeted and by what mechanism. 
 
The second part of this study addressed the physiological consequences of the 
results obtained in part one. Neuronal glial cell co-cultures were taken as a model 
system to verify that KATP channel opening is mandatory for preconditioning by 
those anaesthetics that had been established as KATP channel openers.  
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6. METHODS 
 
6.1 Electrophysiological Experiments 
 
6.1.1 Tissue Culture 
 
Human embryonic kidney (HEK) cells are an invaluable and widely used tool for 
the evaluation of the pharmacological properties, signal transduction mechanisms 
or structure-activity relationships of many ion channels. Because of their ease of 
handling, reliable protein expression and low background currents they have 
become a well-accepted recombinant expression system for electrophysiological 
studies. They are especially popular in neurobiological research since they have 
been found to display similar characteristics to those of early differentiating 
neurons (Thomas and Smart, 2005). With an average diameter of 20-40μm HEK 
cells are considerably smaller than the other popular tool for electrophysiological 
studies, the Xenopus oocyte, which usually has a diameter of around 1mm (Sigel 
and Minier, 2005; Thomas and Smart, 2005). Because of the size Xenopus 
ooctytes usually allow easy generation of excised macropatches. In addition, 
oocytes contain intrinsically only few ion channels on their outer cell membrane, 
which provides them with the advantages of generating minimal noise during 
single channel recordings (Sigel and Minier, 2005). However despite the relative 
ease of use of oocytes, some experts regard the fact that they comprise non-human 
tissue, with consequently different enzymatic systems and signalling cascades, as 
a major disadvantage (Sigel and Minier, 2005). HEK cells because of their human 
origin have hence become the preferred tool in neuroscientific channel research. 
 
HEK cells were sourced from American Type Culture Collection (ATCC; 
Manassas, USA) under the designation ‘293’, accession code CRL-1573 (Thomas 
and Smart, 2005).  
They were stored in aliquots in liquid nitrogen until needed for experiments. 
When required one aliquot was removed from the store and thawed in a waterbath 
at 37°C for 5-10 minutes. The cell suspension was then transferred into a 50ml 
falcon tube. 10ml of growth medium were added slowly to reduce the likelihood 
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of cell damage caused by a rapid change of media. Growth medium was made of 
minimum essential medium (MEM; Gibco, Paisley, UK) that was enriched per 
500ml stock solution with 50,000 units penicillin (Sigma, Poole, Dorset, UK), 
50mg streptomycin (Sigma, Poole, Dorset, UK), 5ml non-essential amino acids 
(Gibco, Paisley, UK), 50ml foetal bovine serum (Gibco, Paisley, UK) and 2mM 
L-Glutamine (Gibco, Paisley, UK). 
After centrifuging at 1100rpm for 5 minutes at 25°C the supernatant was 
discarded and the pellet re-suspended in 15ml growth medium. The cells were 
finally transferred to a T75 flask (Fisher Scientific, Loughborough, Leicestershire, 
UK) and incubated in a humidified atmosphere of 5% CO2 and 95% air at 37°C 
overnight. Twenty-four hours later the attachment of the cells to the flask surface 
was checked under the microscope and the old growth medium was exchanged for 
15ml of fresh medium. Cells were subsequently grown in an incubator at 5% CO2 
and 95% air at 37°C and passaged when about 60% confluent as evidenced by 
light microscopy. This was usually the case after a period of 5-7 days. Cells were 
used for experiments from the second to the 15th passage after thawing. 
Cell passaging normally included plating of one aliquot of cells destined for 
experiments on glass coverslips, re-growing of another aliquot in a T75 flask and 
storing the remaining cells in liquid nitrogen. The process of passaging was 
initiated by removing the growth medium from the T75 flask and replacing it with 
5ml of 0.05% Trypsin-EDTA in growth medium (Gibco, Paisley, UK) to detach 
the cells from the flask surface. To neutralise the trypsin 5ml of growth medium 
was added and the suspension transferred to a 50ml falcon tube. Cells were 
centrifuged for 5 minutes at 1100rpm at 25°C. The supernatant was discarded and 
HEK293 cells re-suspended in 10ml of growth medium. The number of cells in 
the suspension was determined on a haemocytometer. 
2.5x106 of cells were re-suspended in 15ml of growth medium and transferred to a 
new T75 flask. They were subsequently grown in 5% CO2/95% air in a 
humidified incubator at 37°C for about a week until passaged again. 
Cells for experiments were plated onto glass coverslips coated with 1mg/ml poly-
D-lysine in 4-well plates (Nunc, Roskilde, DK) at a density of 2.5x103 cells in 
3ml growth medium per well. The remaining cells of the passage were transferred 
into cryovials at 4-10x106 cells per vial and stored in liquid nitrogen. 
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After resting for 24 hours HEK293 cells dedicated for experiments were 
transiently transfected using the calcium phosphate method (Chen and Okayama, 
1987). To each coverslip plasmids containing the coding sequences of either the 
wild type (Kir6.2/SUR1), a truncated (Kir6.2ΔC26), a KATP channel mutant with 
reduced ATP-sensitivity (Kir6.2-K185Q) or that of a related inwardly rectifying 
potassium channel (Kir1.1) were added respectively (see details below). Also 
added was pcDNA3 containing green fluorescent protein (GFP) cDNA to be able 
to verify successful transfection. Cells were then incubated at 3% CO2/ 97% air 
for 6-8h. Subsequently cells were washed twice with phosphate-buffered saline 
(PBS) and incubated in growth medium in 5% CO2 and 95% air in a humidified 
incubator at 37°C for 24-96h until use for electrophysiological recordings.  
Successful channel expression was verified microscopically. Since abnormal cell 
morphology indicates ill-health of cultured HEK cells with consequently possible 
erratic channel protein expression only cells with normal shape and appearance 
were used for experiments (Thomas and Smart, 2005). In addition, cells needed to 
show also green fluorescence that directly signifies protein transfection to be 
further used. However, green fluorescence is a rather unspecific parameter that 
does not allow identification of either the gene product of interest or its expression 
levels. Therefore electrophysiological parameters were also employed to further 
verify the presence of pKATP and Kir1.1 channels.  
 
For experiments with the wild type pKATP channel HEK293 cells were transfected 
with 0.25μg/well pcDNA3 vectors containing the coding sequence of mouse 
Kir6.2 (Genbank D50581 (Inagaki et al., 1995b; Sakura et al., 1995)) and 
0.35μg/well pcDNA3 vectors of rat SUR1 (Genbank L40624 (Aguilar-Bryan et 
al., 1995)).  
The wild type pKATP channel requires the assembly of both Kir6.2 and SUR1 
subunits to become a functional channel that is able to migrate to the cell surface 
(Schwappach et al., 2000). However, truncation of the last 26 C-terminal amino 
acids from Kir6.2 allows the pore-forming subunit to integrate into the 
plasmamembrane without the presence of the sulphonylurea subunit. This 
Kir6.2ΔC26 complex therefore forms a functional channel in the absence of SUR1 
(Tucker et al., 1997).  
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To produce a C-terminal truncated Kir6.2 a stop codon was introduced at the 
appropriate residue by site directed mutation. The resulting construct makes it 
then possible to attribute drug effects to actions on the different subunits (Tucker 
et al., 1997). The Kir6.2ΔC26 in pcDNA3 was used at a concentration of 5ug/ml. 
 
To explore whether the xenon effect on the wild type pKATP channel was 
dependent on the binding of ATP to Kir6.2 a pore unit was constructed that 
displayed reduced sensitivity to ATP. This was achieved through site-directed 
mutagenesis where the positive lysine residue at position 185 on the C-terminus 
was neutralised by introduction of glutamate (K185Q) (Tucker et al., 1997). This 
mutation was chosen because it had been shown that lysine in position 185 
(K185) of the C-terminus is part of the ATP binding pocket of Kir6.2 (Tanabe et 
al., 1999a). There is now convincing evidence for the phosphate tail of ATP to 
make electrostatic interactions with three positively charged residues at the 
binding site (Figure 6.1): The ATP α-phosphate interacts with arginine in position 
201 (R201), the β-phosphate with the discussed lysine (K185) and the γ-phosphate 
with arginine in position 50 (R50) (Trapp et al., 2003). In previous studies it was 
indeed demonstrated that a Kir6.2-K185Q mutation not only had a reduced 
sensitivity to ATP but also left the intrinsic open probability of the pKATP channel 
grossly unchanged (Tucker et al., 1998). This is important since increasing the 
channel’s intrinsic open probability would effectively also decrease its sensitivity 
to ATP as shown for mutations in position 166 (cysteine to threonine, alanine or 
methionine) (Trapp et al., 1998). However, altering also the channel’s open 
probability would have impaired the ability to test drug effects on that mutant and 
to compare it to the wild type channel. 
Kir6.2-K185Q was generated by site-directed mutagenesis using standard 
techniques (Stratagene, Agilent Technologies UK Ltd, Stockport, Cheshire, UK) 
and verified by direct sequencing. For experiments HEK293 cells were then 
transiently transfected with 2.5μg/ml Kir6.2-K185Q and 0.35μg/ml SUR1 
pcDNA3 plasmids. 
6. Methods 
 78
 
 
 
 
Figure 6.1: Schematic drawing of ATP interaction with Kir6.2 ATP-binding 
site 
(A) Interaction between ATP and amino acid residues in the Kir6.2 ATP-binding 
pocket; hydrogen bonds are indicated by dashed lines and hydrophobic 
interactions by sunbursts. Panel (B) shows a space-filling model of the ATP-
binding pocket. The electron shells of R50, K185 and ATP are shown in 
transparency.  
The figure is modified after Antcliff (2005). 
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To exclude that the action of xenon on Kir6.2/SUR1 represented a selective rather 
than a specific effect on channels containing ATP binding sites the influence of 
xenon on a different type of inwardly rectifying K+ channel was tested. 
For this purpose the renal outer-medullary K+ channel 1 (ROMK1, Kir1.1) was 
chosen. This channel is primarily located in the thick ascending limb of the loop 
of Henle in the kidney. Its physiological role is to participate in the regulation of 
the body’s K+ homeostasis through secretion of K+ into the tubule lumen (Schulte 
and Fakler, 2000). The channel is mainly regulated via intracellular [H+] and 
hence is pH dependent. Acidosis has been found to inhibit Kir1.1 whereas 
alkalosis stimulates K+ conductance (McNicholas et al., 1998). Although the 
channel is inhibited by ATP, compared to Kir6.2 it is regarded only as ATP 
dependent (Wu et al., 2004). This is shown by the fact that the Ki for ATP of 
Kir1.1 is in the millimolar and that of Kir6.2 in the micromolar range (Gribble et 
al., 1997a; McNicholas et al., 1998). 
Phylogenetically Kir1.1 and pKATP (Kir6.2/SUR1) channels are closely related 
showing considerable sequence identity (Figure 6.2) (Nichols and Lopatin, 1997). 
Any effect of xenon on Kir1.1 would therefore indicate a selective interaction with 
proteins that are capable of binding ATP rather than a specific action on Kir6.2. 
For experiments HEK293 cells were transiently transfected with 0.5μg/well 
pcDNA3 vectors coding for rat Kir1.1 (Genbank X72341). 
 
6. Methods 
 80
A) 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Human Kir: Sequence identity and protein alignment 
(A) depicts the amino acid sequence identity of the most important Kir’s in 
relation to Kir6.2 in percent. As expected, Kir6.1 shows the greatest identity with 
Kir6.2. Figure modified after Ashcroft and Gribble (1998)  
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Kir1.1
Kir2.4
Kir5.1
Kir3.1
Kir2.1
67%
36%
40%
38%
33%
41%  
Kir6.2_KCN      ----MLSRKGIIPEEYVLTR-----LAEDPA---------KPRYRARQRRARFVSKKGNC 
KIr6.1_KCN      ----MLARKSIIPEEYVLAR-----IAAENLR--------KPRIRDRLPKARFIAKSGAC 
Kir1.1_KCN      ---MNASSRNVFDTLIR--------VLTESMFKHLRKWVVTRFFGHSRQRARLVSKDGRC 
Kir2.4_KCN      MGLARALRRLSGALDSGDSRAGDEEEAGPGLCRNGWAPAPVQSPVGRR-RGRFVKKDGHC 
Kir3.1_KCN      --MSALRRKFGDDYQVVTTS-----SSGSGLQPQGPGQDPQQQLVPKKKRQRFVDKNGRC 
Kir5.1_KCN      -MSYYGSSYHIINADAKYPG-----YPPEHIIAE-----------KRRARRRLLHKDGSC 
Kir2.1_KCN      MGSVRTNRYSIVSSEE------DGMKLATMAVANGFGNGKSKVHTRQQCRSRFVKKDGHC 
 
                       50 
Kir6.2_KCN      N--VKNIR--EQGRFLQDVFTTLVDLKWPHTLLIFTMSFLCSWLLFAMAWWLIAFAHGDL 
Kir6.1_KCN      NLAHKNIR--EQGRFLQDIFTTLVDLKWRHTLVIFTMSFLCSWLLFAIMWWLVAFAHGDI 
Kir1.1_KCN      NIEFGNVEAQSRFIFFVDIWTTVLDLKWRYKMTIFITAFLGSWFFFGLLWYAVAYIHKDL 
Kir2.4_KCN      NVRFVNLGG-QGARYLSDLFTTCVDVRWRWMCLLFSCSFLASWLLFGLAFWLIASLHGDL 
Kir3.1_KCN      NVQHGNLGS-ETSRYLSDLFTTLVDLKWRWNLFIFILTYTVAWLFMASMWWVIAYTRGDL 
Kir5.1_KCN      NVYFKHIFG-EWGSYVVDIFTTLVDTKWRHMFVIFSLSYILSWLIFGSVFWLIAFHHGDL 
Kir2.1_KCN      NVQFINVGE-KGQRYLADIFTTCVDIRWRWMLVIFCLAFVLSWLFFGCVFWLIALLHGDL 
 
                                                185             201 
Kir6.2_KCN      QNIVGLMINAIMLGCIFMKTAQAHRRAETLIFSKHAVIALRHGRLCFMLRVGDLRKSMII 
Kir6.1_KCN      QNIVGLIINAVMLGCIFMKTAQAHRRAETLIFSRHAVIAVRNGKLCFMFRVGDLRKSMII 
Kir1.1_KCN      QSILGVIINSFMCGAILAKISRPKKRAKTITFSKNAVISKRGGKLCLLIRVANLRKSLLI 
Kir2.4_KCN      QCIAGCVLDAFVVGAVMAKMAKPKKRNETLVFSENAVVALRDHRLCLMWRVGNLRRSHLV 
Kir3.1_KCN      QSILGSIVDAFLIGCMFIKMSQPKKRAETLMFSEHAVISMRDGKLTLMFRVGNLRNSHMV 
Kir5.1_KCN      QSILSCIINTFIIGAALAKMATARKRAQTIRFSYFALIGMRDGKLCLMWRIGDFRPNHVV 
Kir2.1_KCN      QSIVGCIIDAFIIGAVMAKMAKPKKRNETLVFSHNAVIAMRDGKLCLMWRVGNLRKSHLV 
 
                                            301 
Kir6.2_KCN      PSDLHHHQDLEIIVILEGVVETTGITTQARTSYLADEILWGQRFVPIVAEE-DGRYSVDY 
Kir6.1_KCN      ATDLAN-QDLEVIVILEGVVETTGITTQARTSYIAEEIQWGHRFVSIVTEE-EGVYSVDY 
Kir1.1_KCN      AETLLQ-QDFELVVFLDGTVESTSATCQVRTSYVPEEVLWGYRFAPIVSKTKEGKYRVDF 
Kir2.4_KCN      RAELAR-ADFELVVILEGMVEATAMTTQCRSSYLPGELLWGHRFEPVLFQR-GSQYEVDY 
Kir3.1_KCN      QRSMQT-EQFEIVVILEGIVETTGMTCQARTSYTEDEVLWGHRFFPVISLE-EGFFKVDY 
Kir5.1_KCN      RKAVAK-DNFEILVTFIYTGDSTGTSHQSRSSYVPREILWGHRFNDVLEVK-RKYYKVNC 
Kir2.1_KCN      KQDIDN-ADFEIVVILEGMVEATAMTTQCRSSYLANEILWGHRYEPVLFEE-KHYYKVDY 
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(B) Although Kir1.1 shares only 36% identity with Kir6.2, the amino acid 
sequences of the ATP binding site are highly similar. The numbers above the 
letters represent the position of the respective amino acid in Kir6.2. The letters 
aligned in columns show amino acids of other channels in equivalent positions 
compared to Kir6.2.  
The human sequences for Kir were taken from the protein library of the National 
Centre for Biotechnology Information (NCBI - PubMed; Bethesda, Maryland, 
USA). The NCBI reference sequences were encoded in the library with 
NP_000516.3. To obtain images of alignments sequences were copied into 
ClustalW (www.clustal.org). 
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6.1.2 Experimental Solutions 
 
Stock solutions of tolbutamide (50mM) diazoxide (20mM) and pinacidil (10mM) 
were prepared in 100mM NaOH. Each day fractions of these stock solutions were 
added directly to fresh experimental solutions to achieve their final 
concentrations. Before use experimental solutions containing test drugs were pH 
checked and adjusted to pH 7.3 if needed. Saturated aqueous solutions of volatile 
anaesthetics were also freshly made each day and stored in airtight glass 
containers at room temperature until use. In saturation the concentrations for 
isoflurane, halothane and sevoflurane were taken as 15.3mM, 17.5mM and 
11.8mM, respectively (Jenkins et al., 1999). Volume fractions of such saturated 
anaesthetic solutions were then mixed with experimental solution to obtain a test 
solution with the final concentration of the respective anaesthetic. 
Solutions for the xenon experiments were prepared by bubbling extracellular 
solution with pure gases either of xenon, nitrogen or oxygen at a rate of 30ml/min 
for 20min in a Drechsel bottle. This produced saturated solutions for each of the 
individual gases (Gruss et al., 2004). For experiments solutions with fractional gas 
concentrations were then obtained by mixing adequate volumes of the individual 
saturated solutions. The final test solutions always contained 20% oxygen. The 
remaining 80% were made up by varying amounts of nitrogen- and xenon-
saturated solutions. Immediately after preparation the test solutions were 
transferred to glass syringe barrels. The fluid in the barrels was separated from air 
by a polypropylene float, thus preventing gases from escaping (Gruss et al., 2004). 
All chemicals used were purchased from Sigma (Poole, Dorset, UK). Xenon was 
obtained from Air Products (Basingstoke, UK) and nitrogen as well as oxygen 
from BOC (Guildford, UK).  
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6.1.3 Patch Pipettes 
 
Patch pipettes were pulled from thin-walled borosilicate glass (GC150TF; 
Harvard Apparatus, Edenbridge, Kent, UK) and tips polished with a Zeitz-DMZ 
puller (Zeitz Instruments, Martinsried, Germany). The pipettes when filled with 
solution had resistances of 3-5MΩ. The pipette solution contained (in mM): 120 
KCl, 1 NaOH, 1 MgCl2, 1 CaCl2, 5 EGTA, 5 HEPES, 0.3 K2ATP (pH adjusted to 
7.3 with KOH; final [K+] ~140mM). 
 
 
6.1.4 Whole-Cell Recordings 
 
For electrophysiological recordings a coverslip with transfected HEK cells was 
transferred into a recording chamber mounted under an upright microscope (Zeiss 
Axioskop 2FS) with epifluorescence. Only cells with healthy morphology and 
successfully transfected with GFP as evident from green fluorescence (excitation: 
395-440nm, emission: 470-600nm) were selected for electrophysiological 
recordings (Thomas and Smart, 2005).  
During the course of the experiment cells were constantly superfused at 3-
5ml/min with extracellular solution of the following composition (in mM): 118 
NaCl, 3 KCl, 1 MgCl2, 1.5 CaCl2, 25 HEPES (pH adjusted to 7.4 with NaOH). 
Test drugs were added to this solution either directly or from stock solutions as 
described above.  
Whole-cell currents were recorded at a holding potential of -20mV and at 20-
24°C. Currents were evoked by 700ms hyperpolarizing voltage ramps from -
20mV to -120mV every 15s and recorded using an EPC9 patch-clamp amplifier 
(HEKA Elektronik, Lambrecht, Germany). Recordings were digitised at 0.5kHz 
and analysed using Pulse/Pulsefit software (HEKA Elektronik, Lambrecht, 
Germany) running on a personal computer. This protocol allows characterisation 
of the properties of currents through specific ion channels. It is routinely used 
when examining recombinant channels as done here, but has also been used in 
neurons (Millar et al., 2000; Hopwood and Trapp, 2005). 
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To confirm that all effects on the holding current at -20mV were indeed caused by 
modulation of K+ currents, reversal potentials were determined for each 
experimental condition and compared (see results Table 7.1).  
The net ionic flow over a membrane can be expressed with equation 6.1 (Offner, 
1991): 
 
III outinnet −=  
Equation 6.1 
 
Inet represents the net flow whereas Iin and Iout express the current into and out of 
the cell respectively.  
At the reversal potential equation 6.2 can be re-written so that  
 
0=I net . 
     Equation 6.2 
 
The reversal potential is therefore the membrane potential at which there is no net 
flow of ions over the membrane (Offner, 1991). Furthermore it is the potential at 
which the direction of the ion flow across the membrane changes from either 
inward to outward or vice versa. 
In a single-ion system the reversal potential is the same as the equilibrium 
potential of that particular ion. This happens under physiological conditions when 
all channels amongst a population of different ion channels are closed but only 
one channel type with selectivity for a specific ion remains open. The resting 
membrane potential of a cell is the prototypic example for such a condition 
because then the flow across the membrane is dominated and the ensuing 
membrane potential characterised by K+ ions. The resting potential becomes 
therefore close to the equilibrium potential of K+. 
The equilibrium potential is a function of all forces across a membrane – electrical 
and osmotic - which influence the movement and distribution of ions on both 
sides of that membrane. It is termed equilibrium potential because when 
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established it represents the membrane potential at which all those forces are in 
equilibrium. As a consequence there will be no net current flow into or out of the 
cell. 
When a cell has significant permeabilities for more than one ion species the 
equilibrium potential can be calculated accurately with the Goldman-Hodgkin-
Katz equation (Pancrazio, 1997 ). However, in systems where the ion current is 
determined mostly through a single ion species the Nernst equation describes the 
equilibrium potential best (Pancrazio, 1997 ). Since the heterologous HEK293 cell 
expression system of the present study can be assumed to come close to a single-
ion system, the calculation of the equilibrium potential with the Nernst equation 
will also determine the reversal potential. 
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Equation 6.3 
 
R is the gas constant, T is the temperature in Kelvin, F is Faraday’s constant and z 
is the valance of the ion. RT/zF are usually assumed constant. For a monovalent 
cation like K+ its value is about 26mV at 25°C and 27mV at 37°C. 
[ion]o denotes the concentration of the ion on the outside of the cell and [ion]i is 
the concentration of that ion in the cytoplasm. 
Translated into the conditions of the experiments in the present study at 25°C with 
[K]o of 3mM and [K]i of 140mM the equation can be rearranged as  
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Equation 6.4 
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This then equates to  
 
mVE 96−≈  
Equation 6.5 
 
In the present study a reversal potential between -105 and -65mV has been 
accepted as representative for K+ currents. The reversal potentials for all treatment 
groups of the present study were not corrected for the liquid junction potential, 
which was calculated as 4.0mV at 24ºC with Clampex (Molecular Devices, 
Sunnyvale, California, USA). The values for the reversal potentials as determined 
experimentally ranged from -76mV to -84mV (Table 7.1) with no statistical 
significant difference between the groups. 
 
Concentration-response relationships for the volatile anaesthetics were obtained 
by alternating the control solution with a test solution containing a defined 
concentration of anaesthetic. The extent of inhibition by the anaesthetic was then 
expressed as a fraction of the mean of the value obtained in the control solution 
before and after anaesthetic application. Concentration-response curves were 
fitted to a modified Hill equation: 
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Equation 6.6 
 
I is the holding current at -20mV in the presence of the drug, Ic is the current in the 
absence of the drug, [VA] is the volatile anaesthetic concentration, Ki is the 
anaesthetic concentration at which inhibition is half maximal and h is the slope 
factor (Hill coefficient).  
 
6. Methods 
 87
6.1.5 Inside-Out Excised Patch Recordings 
 
Inside-out excised membrane patches of HEK293 cells transfected with either 
wild type (Kir6.2/SUR1) or Kir6.2-K185Q/SUR1 channels were obtained as 
described by Hamill and colleagues (Hamill et al., 1981). A patch pipette was 
moved toward the cell surface and attached to it. After formation of a gigaohm 
seal the pipette was rapidly withdrawn from the cell. This left a crescent shaped 
patch of cell membrane in the pipette lumen close to the tip with the former inside 
of the membrane facing now out towards the bath solution (Figure 6.3). The 
pipette was then carefully placed in the inflow stream of the test solutions to 
optimise the exposure of the membrane patch to drugs and to allow rapid 
exchange of solutions. To achieve this the pipette was positioned close to the 
mouth of a perfusion pipe that supplied the bath constantly with external solution. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Schematic diagram of patch clamp configuration 
For details see text. A pipette is moved toward the cell (left) to form a gigaseal 
(middle). To achieve the inside-out configuration the pipette is quickly withdrawn 
from the cell (right). 
Figure modified after Cahalan (1992) 
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Macroscopic inside-out currents were recorded from excised patches at a holding 
potential of 0mV and at 20-24°C in response to 700ms voltage ramps from -
110mV to +100mV. The pipette (external) solution contained (mM): 140 KCl, 1.2 
MgCl2, 2.6 CaCl2, 10 HEPES (pH 7.4 with KOH). The standard intracellular 
(bath) solution contained (mM): 107 KCl, 2 MgCl2, 1 CaCl2, 10 EGTA, 10 
HEPES (pH 7.2 with KOH; final [K+] ~140mM).  
All inside-out currents were filtered at 1kHz, sampled at 3kHz and analysed using 
Pulse/Pulsefit software (HEKA Elektronik, Lambrecht, Germany). The slope 
conductance was measured by fitting a straight line to the current-voltage relation 
between -20mV and -100mV (Figure 6.4): the average of 5 consecutive ramps 
was calculated in each solution. To control for rundown, that is the spontaneous 
decay of current flow through the channel (Trube and Hescheler, 1984; Hussain 
and Wareham, 1994), the control conductance was usually taken as the mean of 
that obtained in control solution before and after the application of the test 
compound.  
ATP concentration-inhibition curves for Kir6.2/SUR1 currents were fit to a 
modified Hill equation (Equation 6.7): 
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Equation 6.7 
 
G is the conductance in the presence of ATP, Gc is the conductance in the absence 
of ATP, [ATP] is the ATP concentration, IC50 is the ATP concentration at which 
inhibition is half maximal and h is the Hill coefficient (slope factor). Fits were 
obtained using Origin Pro software (Origin Lab Corporation, Northampton, MA, 
USA). 
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Figure 6.4: Determination of slope conductance 
The slope conductance was determined by fitting a straight line through the linear 
part of each original trace. To calculate the slope of this straight line a linear 
regression curve fit was performed using Pulse/Pulsefit software (HEKA 
Elektronik, Lambrecht, Germany).  
The straight line fit was based on the formula y = mx + b, where m is the slope of 
the line and b the intercept value.  
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6.2 Cell Injury Experiments 
 
To gain information about pathways involved in the development of disease 
processes or to increase our knowledge of mechanisms of action of therapeutic 
concepts several basic experimental strategies can be applied. Principally all these 
strategies involve either in vivo or in vitro models with each of them displaying 
specific advantages and disadvantage in addition to different degrees of 
complexity (Abdulla and Campbell, 1993; Stacey and Viviani, 2001). It remains 
the researcher’s responsibility to choose the right experimental approach to test an 
explicit hypothesis. In the following a short description will be laid out about the 
reasoning that led to the employment of neuronal glial cell co-cultures over other 
models in the present study before in the second part a detailed account of the 
used experimental protocol will be given. 
 
Whilst in vivo or whole animal models in neurobiology research have been found 
to be especially valuable to test complex integrated responses, in vitro (tissue or 
cell culture) models usually allow a more detailed analysis of pathways down to 
the molecular level. In neuroscience in particular three different cell culturing 
principles have emerged over the years to explore the specific involvements of 
mechanisms on an intercellular, cellular or subcellular level: These cultures 
include single cell, mixed cell or brain slice preparations (Abdulla and Campbell, 
1993; Gahwiler et al., 1997). 
Primary neuronal cultures although theoretically having the advantage of 
experimental results to be completely independent of secondary influences by 
other cell lines are nevertheless hampered by potentially significant shortcomings: 
Neurons in single cell culture are notoriously difficult to mature and their life span 
is reduced under such artificial conditions. Moreover, it has been found 
surprisingly challenging to obtain pure neuronal cultures to the extent that nearly 
all cultures remain contaminated to some degree with glial cells (Cestelli et al., 
1992; Abdulla and Campbell, 1993). Alternatively, and in addition to acute brain 
slice preparations, which are only short-lived, recently organotypic brain slice 
cultures have been developed (Gahwiler et al., 1997). These preparations have the 
advantage of containing more integrated networks, which come close to the in situ 
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situation. Organotypic brain slices can be generated from various brain regions 
and therefore display region-specific characteristics. They usually survive for 
several weeks. However, they have been found to be relatively susceptible to 
influences from their culturing environment. Additionally, it has been suggested 
that they might not be ideal for the investigation of death pathways since there is 
evidence for them to be more sensitive to excitotoxic stimuli than what was 
expected from acute slice experiments. Moreover, microglial cells, which are also 
present in these organotypic slices, have been found activated for some days to 
potentially influence cell injury mechanisms. Finally, in these preparations lactate 
dehydrogenase (LDH) isoenzymes have been demonstrated to show various 
degrees of maturation indicating an incomplete shift from anaerobic to aerobic 
glycolysis (Gahwiler et al., 1997). 
In the present study neuronal glial cell co-cultures were used because the presence 
of differentiated glial cells encourages neuronal maturation and makes culturing 
of neurons easier, most likely due to the release of growth factors. Additionally, 
this model has been shown to come closer to the physiological conditions in the 
brain than pure neuronal cultures but without displaying the drawbacks attributed 
to the complexity of the slice cultures (Abdulla and Campbell, 1993; Gahwiler et 
al., 1997). Neuronal glial co-cultures therefore represent an established and 
validated model used to investigate the mechanisms involved in hypoxic-
ischaemic brain injury (Goldberg and Choi, 1993). 
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6.2.1 Neuronal Glial Cell Co-Culture Preparation 
 
Neuronal glial cell co-cultures were prepared as described previously (Wilhelm et 
al., 2002). First glial cells were cultured. To obtain them 1-2 day old BALB/c 
mouse pups were anaesthetised with isoflurane and decapitated. Heads were 
immediately placed in ice-cold high sucrose-glucose solution (HSG) that was 
made from Hank’s balanced salt solution (HBSS, Gibco, Paisley, UK) enhanced 
with 4mM NaHCO3, 20mM sucrose, 30mM D-glucose and commercially 
available antibiotic-antimycotic solution (AAS, Gibco, Paisley, UK). 
Brains were removed from the skull and micro-dissected to get whole cerebral 
neocortices devoid of the hippocampus, basal ganglia and meninges. Neocortices 
were then immersed in 10ml of culture medium containing 0.05% trypsin and 
shaken at 37°C in a chamber containing an atmosphere of 5% CO2 and 95% air. 
After 50 minutes DNAse (20-30μl, Sigma, Poole, UK) was added. The solution 
was mixed for another 15 minutes before it was centrifuged at 1600rpm for 10 
minutes at 4°C. The supernatant was discarded. Glia cells were resuspended in 
culture medium that contained Eagle’s minimum essential medium supplemented 
with 20mM glucose, 26mM NaHCO3, 10% foetal bovine serum, 10% heat-
inactivated horse serum, 2mM glutamine (Sigma, Poole, UK), 10ng/ml murine 
epidermal growth factor (Gibco, Paisley, UK) and Antibiotic-Antimycotic 
Solution (AAS; Gibco, Paisley, UK) containing 100U/ml penicillin, 0.1mg/ml 
streptomycin and 0.25μg/ml amphotericin B. Finally the cells were plated at a 
density of 6.25x104 cells/cm2 on 4-well plates (Nunc, Roskilde, DK) and 
incubated at 37°C in humidified air enriched with 5% CO2. 
About 5 days after plating the cells reached confluence and were therefore ready 
to be used as culture ground for newly harvested neuronal cells. These neuronal 
cells were prepared in a similar procedure as the glial cells. They were obtained 
from the neocortices of foetal BALB/c mice at 14-16 days of gestation and plated 
onto the glial cell monolayer at a density of 1.25 Χ 105 cells/cm2. After 5 days of 
neuronal growth co-cultures were exposed for 48 hours to 10μM cytosine 
arabinoside (Sigma, Poole, UK) to stop glial cell proliferation. After 3 additional 
days of culturing and a total of 15+/-1 days neuronal glial cell co-cultures were 
ready for preconditioning experiments.  
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Cultures were assigned to one of the following protocols: Preconditioning, 
oxygen-glucose deprivation only (OGD) or naïve control. Cultures in the 
preconditioning group were exposed to either 1 MAC xenon, 2 MAC sevoflurane, 
or 0.01mM diazoxide for 2 hours in the presence or absence of the pKATP channel 
inhibitor tolbutamide (0.1mM) or the mKATP inhibitor 5-HD (0.5mM). The time 
course of the experiment is depicted in Figure 6.5. 
 
 
 
< 15 +/- 1 days  > 24h 24h         >                  <                  >                 <          
<   2h    > 75min >                            < 
Co-Culture           Preconditioning                  OGD                      MTT-Test
 
 
 
Figure 6.5: Time course of cell injury experiments 
Glial and neuronal cells were co-cultured for a total of two weeks before they 
underwent cell injury experiments. Some cultures (treatment groups) were 
exposed for two hours to a preconditioning stimulus (anaesthetics or diazoxide) 
24 hours before a damaging insult (oxygen-glucose deprivation; OGD). Cultures 
assigned to oxygen-glucose deprivation only (OGD group) underwent a media 
change 24 hours prior to OGD without preconditioning whereas naïve controls 
were just washed at the appropriate time points. 
Twenty-four hours after OGD cell viability was tested with 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction test (for details 
see text). 
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6.2.2 Preconditioning  
 
For the preconditioning experiments a model was used, that was previously 
established by Ma as well as Luo and colleagues (Ma et al., 2004; Luo et al., 
2008). 
Anaesthetic-enriched medium was obtained by bubbling xenon or sevoflurane for 
20 minutes through experimental medium containing Eagle’s minimal essential 
medium, 21.1mM glucose and 38mM NaHCO3 in a Drechsel bottle. This period 
was found to be sufficient to allow equilibrium between the gas phase and the 
liquid phase in the bottle as assessed by gas chromatography (Ma et al., 2003). 
Neuronal glial cell co-cultures were washed twice with HEPES-buffered solution 
(120mM NaCl, 5.4mM KCL, 0.8mM MgCl2, 15mM glucose and 2mM HEPES, 
titrated to pH 7.4 using 1M NaOH) and then incubated with anaesthetic-enriched 
medium, or with experimental medium containing 0.01mM diazoxide. The pKATP 
channel inhibitor tolbutamide (0.1mM) or the mKATP channel inhibitor 5-
hydroxydecanoate (5-HD, 0.5mM) were added to some dishes as appropriate. Co-
cultures were then transferred to an airtight, temperature-controlled gas exposure 
chamber.  
Preliminary experiments had established that xenon and sevoflurane needed a part 
of 75% and 3.3% respectively, of the surrounding gas atmosphere to achieve 
maximum preconditioning (Ma et al., 2006; Luo et al., 2008). If converted to the 
commonly used endpoint for inhalational anaesthetics - the minimum alveolar 
concentration (MAC), which is the concentration in the lungs that is able to 
prevent a purposeful response to painful stimuli (Campagna et al., 2003) - 75% of 
xenon and 3.3% sevoflurane in humans are equal to about 1 MAC and 2 MAC, 
respectively (Cullen et al., 1969; Behne et al., 1999). 
Furthermore the model validation found also a two-hour exposure period of the 
gases to the cultures to be sufficient to achieve maximal preconditioning (Ma et 
al., 2006). This was hence employed in the present study. 
To maintain a constant concentration of gases in the experimental solutions of the 
culture dishes during preconditioning the gases in the culture solutions had to be 
in equilibrium with the gas atmosphere in the airtight chamber. The gas flows 
necessary to achieve the respective atmospheric gas composition were determined 
6. Methods 
 95
by Ma and colleagues (Ma et al., 2003). The gas composition in the chamber for 
the xenon experiments consisted of 20% O2, 5% CO2 and 75% xenon (1 MAC). 
The gas composition in the sevoflurane experiments was 20% O2, 5% CO2, 71.7% 
N2 and 3.3% sevoflurane (2 MAC). The atmosphere in the chamber for diazoxide 
preconditioning consisted of 20% O2, 5% CO2 and 75% N2. After preconditioning 
the co-cultures were washed twice with HEPES-buffered solution and stored in 
culture medium in an incubator at 37°C in a humidified mixture of 5% CO2 and 
95% air. 
Co-cultures in the OGD group underwent the same protocol as the cultures in the 
preconditioning group except that instead of being exposed to HEPES-buffered 
solution containing the preconditioning drugs they were washed with HEPES–
buffered solution only. Cultures in the naïve control group received the same 
pattern of solution changes, but were not exposed to the preconditioning drugs or 
OGD. 
 
 
6.2.3 Oxygen-Glucose-Deprivation (OGD) 
 
Oxygen-glucose deprivation in neuronal glial cell co-cultures is an established 
model to investigate pathways and mechanisms of ischaemic brain injury 
(Goldberg and Choi, 1993). In preliminary studies by Ma and colleagues this 
model was further modified to meet the needs of our laboratory and was 
subsequently validated: For instance the time needed to induce maximal damage 
to neurons was determined and it was found that 60 minutes of OGD were needed 
to develop most significant injury. However extending OGD to up to 100 minutes 
did not achieve any further effect and hence 75 minutes of substrate deprivation 
were applied in the experiments of the present study (Ma et al., 2003; Ma et al., 
2004). 
Additionally, through the use of phase-contrast microscopy, Ma and colleagues 
also excluded a significant influence of OGD on the glial cells of the co-cultures 
(Ma et al., 2005) and therefore confirmed Goldberg’s data indicating that up to 6 
hours of OGD selectively harmed only neuronal cells (Goldberg and Choi, 1993). 
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In the present experiments twenty-four hours after preconditioning co-cultures 
assigned to the OGD group were washed twice with HEPES-buffered solution and 
once with pre-warmed OGD medium. OGD medium contained 116mM NaCl, 
5.4mM KCl, 0.8mM MgSO4, 1mM NaH2PO4, 1.8mM CaCl2 and 26mM NaHCO3 
and was bubbled with 5% CO2 and 95% N2 in a Drechsel bottle at 37°C. Cultures 
were then placed into an airtight gas exposure chamber with an anaerobic 
environment consisting of 5% CO2 and 95% N2 at 37°C for 75 minutes. Oxygen-
glucose deprivation was terminated by washing cultures twice with HEPES-
buffered solution before being incubated in culturing medium and stored at 37°C 
in a humidified atmosphere of 5% CO2 and 95% air.  
Finally, cell viability testing was performed 24 hours after OGD. This time point 
was chosen since Rajakumaraswamy and colleagues in accordance with Goldberg 
and colleagues had found the extent of the cell damage to be unchanged between 
6 and 24 hours after injury (Goldberg and Choi, 1993; Rajakumaraswamy et al., 
2006). 
 
 
6.2.4 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
Reduction Test 
 
The MTT reduction test is a quantitative measurement of cellular metabolic 
activity and therefore widely used for the assessment of cellular viability and cell 
proliferation (Berridge and Tan, 1993; Takahashi et al., 2002). In the presence of 
active mitochondrial and cytosolic redox systems the tetrazolium salts of 3-(4,5-
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) are reduced 
to intensely blue coloured formazans, which can be quantified in a 
spectrophotometer. The measured optical density corresponds directly to the 
viability of the cells in culture.  
 
Twenty-four hours after OGD neuronal-glial co-cultures were incubated for 2 
hours in 0.6ml phosphate-buffered saline with 0.5mg/ml MTT (Merck, Darmstadt, 
Germany) to allow uptake of MTT into the cells. After removing MTT from 
cultures, cells were dissolved and homogenised in 1ml dimethyl sulfoxide 
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(DMSO). 0.3ml of each sample was then transferred to one well of a 96-well 
plate. The optical density (OD) was measured in triplicates at 570nm in a MRX 
Microplate Reader (Dynex Technologies, Chantilly, VA, USA).  
The OD readings were then converted into normalised cell viability readings 
using the following equation:  
 
100
)OD(OD
)OD(ODC% ×−
−=
OGDcontrol
OGDdrug
via   Equation 6.8, 
 
where % Cvia is cell viability expressed in percent, ODdrug is the optical density 
reading of preconditioned cells, ODcontrol is the optical density reading of untreated 
naïve cells and ODOGD is the optical density reading of non-preconditioned cells, 
which were exposed to OGD only. Uninjured neurons in co-cultures would 
therefore express a Cvia of 100%, whereas a Cvia of 0% represents maximal 
neuronal damage. In preliminary experiments the possible damaging effect of test 
drugs on neuronal-glial cell co-cultures was assessed (Figure 7.19). Neuronal 
injury in those experiments was quantified by the amount of lactate 
dehydrogenase (LDH) released into the culture medium. LDH activity in each 
sample was determined spectrophotometrically (MRX Microplate Reader; Dynex 
Technologies, Chantilly, VA, USA) at room temperature using a standard 
colorimetric enzyme kit (Sigma 500 C; Sigma-Aldrich, Poole, UK). The degree of 
neuronal damage was shown to be proportional to the LDH activity in the sample 
(Wilhelm et al., 2002). 
 
 
6.3 Statistics 
 
Statistical analysis was performed using GraphPad Prism (GraphPad Software 
Inc. San Diego, California, USA). All data were expressed as mean +/- SEM. To 
test for differences between groups two-tailed unpaired t-test or one-way ANOVA 
followed by Tukey’s multiple comparison test were used as appropriate. A value 
of p < 0.05 was considered significant. 
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7. RESULTS 
 
 
7.1 Whole-Cell Patch-Clamp Experiments 
 
7.1.1 Potassium Current in Kir6.2/SUR1 Transfected HEK293 Cells 
 
Kir6.2 and SUR1 subunits as the predominant constituents of neuronal 
plasmalemmal KATP channels (Karschin et al., 1997; Liss and Roeper, 2001) were 
expressed in a HEK293 cell recombinant system. Successful expression of 
Kir6.2/SUR1 was confirmed morphologically as described in the methods (see 
chapter 6.1). In addition, electrophysiological determination of current 
characteristics also verified the presence of plasmalemmal KATP channels in 
transfected cells. 
Under voltage clamp conditions naïve HEK293 cells normally display a very 
small intrinsic membrane conductance (Gruss et al., 2004). This was also found in 
the current study where untransfected HEK293 cells showed whole-cell current 
amplitudes of 22+/-10pA at -20mV (n=12). This current could not be enhanced by 
the application of the specific KATP channel opener diazoxide (0.2mM; n=6). Only 
upon transfection with Kir6.2 and SUR1 500 times larger outward currents were 
recorded at -20mV, which also responded to diazoxide application (Figure 7.1).  
Also analysis of the zero-current potentials provided further evidence for the 
presence of neuronal type pKATP channels in transfected HEK293 cells. The zero-
current potential for Kir6.2 and SUR1 transfected HEK293 cells was –77+/-2mV 
(n=30), consistent with the fact that most of the whole-cell conductance was made 
up by KATP channels. In contrast, untransfected HEK293 exhibited a zero-current 
potential of –40+/-5mV (n=13). 
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Figure 7.1: K+-current of untransfected and transfected HEK cells 
Mean K+-current at a holding potential of -20mV of untransfected and 
Kir6.2/SUR1 transfected HEK293 cells. Diazoxide (Dz; 0.2mM) was bath applied 
to some cells. N-numbers are given above the bars. 
* indicates p < 0.05 compared to respective untransfected group. 
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Thirdly, the potential at which the drug-modified current changes its direction, the 
reversal potential, was determined for every experimental group each time an 
experiment was conducted. Reversal potentials served as a quality control to 
exclude currents other than potassium for analysis. They should be close to the K+ 
equilibrium potential (EK) as determined by the Nernst equation (see methods 
Equation 6.3).  
Experiments showing reversal potentials more negative than -105mV or more 
positive than -65mV were discarded. The average reversal potentials for each 
experimental group are shown in table 7.1. Their values were not significantly 
different. 
 
 
 
 
 
Table 7.1 
 
Reversal Potential (mV) 
 
n 
 
Xenon 
 
-80 +/- 3 
 
10 
 
Sevoflurane 
 
-83 +/- 3 
 
22 
 
Halothane 
 
-76 +/- 2 
 
22 
 
Isoflurane  
 
-77 +/- 2 
 
14 
 
Diazoxide 
 
-77 +/- 3 
 
10 
 
Tolbutamide 
 
-84 +/- 3 
 
10 
 
Washout 
 
-80 +/- 2 
 
12 
 
 
Table 7.1 shows the reversal potential of the current elicited or inhibited by the 
drugs indicated. No significant difference was observed between any of the 
treatment groups. The reversal potentials are not corrected for the liquid junction 
potential, which was determined as 4.0mV (see methods). 
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Finally, in HEK293 cells transfected with Kir6.2/SUR1 there was an increase of 
outward current during the first 5 minutes of whole-cell voltage-clamp recordings 
(Figure 7.2). It was then followed by a stable holding current of 1.05+/-0.12nA 
(n=30) (Figure 7.2A, B). The initial increase in current is a common phenomenon 
in whole-cell patch-clamp experiments involving pKATP channels and has been 
attributed to the washout of ATP from the cytosol and subsequent progressive 
opening of plasmalemmal ATP-sensitive K+ channels (Trapp et al., 1994). In 
support of this hypothesis, the stable holding current was reversibly inhibited by 
the specific pKATP channel blocker tolbutamide (0.1mM; n=17; Figure 7.2A,C).  
In summary, the expression of plasmalemmal KATP channels in the HEK293 cell 
system of the current study was suffienctly validated through the presence of 
increased current amplitudes, characteristic zero-currents and reversal potentials 
as well as observed washout currents. 
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Figure 7.2: Washout current 
(A) Whole-cell recording at a holding potential of -20mV from a HEK293 cell 
transfected with Kir6.2 and SUR1. The trace is taken from a sevoflurane 
experiment that will be explained in further detail below (Figure 7.6). It 
exemplifies the washout current between points i and ii. The dashed line indicates 
the zero-current level. Vertical deflections indicate the current response to a 
700ms voltage ramp from -20mV to -120mV. These current responses between 
points i and ii are shown in greater detail in (B). In (C) they were plotted against 
the command voltage to obtain current voltage relations. These demonstrate that 
the washout current has a reversal potential near the K+ equilibrium potential 
(EK). The plot further shows the sensitivity of the current to the selective pKATP 
channel inhibitor tolbutamide (Tb;0.1mM). 
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7.1.2 Lack of Modulation of pKATP Channels via Mitochondrial ATP-sensitive 
K+ Channels  
 
Studies, mostly on cardiomyocytes, have identified both pKATP and mKATP 
channels as key mediators of preconditioning. Independent of type and tissue 
distribution the initiating event of KATP channel-dependent protection is channel 
opening (O'Rourke, 2000a; Hanley and Daut, 2005). To what extend both 
channels contribute to organ protection and whether there are tissue differences 
remains still unclear. However, as reviewed by Zaugg and colleagues there is the 
possibility that both channels interact on a sub-cellular level. In this model 
mKATP channels are seen as central mediators that could activate pKATP channels 
as downstream end-effectors (Zaugg et al., 2003).  
To exclude such modulatory effects of mKATP channels on whole-cell channel 
activity in HEK293 cells a series of experiments with specific KATP channel 
openers and inhibitors were performed (see Table 5.9).  
Tolbutamide has become the standard Kir6.2/SUR1 pKATP channel antagonist 
because it closes the channel with high affinity but leaves Kir6.2/SUR2A 
unaffected (Table 5.9) (Ashcroft and Gribble, 2000; Gribble and Ashcroft, 2000; 
Gribble and Reimann, 2003a). Furthermore, Sato and colleagues demonstrated 
that 0.1mM of tolbutamide, which efficiently closes pKATP channels, had no effect 
on mKATP channels (Sato et al., 2006). As with tolbutamide for Kir6.2/SUR1, 5-
hydroxydecanoate (5-HD) at a concentration of 0.5mM is regarded as the 
prototypical inhibitor of mKATP channels (Table 5.9). In contrast, it has no effect 
on cardiac type pKATP channels (Jaburek et al., 1998; Sato et al., 1998; O'Rourke, 
2000a; Lebuffe et al., 2003). Therefore, in a first set of experiments we 
determined whether tolbutamide and 5-HD could suppress K+ currents in 
Kir6.2/SUR1 transfected HEK293 cells. Whilst 0.1mM tolbutamide (n=10) 
decreased current amplitude dramatically by 84+/-4%, no significant reduction in 
whole-cell current was observed using 0.5mM 5-HD (n=5) (Figure 7.3).  
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Figure 7.3: KATP currents in whole-cell recordings are not affected by specific 
blockers of mitochondrial ATP-sensitive K+ channels 
(A) Whole cell recording demonstrating the lack of effect of the mitochondrial 
KATP channel blocker 5-HD (0.5mM) on KATP channels made up of Kir6.2 and 
SUR1. In contrast, tolbutamide (Tb, 0.1mM) strongly and reversibly inhibited the 
whole-cell current. The drugs were applied as indicated by the bars above the 
recording. (B) Current-voltage relations in the absence (control) and presence of 
0.5mM 5-HD or 0.1mM tolbutamide. (C) Mean data from experiments as that 
shown in (A). N-numbers are given above the bars. * indicates p < 0.05. 
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Equivalent results were obtained when using KATP channel openers. Pinacidil has 
been shown to open mKATP and cardiac type Kir6.2/SUR2A pKATP channels 
(Table 5.9) (Shindo et al., 1998; Sato et al., 2006). In contrast, it has no effect on 
Kir6.2/SUR1 (Gribble et al., 1998b; Ashcroft and Gribble, 2000; Gribble and 
Reimann, 2003a). Therefore under conditions where Kir6.2/SUR2A channel types 
are absent - such as in neurons or in the heterologous HEK cell expression system 
of the present experiments - pinacidil at a concentration of 0.1mΜ can be assumed 
to be mKATP channel specific (O'Rourke, 2000b). In addition to pinacidil 
diazoxide has also been reported to open mKATP channels (Table 5.9) (Garlid et 
al., 1996; Garlid et al., 1997; Liu et al., 1998). However, in contrast to pinacidil it 
also activates KATP channels containing SUR1 with an EC50 of 30μM but has 
negligible effects on Kir6.2/SUR2A (Garlid et al., 1997; Liu et al., 1998; Lawson, 
2000; Dabrowski et al., 2003). Consequently, diazoxide is expected to be mKATP 
channel specific in systems that do not contain SUR1 (e.g. heart muscle).  
In the present study diazoxide at concentrations of 0.01mΜ (n=10) and 0.2mM 
(n=5) significantly increased whole-cell currents in HEK293 cells expressing 
Kir6.2 and SUR1 by 44% and 120%, respectively (Figure 7.4A). Since 0.1mΜ 
pinacidil (n=8) failed to show any effect in these experiments it is unlikely that 
opening of mKATP channels modulates pKATP currents (Figures 7.4A and 7.5). 
These results rather indicate a direct concentration-dependent effect of diazoxide 
on Kir6.2/SUR1 channels (Figures 7.4A). 
 
7. Results 
 106
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4: Whole-cell KATP currents are not affected by specific openers of 
mKATP channels 
(A) Mean effects of various K-channel openers on Kir6.2/SUR1 currents. 
Diazoxide (Dz) at concentrations of 0.01mM (Dz10) and 0.2mM (Dz200) 
increases K+-current significantly by 44+/-13% and 120+/-22%, respectively. In 
contrast, pinacidil (Pin; 0.1mM) increased the current only by 10+/-4%. This was 
not significantly different from baseline.  
(B) Diazoxide at 0.01mM increases the pKATP current independently of its 
potential effect on mKATP channels, as demonstrated by the lack of effect of the 
mKATP channel inhibitor 5-HD on the diazoxide activation of the whole-cell 
current. N-numbers are given above the bars. * indicates p < 0.05; ns denotes 
non significant results. 
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However, because diazoxide potently opened mitochondrial ATP-sensitive K+ 
channels in other studies it was further evaluated whether mKATP channel 
activation, and subsequent alterations in mitochondrial function, might contribute 
significantly to the KATP current seen with 0.01mM diazoxide (Garlid et al., 1996; 
Garlid et al., 1997; Liu et al., 1998). In order to test this hypothesis the KATP 
current was enhanced with 0.01mM diazoxide (n=4) and then 0.5mM 5-HD (n=4) 
was added. No significant reduction of the diazoxide-elicited current was 
observed under these conditions and the results established that 0.01mM 
diazoxide activates pKATP channels independently from its effects on mKATP 
channels (Figure 7.4B). Taken together these results provide strong evidence that 
the effects of inhalational anaesthetics on KATP whole-cell currents, which will be 
discussed below, are not secondary to an interaction of these drugs with 
mitochondrial ATP-sensitive K+ channels.  
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Figure 7.5: Pinacidil has no effect on whole-cell KATP currents 
(A) Whole-cell recording from a HEK293 cell expressing Kir6.2 and SUR1. 
Plotted is the mean holding current at -20mV every 15s. The SUR1-specific K+-
channel opener diazoxide (Dz; 0.01mM) as well as the mKATP channel specific 
opener pinacidil (Pin; 0.1mM) are applied as indicated by the solid bars. 
Diazoxide but not pinacidil potentiated the whole-cell current. (B) Current-
voltage relations demonstrating the lack of effect of pinacidil (0.1mM) on 
Kir6.2/SUR1 currents in HEK293 cells. 
 
7. Results 
 109
7.1.3 Evaluation of the Effects of Inhalational Anaesthetics on pKATP Currents 
 
Three different classes of inhalational anaesthetics were tested for their effects on 
Kir6.2/SUR1 channels. Xenon represented the noble gases with anaesthetic 
properties, halothane the hydrocarbons and isoflurane as well as sevoflurane the 
ethers (Campagna et al., 2003). Isoflurane and sevoflurane are standard drugs in 
daily anaesthetic practice whilst xenon is precluded from widespread use mainly 
because its high costs. Halothane in contrast is outdated clinically but still widely 
used experimentally (Sanders et al., 2003; Hecker et al., 2004). 
The addition of all tested volatile anaesthetics (halothane, isoflurane, sevoflurane) 
to the superfusate in the recording chamber reduced the KATP current reversibly in 
a concentration-dependent manner. This is exemplified for sevoflurane in Figure 
7.6.  
Interestingly this lack of activation of pKATP current by volatiles was seen at 
clinically relevant concentrations (Figure 7.7 and 7.8). Halothane for instance was 
given in a concentration range of 0.125–2.0mM which equates to 0.9-7.1 MAC 
whereas the range for isoflurane was 0.25–2.0mM (0.5-8.7 MAC) and that for 
sevoflurane 0.3-2.5mM (0.9-7.5 MAC) (Jenkins et al., 1999). Doses higher than 
maximum concentrations used in these experiments were applied in preliminary 
experiments but was found to damage the cells. 
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Figure 7.6: KATP channels expressed in HEK293 cells are mildly inhibited by 
sevoflurane  
(A) Whole-cell recording at a holding potential of -20mV from a HEK293 cell 
transfected with Kir6.2 and SUR1. Sevoflurane (Sev) and tolbutamide (Tb) were 
bath-applied as indicated by the horizontal bars. The dashed line indicates the 
zero-current level. Vertical deflections indicate the current response to a 700ms 
voltage ramp from -20mV to -120mV. (B) Current voltage relations taken from 
(A) showing the concentration-dependent small inhibition of the KATP current by 
sevoflurane (Sev) at clinically relevant concentrations, compared to the block by 
tolbutamide (Tb). 
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The tested volatile anaesthetics displayed different potencies in their inhibitory 
effect on pKATP channels composed of Kir6.2/SUR1. This is represented in Figure 
7.7 where equimolar concentrations of halothane, isoflurane and sevoflurane 
reduce whole-cell KATP currents to varying degrees. 
The difference in potency is also reflected in the concentration-response curves of 
each volatile (Figure 7.8). Halothane inhibited pKATP currents with an IC50 of 
1.3+/-0.4mM (n=4-8), isoflurane had an IC50 of 2.1+/-0.6mM (n=3-5), and the 
effect of sevoflurane was extrapolated to an IC50 of approximately 50mM (n=3-8).  
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Figure 7.7: Halogenated volatile anaesthetics inhibit pKATP channels  
(A) Whole-cell recording at a holding potential of -20mV from a HEK293 cell 
transfected with Kir6.2 and SUR1. The dashed line indicates the zero-current 
level. Halothane, isoflurane and sevoflurane (1mM each) were bath-applied as 
indicated by the horizontal bars. Each drug reversibly inhibited the whole-cell 
KATP current. (B) Current voltage relations taken from a recording as that shown 
in (A) demonstrating that the current inhibited by the volatile anaesthetics has a 
reversal potential near EK. 
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Figure 7.8: Concentration-response relationships of volatile anaesthetics on 
Kir6.2/SUR1 channels expressed in HEK293 cells 
Concentration-response curves of the inhibitory effect of (A) halothane (n=4-8), 
(B) isoflurane (n=3-5) and (C) sevoflurane (n=3-8) on whole-cell KATP currents. 
The current in presence of the drug (I) is expressed as a fraction of the current in 
its absence (IC). The solid lines describe the best fit with a modified Hill equation 
using Ki = 1.32mM and Hill coefficient (h) = 1.75 for halothane, Ki = 2.08mM 
and h = 1.39 for isoflurane and Ki = 47mM and h = 0.34 for sevoflurane. In each 
case it is assumed that complete inhibition of the pKATP current could 
theoretically be achieved with high enough concentrations of the anaesthetic. 1 
MAC is indicated by the vertical dashed line in each graph. 
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Next the effects of xenon were tested on pKATP currents. Xenon was applied at 
two concentrations: 50% and 80%. An 80% xenon solution is equivalent to 1 
MAC in humans or 3.4mM of xenon (White et al., 2005). Consequently, 50% 
xenon equates to 0.6 MAC and 2.1mM. HEK293 cells transfected with Kir6.2 and 
SUR1 showed an increase in outward current by 19+/-7% when superfused with a 
50% xenon solution (n=5) and by 44+/-7% (n=5) when exposed to 80% xenon 
solution as compared to control solution (80% N2; Figure 7.9). The reversal 
potential of this current (Figure 7.10B; Table 7.1) indicated it being a K+ current. 
Furthermore, the current was inhibited by 0.1mM tolbutamide (Figure 7.10). 
These results strongly suggest that the xenon-induced K+ current was due to the 
opening of Kir6.2/SUR1 channels.  
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Figure 7.9: Xenon activates KATP channels 
(A) Whole-cell recording froma a HEK293 cell transfected with Kir6.2 and SUR1 
demonstrating reversible activation of the current by 80% xenon. Xenon was 
applied as indicated by the horizontal bar. (B) Mean effects of the two test-
concentrations of xenon on the pKATP current at a holding potential of -20mV. (C) 
Mean affects of xenon (80%) on K+-currents at a holding potential of –20mV of 
transfected and untransfected cells. 
N-numbers are given above the bars. * indicates p < 0.05 compared to baseline; 
** indicates p < 0.01 as compared to untransfected control. 
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Figure 7.10: Tolbutamide reversibly inhibits pKATP currents in presence of 
xenon  
(A) Whole-cell recording from a HEK293 cell transfected with Kir6.2 and SUR1 
showing an activation of the K+-current by 80% xenon. Tolbutamide (Tb;0.1mM), 
even in the presence of xenon, reversibly inhibited the pKATP current. Xenon and 
tobutamide were applied as indicated by horizontal bars. 
(B) Current-voltage relations in the absence and presence of 80% xenon and 
xenon + 0.1mM tolbutamide (Tb). Xenon potentiated the pKATP current, whereas 
tolbutamide completely inhibited the current, even in the presence of xenon. (C) 
Mean data from experiments as depicted in (A). Mean holding current at -20mV 
in the presence of the drug expressed as a fraction of that in the absence of any 
drug. Xenon led to an increase in holding current and tolbutamide blocked both 
the xenon-potentiated current and the current in the absence of xenon (dashed 
line). N-numbers are given above the bars. * indicates p < 0.05 compared to 
groups exposed only to xenon. 
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7.1.4 Xenon-Induced KATP Channel Opening: Insights into Possible 
Mechanisms 
 
In the previous section xenon was established as an opener of plasmalemmal 
ATP-sensitive potassium channels. This conclusion was drawn from the following 
data: a) When applied at a concentration of 80%, which is the concentration that 
achieves anaesthesia in humans (Rossaint et al., 2003), xenon increased the 
outward current in Kir6.2/SUR1 transfected HEK293 cells by 49+/-8% (n=7) 
(Figure 7.12B). b) The reversal potential of this current indicated it to be a K+ 
current (Figures 7.10B and 7.11B). c) No increase in outward current in response 
to 80% xenon was observed when the current was pre-blocked with tolbutamide 
(n=7) (Figure 7.11A). d) 0.1mM tolbutamide were still capable of completely 
blocking K+-currents, even in the presence of xenon (Figure 7.10A). e) Xenon 
increased an outward current in Kir6.2/SUR1 transfected but not in untransfected 
HEK293 cells (n=6-8; Figure 7.11D). 
For comparison, the traditional KATP channel opener diazoxide was also tested at a 
concentration of 0.01mM (typically used for preconditioning) and at 0.2mM, a 
concentration routinely used to activate the channel in vitro. As expected, 
diazoxide increased the whole-cell Kir6.2/SUR1 current at both concentrations 
(Figure 7.12).  
 
However, from these results it was not possible to draw any conclusions as to how 
xenon might facilitate pKATP channel opening. Therefore in this section 
experiments are presented that were designed to shed some light into the 
mechanism of xenon induced KATP channel activation. For this two different 
electrophysiological approaches were used: The whole-cell patch clamp as well as 
the excised inside-out macro-patch technique. In the following the findings from 
the whole-cell recordings are described first. 
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Figure 7.11: Xenon induced outward K+-current is achieved by pKATP 
channel opening 
(A) Whole-cell recording at a holding potential (VH) of -20 mV from a HEK293 
cell transfected with Kir6.2 and SUR1 demonstrating the reversible activation of 
the current by 80% xenon and it’s preclusion by tolbutamide. The dashed line 
indicates the zero-current level. Xenon and tolbutamide (Tb;0.1mM) were bath-
applied as indicated by the horizontal bars. (B) Current-voltage relations 
demonstrating the activation of the pKATP current by xenon compared to the block 
by tolbutamide (C).  
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Figure 7.12: Effect of xenon, diazoxide and tolbutamide on pKATP currents  
(A) Whole-cell recording from a HEK293 cell expressing Kir6.2 and SUR1. 
Plotted is the mean holding current at -20mV applied every 15s. The SUR1-
specific K+ channel opener diazoxide (Dz) is applied as indicated by the solid 
bars. (B) Mean effects of the K-channel openers xenon and diazoxide on 
Kir6.2/SUR1 currents. Expressed is the holding current at -20mV in the presence 
of the drug as a fraction of the current in the absence of the drug. Xe+Tb: effect of 
xenon (80%) on current pre-blocked with tolbutamide (0.1mM). N-numbers are 
given above the bars.* indicates p < 0.05 as compared to control. # indicates p < 
0.05 as compared to lower drug concentration. 
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7.1.4.1 Xenon as KATP channel opener: A SUR1 independent process 
 
Since neuronal plasmalemmal KATP channels are built of Kir6.2 and SUR1 
subunits in a 4:4 stoichiometry (Clement et al., 1997; Inagaki et al., 1997; Shyng 
and Nichols, 1997), xenon can potentially interact with either of these components 
to induce channel opening.  
Normally both Kir6.2 and SUR1 carry a signal that prevents travelling of each 
component from the endoplasmic reticulum to the cell membrane on its own. 
Only co-expression of the two subunits masks that signal and allows trafficking to 
the cell surface (Schwappach et al., 2000). This signal, which has been termed 
endoplasmic reticulum retention signal, is present in the C-terminal region of 
Kir6.2 and in an intracellular loop between the 11th transmembrane region and the 
1st nucleotide-binding fold of SUR1 (Zerangue et al., 1999; Seino and Miki, 
2003). However, truncation of the C terminus of Kir6.2 with deletion of the last 26 
amino acids removes the retention signal. Such Kir6.2ΔC26 units form functional 
channels without the need to assemble with SUR1 (Tucker et al., 1997; Tucker 
and Ashcroft, 1998). This makes it possible to study the pharmacology of Kir6.2 
independently of SUR1. To address the question which subunit is essential for 
xenon induced pKATP channel opening, whole-cell experiments were performed in 
HEK293 cells expressing Kir6.2ΔC26 without SUR1. 
 
The results of these experiments showed that xenon increased K+ current through 
the truncated channel to the same extent as to the wild type channel (Figures 
7.13A and 7.14). In contrast diazoxide and tolbutamide, which both require the 
SUR1 subunit in order to open and close the channel, respectively, were 
ineffective (Figure 7.14). These results provided evidence that the SUR1 subunit 
is not required for xenon induced pKATP channel opening.  
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Figure 7.13: Xenon does not require the SUR1 subunit to activate KATP 
channels  
(A) Whole-cell recording from a HEK293 cell expressing Kir6.2ΔC26. Plotted is 
the mean holding current at -20mV every 15s. Xenon activates Kir6.2ΔC26 
currents. Note the enhanced rundown of current compared to channels containing 
the SUR1 subunit (Tucker et al., 1997; Trapp et al., 1998). Dashed line: 
approximation of slower phase of rundown. (B) Whole-cell recording from a 
HEK293 cell expressing Kir6.2-K185Q and SUR1. Tolbutamide (Tb;0.1mM) 
inhibited this current, but xenon failed to affect it. (C) Whole-cell recording from 
a HEK293 cell expressing Kir1.1. Shown is the mean current at a holding 
potential of –20mV every 15s. Xenon does not affect Kir1.1 activity. In contrast, 
barium chloride (1mM) inhibited the channel verifying the potential 
responsiveness of the channel in the HEK293 expression system. 
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Figure 7.14: Mean effect of xenon on Kir1.1 and Kir6.2 channel variants  
Mean data from experiments with Kir6.2ΔC26, Kir6.2-K185Q/SUR1 and Kir1.1 as 
shown in Figure 7.13. Note the lack of effect of tolbutamide (Tb) and diazoxide 
(Dz) on Kir6.2ΔC26 currents.  
N-numbers are given above the bars. * indicates p<0.05 as compared to control. 
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7.1.4.2 Kir6.2 activation by xenon: ATP sensitivity critically involved  
 
After it was established that xenon interacts with Kir6.2 to induce pKATP channel 
opening the question remained by what mechanism this stimulating effect was 
achieved. Given that Kir6.2 is inhibited by ATP it seemed plausible to hypothesise 
an interference of xenon with the inhibitory action of ATP to aid channel 
activation. This essentially implies pKATP channel disinhibition by xenon as its 
underlying mechanism of action. However such a mechanism would be reliant on 
the presence and activity of ATP at Kir6.2. It can consequently be expected, that 
any reduction of the sensitivity of the channel pore to ATP should also reduce the 
effect of xenon. 
Recently mutations of Kir6.2 have been employed to reduce its sensitivity to ATP 
(Tucker et al., 1997; Tucker et al., 1998). Since the nucleotide exerts its effect 
from the cytoplasmic site onto the channel, it became feasible to postulate an 
interaction with the intracellular termini of Kir6.2. Therefore the mutations were 
directed towards the N- and C-terminus of Kir6.2 (Tucker et al., 1998; Proks et al., 
1999). However, although most of the channel mutations maintained channel 
function, channel characteristics - especially channel open probabilities - were 
often considerably altered (Trapp et al., 1998; Tucker et al., 1998). In this regard 
the exchange of the positively charged lysine to the negatively charged glutamine 
at position 185 at the C-terminal end of Kir6.2 has been shown to be exceptional: 
This mutation (Kir6.2-K185Q) displays a markedly reduced sensitivity to ATP 
because of a disrupted interaction with the β-phosphate of the nucleotide 
(Reimann et al., 1999; Trapp et al., 2003). However, channel function as well as 
channel open probability are maintained, thus excluding changes in ligand-
sensitivity secondary to intrinsic gating (Trapp et al., 1998; Tucker et al., 1998).  
When co-expressed with SUR1 in the present study this channel (Kir6.2-K185Q/ 
SUR1) expressed large whole-cell currents, but addition of 80% xenon had no 
significant further effect (Figure 7.13B). It increased the current at -20mV by 7+/-
3% (n=6; Figures 7.14). In contrast, diazoxide (n=4) enhanced and tolbutamide 
(n=5) inhibited these whole-cell currents (Figure 7.14). 
These results implicate that a loss of ATP-sensitivity of Kir6.2 leads also to a loss 
of xenon’s ability to induce channel opening. Furthermore, these results also add 
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further evidence that xenon mediated activation - unlike that of diazoxide - is 
independent of the SUR subunit. 
Since ATP is a strong inhibitor of Kir6.2 it could be argued that xenon’s effect is 
state dependent, relying on a closed channel conformation. However, the results 
of experiments where the channel was pre-blocked with tolbutamide (Figure 7.11) 
do not support this hypothesis. If xenon’s mechanism of action were to be 
dependent on a closed channel state pre-blocking with tolbutamide should have 
magnified the xenon effect. These results support the findings with Kir6.2-
K185Q/SUR1, arguing for a xenon induced ATP disinhibition at Kir6.2. 
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7.1.4.3 Specificity of involvement of ATP: Xenon does not affect Kir1.1 
 
In order to explore whether xenon stimulated KATP channel opening relies 
specifically on the presence and action of ATP at Kir6.2, another inward rectifier 
K+ channel was exposed to xenon. For those experiments Kir1.1 was chosen 
because it shares significant sequence identity with Kir6.2. In addition Kir1.1 is the 
only inward rectifier outside the Kir6.x subfamily that is also inhibited by ATP, 
albeit in the millimolar range (Ho et al., 1993; Vanoye et al., 2002; Haider et al., 
2007a).  
When expressed in HEK293 cells, Kir1.1 exhibited whole-cell currents of 672+/-
96pA (n=8) at -20mV. The addition of 80% xenon did not enhance those currents 
(Figure 7.13C and 7.14) but decreased the amplitude marginally by 4+/-9% (n=4).  
In contrast and as expected Kir1.1 was sensitive to BaCl2, that blocked the channel 
by 80+/-6% (n=4) (Figure 7.13C and 7.14) (Bhandari and Hunter, 2001). Kir1.1 
was also not affected by 0.1mM tolbutamide (99+/-1% of control current 
remaining; n=5; Figure 7.14). 
Since xenon does not activate another inwardly rectifying K+ channel (Kir1.1), 
which has an intrinsically low affinity to ATP, and since xenon loses its channel 
opening properties once the ATP sensitivity of Kir6.2 is reduced, it is feasible to 
suggest that the xenon induced KATP channel activation is specifically linked to an 
ATP-dependent mechanism. 
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7.2 Inside-Out Macropatch Experiments 
 
The results presented so far demonstrate that the SUR1 subunit of plasmalemmal 
KATP channels is not essential for xenon activation and that activation is not 
universal between inwardly rectifying K+ channels. The results further suggest 
that the effect of xenon in contrast to that seen with the prototypical K+ channel 
opener diazoxide requires the integrity of ATP-inhibition on pKATP channels in 
order to stimulate K+ currents. However, these results do not exclude a possible 
interaction of xenon with intracellular pathways such as mitochondrial 
metabolism and subsequent reduction of ATP concentration within the cell which 
then in turn causes an increase in KATP currents. Consequently, inside-out patch-
clamp recordings were used to separate the pKATP channels from potential 
influences of either cell metabolism or intracellular signalling cascades. This 
technique also allows the direct exposure of pKATP channels to defined ATP and 
test-drug concentrations to further explore the relation between ATP-inhibition 
and xenon-activation of KATP currents. 
 
 
7.2.1 Xenon Interaction with Kir6.2: The Critical Role of ATP  
 
In the previous section it was described how mutations at the C- or N-terminal 
cytoplasmic endings of Kir6.2 could reduce the channel’s sensitivity to ATP. With 
the help of those mutations it was subsequently possible to identify and model the 
binding site of ATP on Kir6.2 (Trapp et al., 2003; Antcliff et al., 2005). Part of 
this binding site is lysine at position 185 on the C-terminus (Tucker et al., 1997; 
Tanabe et al., 1999a). Mutations in this position, for instance lysine to glutamine 
(K185Q) as used in the present study, will therefore reduce the sensitivity of 
Kir6.2 to ATP. This is because the mutation is suggested to impair the ability of 
the β-phosphate of ATP to interact with the channel protein (Trapp et al., 2003). 
If such a mutation with reduced sensitivity to ATP would also show diminished 
responsiveness to xenon, even under excised patch conditions, that would further 
strengthen the hypothesis that the xenon effect on pKATP channels is crucially 
dependent on ATP. 
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Figure 7.15: ATP inhibition of wild type but not Kir6.2-K185Q/SUR1 
currents 
(A) Inside-out patches excised from a HEK293 cell expressing Kir6.2/SUR1 
revealed macroscopic inwardly rectifying ATP-sensitive currents under 
symmetrical K+ concentrations. (B) Mean slope conductance in the presence of 
ATP expressed as a fraction of the current in the absence of ATP. ATP-inhibition 
was concentration-dependent in the wild type and absent in the Kir6.2-
K185Q/SUR1 mutant. N-numbers are given above the bars. * indicates p<0.05 
compared to Kir6.2/SUR1. ** indicates p<0.01 compared to Kir6.2/SUR1. 
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Figure 7.15A shows typical current-voltage relations for Kir6.2/SUR1 currents in 
inside-out macropatches. The wild type Kir6.2/SUR1 current was highly sensitive 
to ATP, with 0.05mM ATP inhibiting the current by ~70% and 1mM ATP 
causing virtually complete inhibition. In contrast, Kir6.2-K185Q/SUR1 currents 
were not reduced by 0.05mM or 1mM ATP (Figure 7.15AB). These results 
verified the effectiveness of the K185Q mutation on ATP sensitivity of Kir6.2. 
Similar to what was found in whole-cell experiments, xenon enhanced wild type 
Kir6.2/SUR1 currents, but not mutant Kir6.2-K185Q/SUR1 currents (Figure 7.16). 
This distinctiveness also remained at various ATP concentrations (Figure 7.16 and 
7.17): In the nominal absence of ATP xenon did not activate Kir6.2-K185Q/SUR1 
currents but was still able to increase the slope conductance of the Kir6.2/SUR1 
current by about 20%, although this was significantly less than found in the 
presence of ATP (Figure 7.17B). In the presence of 0.05mM ATP xenon 
enhanced wild type currents by more than 50% (Figure 7.17B). This is 
comparable to the situation in whole-cell recordings where similar increases were 
achieved by xenon. In contrast, xenon had no effect on Kir6.2-K185Q/SUR1 
currents (Figure 7.17B).  
Since the results of these inside-out patch-clamp experiments were similar to what 
was demonstrated in whole-cell experiments, they also support the idea that 
xenon-induced with KATP channel opening is critically dependent on the presence 
of ATP.  
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Figure 7.16: Xenon enhances wild type but not Kir6.2-K185Q/SUR1 currents 
(A) Xenon enhanced Kir6.2/SUR1, but not Kir6.2-K185Q/SUR1 currents in the 
presence of 1mM ATP. (B) In contrast, the Kir6.2-K185Q/SUR1 current was 
increased by 1mM ATP due to Mg-ATP-dependent refreshment, i.e. reconstitution 
of a greater and stable channel conductance that was previously diminished by 
rundown (Tucker et al., 1997; Xie et al., 1999b). However, xenon could exert no 
further effect. 
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Figure 7.17: Xenon increases Kir6.2/SUR1 currents at various ATP 
concentrations 
(A) Xenon enhanced Kir6.2/SUR1 currents in the presence of 0.1mM ATP. (B) 
Xenon enhancement of the wild type channel was reduced in the absence of ATP 
and it was abolished in the Kir6.2-K185Q mutant both in the absence and in the 
presence of 0.05mM ATP. N-numbers are given above the bars. ** indicates 
p<0.01 compared to Kir6.2/SUR1 in presence of 0.05mM ATP. 
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7.2.2 Xenon and ATP: Evidence for a Competitive Antagonism 
 
The final experiments were conducted to further clarify the nature of the 
interference of xenon with ATP at the pKATP channel. For this purpose 
concentration-response relationships of ATP on Kir6.2/SUR1 were constructed in 
the absence or presence of 80% xenon. Also, to minimize a theoretical influence 
of an ATP effect on SUR1 as a contributing factor to channel opening, recordings 
were performed in Mg2+-free solutions (Gribble et al., 1998a). Data showed a 
parallel shift of the ATP concentration-inhibition curve to the right when xenon 
was added (Figure 7.18). This was reflected by an increase of the Ki of ATP from 
26+/-4μM (n=5) in the absence to a Ki of 96+/-6μM (n=6) in the presence of 80% 
xenon. These results therefore showed a reduced potency of the inhibitory action 
of ATP at Kir6.2/SUR1 in the presence of xenon, which is suggestive of a 
competitive interaction of xenon with ATP at the pore-forming subunit Kir6.2. 
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Figure 7.18: Concentration-response effect of ATP in the absence and 
presence of xenon 
ATP concentration-inhibition curves for Kir6.2/SUR1 currents in the absence of 
MgCl2. Experiments were performed either in the absence (open circle) or 
presence of 80% xenon (filled circle). Solutions containing ATP were alternated 
with ATP-free solutions. Slope conductance (G) in the presence of the drug is 
expressed as a fraction of the slope conductance in its absence (Gc). The slope 
conductance was determined between -20 and -100mV and is the mean of five 
voltage ramps. The lines are the best fit to the data using a modified Hill equation 
(Equation 6.7). 
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7.3 Anaesthetic Preconditioning: Functional Relevance of pKATP Channel 
Opening  
 
The establishment of halothane and isoflurane as potent pKATP channel inhibitors 
in the present study made them unlikely candidates for any neuronal 
preconditioning that is dependent on pKATP channel opening. Therefore they were 
not further tested in a functional preconditioning assay. Sevoflurane in contrast 
exhibited only minor channel inhibitory properties in the heterologous HEK cell 
expression system. However, to what degree the sevoflurane induced channel 
inhibition had consequences for sevoflurane preconditioning remained elusive. 
Therefore experiments investigating the pKATP channel dependence of sevoflurane 
induced preconditioning were conducted. In addition the functional relevance of 
xenon’s newly established pKATP channel opening properties were investigated in 
these experiments as well.  
The final part of the present study was therefore designed to analyse the role of 
KATP channels in preconditioning induced by xenon and sevoflurane using 
oxygen-glucose-deprivation (OGD) in neuronal-glial co-cultures as an in vitro 
model of ischaemic brain injury. In this model 70 to 80 minutes of OGD was 
sufficient to maximally damage neurons, with glial cells being left largely 
unharmed (Ma et al., 2004; Rajakumaraswamy et al., 2006). The extent of the 
injury was found to remain unchanged from 6 to 24h after OGD with no further 
evidence for either a delayed second burst of damage or repair mechanisms taking 
place (Ma et al., 2004). In preliminary experiments it was also determined that the 
pKATP channel openers and inhibitors used in the preconditioning experiments had 
no intrinsic damaging effect on neuronal-glial co-cultures (Figure 7.19). 
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Figure 7.19: No damaging effect of KATP channel openers and inhibitors on 
neuronal-glial cell co-cultures 
Direct damaging effects of test drugs on neuronal-glial co-cultures were excluded 
in preliminary experiments. 
Neuronal-glial co-cultures were exposed for 2 hours to either the KATP channel 
opener diazoxide (Dz; 0.01mM) or to the channel inhibitors tolbutamide (Tb; 
0.1mM) and 5-HD (0.5mM). Cell damage was unchanged compared to naïve 
control (C) but significantly less compared to co-cultures exposed to oxygen-
glucose deprivation (OGD). 
Cell damage was assessed through the amount of lactate dehydrogenase (LDH) 
released from the cells into the culture medium (see methods). LDH 
concentrations were determined spectrophotometrically. Optical density (OD) is 
given in arbitrary units. Cell damage is proportional to the OD reading. 
** indicates p<0.01 compared to control. N-numbers are given above the bars.  
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Figure 7.20: Neuronal-glial cell culturing and preconditioning experiment 
(A) Phase-contrast microscopical image under 120x magnification of a typical 
neuronal-glial co-culture ready for use in preconditioning experiments. Clearly 
visible are intact neurons (arrow) on a dense layer of glial cells. 
(B) Representative raw data of different preconditioning experiments (1-6). Cell 
viability was assessed with 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) reduction test and expressed in arbitrary units of 
optical density reading. Viability (survival) is proportionate to OD with a low 
reading being indicative for cellular damage. 
C: naïve control cultures; OGD: co-cultures exposed to oxygen-glucose 
deprivation; Xe: xenon treated cultures; Xe+Tb: cultures exposed to xenon and 
tolbutamide; Xe+5HD: cultures exposed to xenon and 5-HD 
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Exposure to the anaesthetics xenon or sevoflurane, or to the potassium channel 
opener diazoxide 24 h prior to the OGD insult, effectively prevented neuronal cell 
loss (survival: 80-100%; Figure 7.21). The addition of the pKATP channel inhibitor 
tolbutamide to the xenon group during preconditioning completely abolished the 
protective effect of xenon (Figure 7.21A). Xenon’s protective effect was also 
slightly reduced by the addition of the mKATP channel inhibitor 5-
hydroxydecanoate (5-HD). Although statistically significant, the reversal was not 
complete since cell viability remained high in cultures treated concomitantly with 
xenon and 5-HD (Figure 7.21A). In contrast, the preconditioning effect of 
sevoflurane could not be reversed with either the pKATP channel inhibitor 
tolbutamide or the mKATP channel inhibitor 5-HD (Figure 7.21B). Finally, 
diazoxide preconditioning was completely abolished by 5-HD and to a slightly 
lesser extent by tolbutamide (Figure 7.21C). Diazoxide, at a concentration of 
0.01mM, is widely seen as specific for mKATP channels (Garlid et al., 1996; 
Garlid et al., 1997). However, this is only true for cardiac tissue where KATP 
channels have a SUR2A subunit. The SUR1 subunit of neuronal pKATP channels 
has also been shown to respond to diazoxide (Dabrowski et al., 2003). These 
findings were supported by the results of whole-cell recordings in the present 
study (Figures 7.4, 7.5 and 7.12). Thus it is not surprising that the preconditioning 
effect of diazoxide was sensitive to the pKATP channel blocker tolbutamide as well 
as the mKATP channel antagonist 5-HD, suggesting a role for both channels. 
These results indicated that opening of plasmalemmal KATP channels, but not 
mKATP channels, is essential for neuronal preconditioning by xenon, and 
demonstrated that sevoflurane preconditioning does not involve the opening of 
either plasmalemmal ATP-sensitive K+ channels or mKATP channels. The clear 
pKATP channel-dependence of xenon preconditioning and the lack of KATP channel 
involvement in sevoflurane preconditioning were consistent with the results from 
of the electrophysiological experiments. Therefore these results suggest that 
xenon’s pKATP channel opening properties are functionally important for its 
neuroprotective actions. In contrast, this study provides evidence that sevoflurane 
preconditions via other, not yet determined, pathways. 
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Figure 7.21: Preconditioning by xenon but not sevoflurane involves KATP 
channels 
(A), (B) and (C) show the mean +/- SEM data for preconditioning experiments. 
Cell viability was measured with MTT as optical density (O.D.) at 570nm. The 
‘normalised effect’ describes the relative viability compared to maximal damage 
(OGD only, no preconditioning) and maximal survival (no OGD; naïve cultures). 
100% cell viability therefore represented the viability observed in naïve cultures 
at the end of the protocol, whereas 0% cell viability indicated the viability found 
in cultures exposed to OGD only. (A) Xenon preconditioning (Xe; 1MAC) is 
abolished by the KATP channel inhibitor tolbutamide (Xe+Tb; 0.1mM), but not the 
mKATP channel blocker 5-HD (0.5mM). (B) Sevoflurane (Sev; 2MAC) effectively 
preconditions, however this effect is not significantly reduced by tolbutamide (Tb) 
or 5-HD. (C) Preconditioning by the KATP channel opener diazoxide (0.01mM) is 
blocked by either tolbutamide or 5-HD. N-numbers are given above the bars. * 
indicates p<0.05, ** indicates p<0.01 compared to groups only treated with 
either xenon or diazoxide, respectively. 
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8. DISCUSSION 
 
8.1 Anaesthetic Effects on Recombinant Neuronal Plasmalemmal KATP 
Channels 
 
This is the first study to show that the noble gas xenon opens plasmalemmal ATP-
sensitive K+ channels whereas the volatile anaesthetics halothane, isoflurane and 
sevoflurane were established as pKATP channel inhibitors. It was further 
demonstrated that the pKATP channel opening effect of xenon is mediated via its 
interaction with the pore forming Kir6.2 rather than the regulatory SUR1 channel 
subunit. For this interaction not only the presence of ATP was found to be 
essential but data also indicated a direct competition of xenon with ATP at the 
channel’s ATP binding site. From these results it can therefore now be 
hypothesised that xenon induced pKATP channel opening is caused by a 
disinhibiton of Kir6.2 from ATP. 
 
 
8.1.1 Contribution of Mitochondrial KATP (mKATP) Channels 
 
Recent research has suggested the possibility that mitochondrial KATP channels, 
could interfere with the activity of plasmalemmal KATP channels (Zaugg et al., 
2003).  
Two different pathways could achieve mKATP channel induced pKATP channel 
opening: The first is mediated via intracellular signalling cascades whereas the 
second involves changes of intracellular ATP concentration.  
Nitric oxide (NO), reactive oxygen species (ROS) and protein kinase C (PKC) 
amongst others have been suggested as mediators of those pathways between 
mKATP and pKATP channels (Zhuo et al., 2005). For instance opening of mKATP 
channels has been proposed to induce NO and ROS generation as well as PKC 
translocation (Lebuffe et al., 2003; Xi et al., 2005; Roth et al., 2006). In this 
pathway ROS are located up-stream from PKC, which in turn increases K+ 
conductance of cardiac and pancreatic type pKATP channels by increasing the 
channel open probability (Light et al., 2000; Juhaszova et al., 2004; Jung et al., 
8. Discussion 
 139
2004). NO on the other hand can independently induce both mKATP and pKATP 
channel opening. The effect on vascular smooth muscle type (Kir6.2/SUR2B) and 
likely also on neuronal type pKATP channels has been suggested to be mediated 
via a mitogen-activated protein kinase pathway whereas opening of mKATP 
channels in cardiomyocytes is achieved via a cGMP-protein-kinase G mechanism 
(Lin et al., 2004; Oldenburg et al., 2004). However, mKATP channel opening 
through NO might also induce the described ROS and PKC dependent cascade 
with the subsequent opening of pKATP channels (Zaugg et al., 2003). 
In addition to the interaction of mKATP and pKATP channels via signalling 
cascades it has also been suggested that mKATP channel activity might influence 
opening of pKATP channels via regulation of mitochondrial oxidative 
phosphorylation and hence cellular ATP production. This hypothesis is supported 
for example by data showing that myocardial pKATP channels are directly 
regulated via cytosolic ATP that was predominantly produced through oxidative 
phosphorylation in the mitochondria (Knopp et al., 2001). 
If in contrast ATP hydrolysis would occur in mitochondria instead of ATP 
production, the cytoplasmic ATP concentration could be expected to drop. 
Subsequently, plasmalemmal ATP-sensitive K+ channels as the archetypal ATP 
sensors would likely become activated, which would be followed by an increased 
outward K+ current (Ashcroft and Trapp, 2001; Sasaki et al., 2001). Mitochondrial 
ATP hydrolysis has been suggested to occur if the inner mitochondrial membrane 
is depolarised as a consequence of increased potassium influx through mKATP 
channels. Furthermore, inner mitochondrial membrane depolarisation has also 
been suggested to directly reduce ATP production via inhibition of oxidative 
phosphorylation (Holmuhamedov et al., 1998). Therefore activation of mKATP 
channels is hypothesised to lead to mitochondrial uncoupling with the 
consequence of reduced ATP production (Kopustinskiene et al., 2003). 
Any significant interaction between mKATP and pKATP channels in the 
heterologous HEK293 cell system of the present study could be expected to be 
reflected in an increased K+ current measured in whole-cell patch clamp 
recordings in response to the addition of the mKATP channel opener pinacidil. 
Conversely, the mKATP channel inhibitor 5-HD should be able to reduce K+ 
current. However, our observation that neither pinacidil nor 5-HD had any effect 
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on the activity of plasmalemmal KATP channels, indicates that modulation of 
mKATP channels cannot influence pKATP channels in our system. Thus the 
observed effects of anaesthetics on these channels cannot be explained by an 
indirect effect via mKATP channels. 
 
 
8.1.2 Direct Anaesthetic Effects on Plasmalemmal KATP Channels 
 
One exciting finding of the present study was that the noble gas xenon was able to 
open KATP channels in whole-cell patch-clamp experiments. So far in the search 
for the mechanisms of the anaesthetic actions of xenon its effects on some ion 
channels had already been investigated (for reviews see Sanders (Sanders et al., 
2003) and Preckel (Preckel et al., 2006)). However in most cases xenon was 
incapable of influencing the current through the channels in question. De Sousa 
and colleagues for instance found xenon to be ineffective on GABAA, alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or kainate 
receptors (de Sousa et al., 2000). In addition Stowe as well as White and 
colleagues could not find evidence in their experiments for xenon being able to 
alter current flow through Na+ or L- and N-type Ca2+ channels (Stowe et al., 2000; 
White et al., 2005). 
These data would have easily led to the suggestion that xenon is unlikely to be 
capable of interacting with ion channels in keeping with its role as an inert gas. In 
contrast and as early as these ‘negative’ results there have also been reports of 
xenon as having inhibitory properties on some channels. Suzuki for example 
demonstrated the inhibition of neuronal type nicotinic acetylcholine receptors by 
xenon in voltage-clamp experiments (Suzuki et al., 2003). However, the so far 
most important finding in the search to uncover the mechanisms of xenon-induced 
anaesthesia was its establishment as N-methyl-d-aspartate (NMDA) receptor 
antagonist by de Sousa in 2000 (de Sousa et al., 2000). This antagonistic effect 
was later shown by Dickinson to be mediated through the interaction of xenon 
with the glycine-binding site at the NMDA receptor (Dickinson et al., 2007). 
Xenon’s effect on K+ channels has also been investigated recently: In the above 
described publication by Stowe and colleagues the authors looked at the actions of 
8. Discussion 
 141
xenon on inward rectifying K+ currents in isolated cardiomyocytes (Stowe et al., 
2000). Although they found that xenon was ineffective in altering K+ currents in 
their experiments, the study was hampered by the fact that it did not distinguish 
between the different types of inwardly rectifying potassium channels. This is 
especially important in the heart since at least three different Kir subfamilies (Kir2, 
Kir3 and Kir6) have been described in myocardial cells (Ehrlich, 2008). Stowe’s 
results therefore most likely reflect a net-effect of xenon on the various cardiac 
type inwardly rectifying K+ channels. 
First evidence that xenon might be able to influence K+ currents came from 
whole-cell patch-clamp experiments in human cardiomyocytes. In those 
preparations Hueneke and colleagues demonstrated a small inhibitory effect of 
xenon on voltage-gated K+ channels (Huneke et al., 2001). Furthermore, Gruss 
and colleagues investigated xenon’s action on 2-pore-domain potassium channels 
and found subtype specific xenon effects (Gruss et al., 2004). Whilst xenon was 
unable to alter TASK-3 currents, the authors were able to demonstrate xenon 
dependent activation of TREK-1 channels. Therefore their results provided the 
first evidence that xenon is able to open K+ channels. The current results with 
xenon enhancing current flow through pKATP channels advance Gruss’ findings to 
another family of potassium channels.  
The physiological role of this newly discovered K+ channel opening in the context 
of xenon induced preconditioning will be discussed in detail below. 
In contrast to xenon the volatile anaesthetics halothane, isoflurane and sevoflurane 
failed to activate plasmalemmal KATP channels. In fact, dose dependent inhibition 
was observed. At 1 MAC halothane and isoflurane inhibited pKATP channels 
mildly but more substantially than sevoflurane at higher concentrations. These 
results were similar to what has been described previously for the effects of 
barbiturates: At supra-clinical concentrations they are capable of inhibiting 
neuronal KATP channels (Ohtsuka et al., 2006). Indirect evidence that halothane 
might act as an inhibitor of KATP channels came also from experiments with likely 
Kir6.2/SUR2B involvement: Larach and colleagues instead of reversing halothane 
induced smooth muscle relaxation with the KATP channel inhibitor glybenclamide 
found an increased effect (Larach and Schuler, 1993). These results were later 
supported by Fukushima and colleagues who found no evidence that smooth 
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muscle relaxation through halothane is mediated by KATP channel opening 
(Fukushima et al., 1996). More direct evidence for halothane and isoflurane being 
inhibitors of KATP channels was provided by studies of Roscoe and Han, 
respectively. They found a reduction of KATP currents in whole-cell patch-clamp 
experiments in cardiomyocytes in keeping with inhibitory effects of both agents 
on cardiac type pKATP channels (Han et al., 1996; Roscoe et al., 2000) 
Furthermore, a recent study investigating the acute effects of 4% sevoflurane on 
the membrane potential of hippocampal CA1 pyramidal cells also failed to see an 
activation of neuronal type KATP channels despite the fact that hypoxia elicited 
such a hyperpolarisation, which was also enhanced after preexposure to 
sevoflurane (Wang et al., 2007b). These results probably reflect our finding that 
sevoflurane is able to precondition, but not in a KATP channel dependent manner.  
Inhibition by halogenated anaesthetics might be a general feature of inwardly-
rectifying K+ channels as several members of this ion channel family were 
inhibited to varying degrees by these agents (Yamakura et al., 2001). In the case 
of the KATP channel the SUR subunit might have an additional modulatory 
influence on the anaesthetic sensitivity as Bienengraeber and colleagues reported 
that the SUR2A subunit of cardiac plasmalemmal KATP channels conferred 
isoflurane activation of the K+ current under acidic conditions (Bienengraeber et 
al., 2006). 
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8.1.3 Mechanism of Xenon-Induced Plasmalemmal KATP Channel Opening 
 
In the previous section the data was discussed that established xenon as an opener 
of plasmalemmal KATP channels. It was further argued that mitochondrial KATP 
channels do not contribute to xenon induced pKATP channel opening. However 
from this data the mechanism of interaction of xenon with Kir6.2/SUR1 could not 
be deduced. This will be done in the following section using the results of further 
whole-cell and excised patch electrophysiology experiments. 
 
 
8.1.3.1 Kir6.2: Xenon’s principal target 
 
In addition to the more general observation, which found xenon to be capable of 
activating KATP channels, the present study also provides more insight into 
possibly involved mechanisms.  
Most neuronal pKATP channels are complexes composed of Kir6.2 and SUR1 
subunits. Since xenon could theoretically interact with each of those subunits to 
induce channel opening, this study sought to determine the principally involved 
target. This was especially important since to this point endogenous modulation of 
SUR1 has been predominantly linked with channel opening whereas actions on 
Kir6.2 are classically inhibitory (Tucker and Ashcroft, 1998). However, the data 
presented here indicate that xenon interacts with Kir6.2 rather than SUR1 to 
facilitate channel opening. This notion is based on the results obtained from 
experiments using truncated pKATP channels (Kir6.2ΔC26). Tetrameric assembly 
of Kir6.2ΔC26 forms a functional channel in the absence of sulphonylurea 
receptors that has similar characteristics to the wild type channel. Kir6.2ΔC26 has 
therefore become an invaluable tool to study the channel pore independently of 
SUR1 (Tucker et al., 1997). Since xenon activated Kir6.2ΔC26 channels to a 
similar extent as Kir6.2/SUR1 channels it is feasible to assume that Kir6.2 
comprises xenon’s principal target. This is in contrast to all other pKATP channel 
openers (Lawson, 2000). Although chemically diverse they all interact mainly 
with the second transmembrane domain (TMD2) of the sulphonylurea receptor 
(Jahangir and Terzic, 2005). Therefore the data of the present study suggest xenon 
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to be not simply another KATP channel opener but possibly to represent an entirely 
different class of KATP channel modulators.  
This idea is further supported by experiments using Mg2+ free solution. Mg2+ is 
the compulsory co-factor that enables nucleotides but especially di-phosphate-
nucleotides like ADP or GDP to exert their stimulatory (opening) action on wild 
type pKATP channels (Nichols, 2006). Furthermore the nucleotide binding domains 
(NBD) on sulphonylurea receptors (SUR) have been identified as the molecular 
target of Mg2+-nucleotides (Ueda et al., 1997; Sakura et al., 1999; Moreau et al., 
2005). Therefore the ability of xenon in the present study to open Kir6.2/SUR1 
even under Mg2+ free experimental conditions excludes a possible indirect effect 
via interaction with Mg2+-nucleotides on SUR1 (Craig et al., 2008). This again is 
in contrast to classical K-channel openers, since the action of these drugs is 
abolished in the absence of Mg2+ or when the nucleotide binding domains of SUR 
are functionally disabled by point mutation (Gribble et al., 1997b). 
Additional evidence that supports a SUR1 independent action of xenon is 
provided by the results of experiments using the K185Q mutation of Kir6.2, which 
reduces the ATP sensitivity of the pore forming subunit (Tucker et al., 1997). The 
present study not only verified that Kir6.2-K185Q is ATP insensitive but also 
demonstrated that Kir6.2-K185Q is unresponsive to xenon. Since these 
experiments were performed in the presence of SUR1 it is unlikely that SUR is of 
importance for xenon induced channel opening. 
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8.1.3.2 Xenon induced channel opening: Independence from cellular signalling 
cascades 
 
After establishing Kir6.2 as the principal target for xenon it remained 
undetermined whether the xenon effect was dependent on intracellular signalling 
cascades or not. 
Since the hallmark feature of ATP-sensitive potassium channels is their inhibition 
by intracellular ATP (Ashcroft and Trapp, 2001), it is reasonable to hypothesise 
that xenon might activate the channel via xenon-induced changes in cellular ATP 
concentrations. Here mKATP channels have been suggested to play a major role 
since their activation has been found to reduce ATP synthesis (Holmuhamedov et 
al., 1998). However, this study provides no evidence for a contribution or an 
involvement of mKATP channels in xenon induced pKATP channel opening. 
Furthermore, instead of decreasing mitochondrial ATP production via mKATP 
channel activation, xenon might have a direct blocking effect on the electron 
transport chain hence serving as metabolic inhibitor. Xenon might therefore act 
similarly to what has been found for volatile anaesthetics, which are capable of 
reducing respiratory chain function (Hanley et al., 2002b; Bains et al., 2006).  
This hypothesis is not supported by the present study since xenon not only 
enhances KATP currents in intact cells, but also in inside-out macropatches where 
ATP concentrations are dictated by the bath solution. These findings rule out the 
possibility that xenon exerts its effect indirectly, via altering cellular metabolism 
and thus intracellular ATP content.  
In addition to its possible interaction with mitochondria xenon could potentially 
also interfere with cellular signalling cascades that are known to regulate pKATP 
channels. Protein kinase C (PKC) for instance increases the open probability of 
cardiac and pancreatic pKATP channels via phosphorylation of a threonine residue 
on Kir6.2 (Light et al., 2000). As xenon has been shown to induce PKC in rat 
hearts, one could hypothesise a PKC-dependent mechanism of xenon induced 
neuronal pKATP channel opening as well (Weber et al., 2005). However, the 
results of the excised macropatch experiments where intracellular signalling 
cascades are eliminated refute this assumption. The data are rather highly 
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suggestive of a direct effect of xenon on the channel, although membrane-
delimited signalling cascades cannot be excluded.  
Probably the most important membrane-restricted signalling pathway for 
modification of KATP channel activity involves phospholipids such as 
phosphatidylinositol-4, 5-bisphosphate (PIP2) and phosphatidylinositol-4-
phosphate (PIP). Phospholipids are modulated by phosphatidylinositol-4-
phosphate 5 (PIP5)-kinase (Shyng et al., 2000), some neurotransmitters 
(Baukrowitz et al., 1998; Xie et al., 1999b) and phospholipase C (PLC), with most 
information so far available for PLC mediated KATP channel regulation. Since 
PLC has been demonstrated to reduce pKATP currents, a PLC blocking mechanism 
of xenon could be hypothesised (Xie et al., 1999a). The substrate of PLC, 
phosphoinositol bisphosphate (PIP2), is known to activate pKATP channels via 
reducing the sensitivity of the channel to ATP. However, other studies have found 
that PIP2 activation of the channel is not precluded by tolbutamide, but on the 
contrary, PIP2 decreases the efficacy of tolbutamide and other sulphonylureas 
(Koster et al., 1999; Krauter et al., 2001). This is in contrast to the findings 
described here where tolbutamide not only reversed xenon induced channel 
activation (Figure 7.10) but also prevented it (Figure 7.11). Furthermore 
phospholipid activation is a common feature for inward rectifying K+ channels 
(Huang et al., 1998; Zhang et al., 1999). Since xenon opened Kir6.2 but not Kir1.1 
this further supports the idea that xenon induced pKATP channel activation does 
not involve PLC or phospholipids. However, a definite answer would require the 
crystallisation of the channel in the presence of xenon (and ATP). 
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8.1.3.3 Xenon modulated channel gating: An ATP-dependent process? 
 
A simple explanation for xenon’s effect on KATP channels would be that it 
reverses ATP-inhibition at Kir6.2. Support for this hypothesis was gained in the 
present study from concentration-effect experiments. Here it was found that xenon 
shifted the Ki of ATP to a fourfold higher concentration. These results are 
indicative of a competition of xenon with ATP at the channel pore (Tallarida, 
2000). More precisely, the fact that the xenon effect could be overcome 
(surmounted) fulfils the classical criteria of competitive antagonism (Taylor and 
Insel, 1990). This notion appears even stronger since Mg2+ free experimental 
conditions were employed to exclude a possible interference of Mg-nucleotides 
with the xenon effect as discussed in section 8.1.3.1 (Craig et al., 2008).  
Furthermore, it was found that xenon activation of KATP currents in inside-out 
patches was more pronounced in the presence of ATP than in its nominal absence. 
These observations - the xenon induced shift of Ki for ATP inhibition and the 
increased efficacy of xenon in the presence of ATP - would be consistent with 
xenon interfering with ATP inhibition of the KATP channel. Alternatively, xenon 
might require a pre-blocked channel in order to cause activation. However, the 
finding that inhibition of the channel by tolbutamide prevents xenon activation 
argues against the latter possibility. 
Xenon therefore seems to specifically involve an ATP-dependent process in its 
KATP channel opening mechanism. This idea is supported by the data from some 
additional experiments:  
In employing a site-directed mutation of Kir6.2 (Kir6.2-K185Q/SUR1) as 
described by Tucker and colleagues (Tucker et al., 1998) not only the sensitivity 
of the channel to ATP was greatly diminished but also the opening effect of xenon 
lost. This failure of xenon to enhance Kir6.2-K185Q/SUR1 currents was observed 
both in intact cells and in inside-out patches. The residue K185 of Kir6.2 interacts 
with the β-phosphate of ATP and thus contributes to the ATP-binding site (Trapp 
et al., 2003; Antcliff et al., 2005). This mutant has a greatly reduced ATP-
sensitivity, but compared to the wild type channel a virtually identical intrinsic 
open probability (Tucker et al., 1998). This is important because ligand binding to 
the KATP channel tends to be state-dependent (Trapp et al., 1998; Enkvetchakul et 
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al., 2000; Krauter et al., 2001). A number of additional residues have been shown 
to contribute to the ATP binding site on Kir6.2 by interacting with the adenine and 
ribose ring of ATP, but these were not tested with xenon because they have a 
more profound effect on the intrinsic open probability of the mutant channel 
(Antcliff et al., 2005). With the data available from experiments using the K185Q 
mutant it was not possible to distinguish whether xenon activation is lost in the 
mutant channel, because K185 forms part of the xenon interaction site, or whether 
the lack of ATP inhibition simply prevented any xenon enhancement. However, 
the latter possibility would be in agreement with the hypothesis that xenon 
disinhibits the channel from the action of ATP. In any case, it is clear, that xenon 
works very differently from other K-channel openers, as diazoxide activation 
remains unchanged by the K185Q mutation.  
Further support for an ATP-dependent effect of xenon was gained from 
experiments with a different inward rectifier K+ channel, Kir1.1. Phylogenetically 
Kir1.1 is a close relative of Kir6.2 (Isomoto et al., 1997) that shares about 36% 
sequence homology with the KATP channel (Proks et al., 2001). It even contains a 
lysine in position 185 and therefore an ATP binding-site. The most obvious 
difference between Kir6.2 and Kir1.1 channels however is that the former, but not 
the latter, is inhibited by micromolar concentrations of ATP (Tucker et al., 1997; 
Hebert et al., 2005). Therefore, under physiological conditions, ATP does not 
seem to regulate Kir1.1 (Schulte and Fakler, 2000). An effect of xenon on this 
channel would have been an indication for an ATP independent, in this regard 
unspecific, action of xenon. The results presented here show that xenon did not 
exert any significant change in current flow through Kir1.1. Hence all data 
discussed in this section are in agreement with the idea of xenon specifically 
interfering with the action of ATP on Kir6.2. However, the precise mechanism of 
this interference remains elusive. For example, xenon atoms could physically 
obstruct the ATP-binding pocket to prevent ATP gaining access to an empty 
binding site. Since ligand binding is a dynamic process with molecules constantly 
associating to or dissociating from their receptor, over time xenon might just 
displace ATP and thus disinhibit the channel. The kinetics of this process would 
be entirely determined by the concentration of each ligand. Furthermore, such a 
mechanism would be in agreement with the observed competitive antagonism 
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between xenon and ATP, which can be described by the law of mass action 
(Taylor, 1990).  
Based on the assumption of ‘intrinsic gating’, which describes the observation of 
ATP-sensitive K+ channels being spontaneously active in the absence of 
nucleotides (Proks and Ashcroft, 2009) another model could also explain xenon’s 
effect. This model would be similar to what has been described to explain the 
channel opening properties of the already discussed phosphoinositol bisphosphate 
(PIP2): PIP2 has been demonstrated to have its binding site close to that of ATP on 
Kir6.2 (Baukrowitz et al., 1998; Shyng and Nichols, 1998; Haider et al., 2007b). 
Functional studies have further shown that binding of PIP2 leads to displacement 
of ATP from Kir6.2 (Wang et al., 2002), which subsequently increases the 
intrinsic open probability of pKATP channels (Shyng and Nichols, 1998) and 
therefore blocks the inhibitory effect of ATP at Kir6.2 (Fan and Makielski, 1999). 
Applied to a potential xenon model of action this would imply that - instead of 
physically obstructing the ATP-binding site on Kir6.2 - xenon associates with the 
pore-forming unit most likely close to the ATP binding site. Although this 
association of xenon with Kir6.2 might not lead to a significant conformational 
change at the pore it might nevertheless change the energy status of the ATP 
binding site. This in turn might make ATP binding energetically less desirable and 
therefore reduce the re-association rate of ATP with Kir6.2. However, given the 
nature of xenon as noble gas, its effect can be expected not to be very strong so 
that it could be overcome by a concentration effect, i.e. by increasing the number 
ATP molecules. 
However, at present all the above suggested models are speculative and therefore 
future research necessary to establish the precise mechanism of xenon induced 
pKATP channel opening. Here uncovering the exact site of interaction of xenon 
with Kir6.2 could provide some valuable information to further characterise the 
xenon-ATP relationship. 
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8.2 Neuronal Preconditioning 
 
Evidence for the involvement of ATP-sensitive potassium channels in organ 
protection and especially in preconditioning so far is mostly derived from studies 
in myocardial tissues. Especially the exploit of Kir6.2-/- knockout mice has 
provided valuable information in this regard (Seino and Miki, 2003). For instance, 
Suzuki and colleagues as well as Gumina and colleagues found a lack of 
preconditioning in cardiac muscle of Kir6.2-/- animals (Suzuki et al., 2002; 
Gumina et al., 2003). Furthermore, the observation that KATP channel openers 
mimic whilst KATP channel inhibitors reverse preconditioning established the role 
of KATP channel opening as a major pathway in myocardial preconditioning 
(Cavero et al., 1995). In addition to the suggested involvement of plasmalemmal 
KATP channels in cardiac preconditioning, recent research indicated a critical role 
of mitochondrial KATP channels as well. As a matter of fact at present the 
predominant opinion favours mKATP rather than pKATP channels as central 
effectors in myocardial protection. However, this notion is not undisputed since 
some researcher regard the support for the presence of mKATP channels in heart 
muscle cells as unconvincing (Seino and Miki, 2003; Zaugg et al., 2004; Hanley 
and Daut, 2005).  
This ‘KATP channel controversy’ is even stronger amongst neuroscientists since 
evidence for the presence of mitochondrial KATP channels in the brain is fairly 
recent and therefore scarce. Bajgar and colleagues were the first to report partial 
purification and reconstitution of mKATP channels from rat mitochondria in 
proteoliposomes and to successfully measure K+ flux through these channels 
(Bajgar et al., 2001). They even claim that the concentration in the brain of those 
newly characterised mKATP channels exceeded the concentration of mKATP 
channels in heart and liver by six to seven times. Additional functional evidence 
for the involvement of neuronal mKATP channel in preconditioning seems to be 
provided by a study from Kis and colleagues. They report that pre-treatment with 
a newly developed allegedly selective mKATP channel opener was able to protect 
primary neuronal cultures against OGD induced injury (Kis et al., 2004). 
Nevertheless, evidence for the involvement of plasmalemmal KATP channels in 
protection and preconditioning of the brain is more substantial. For instance, over-
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expression of the channel pore Kir6.2 in mice provided increased protection 
against hypoxic-ischaemic injury compared to wild type mice (Heron-Milhavet et 
al., 2004). Conversely, mice lacking functional pKATP channels were more 
vulnerable to focal ischaemia in vivo (Sun et al., 2006). Also Kir6.2 knockout mice 
developed enhanced seizure activity in response to hypoxia compared to normal 
controls (Yamada et al., 2001).  
Despite the mounting data that KATP channels might also play a significant role in 
neuronal preconditioning the involvement of ATP-sensitive potassium channels in 
pharmacological, especially anaesthetic, preconditioning is still poorly 
characterised. The present study aimed to shed some light onto the kind of 
interaction of some inhalational anaesthetics with plasmalammal KATP channels 
and the physiological consequences of it. After the establishment of xenon as 
plasmalemmal KATP channel opener the functional relevance of this newly 
discovered property was determined in the context of neuronal preconditioning. 
The effect of xenon was compared to the actions of the established KATP channel 
opener diazoxide and the volatile anaesthetic sevoflurane. Sevoflurane was chosen 
because of all volatiles tested in this study it had displayed the least inhibitory 
effect on pKATP channels. 
The present study showed that all three different drugs were able to precondition 
neuronal cells against injury induced by oxygen-glucose deprivation in vitro. 
However, the results also suggest that individual inhalational anaesthetics 
facilitate different pathways to provoke protection in this model. This hypothesis 
is deduced from the observation that xenon preconditioning required opening of 
plasmalemmal KATP channels, whereas sevoflurane preconditioning was pKATP 
channel independent.  
Also, neither of the anaesthetics showed a substantial involvement of mKATP 
channels in its preconditioning action. This finding is unlikely to be attributable to 
a systemic error in the experimental set-up since preconditioning with diazoxide 
that is known to open both pKATP and mKATP channels also induced protection. 
Moreover the effect of diazoxide was also sensitive to the actions of both the 
pKATP channel inhibitor tolbutamide and the mKATP channel blocker 5-HD. 
However, whilst appreciating a potential effect of diazoxide on mKATP channels, 
it has to be emphasized that diazoxide – despite being regarded as the gold 
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standard mKATP channel opener in cardiac tissue – is not specific for mKATP 
channels in organs that have pKATP channels with SUR1 subunits (Garlid et al., 
1996; Quast et al., 2004).  
This notion is supported by Kis and colleagues in a recent study investigating the 
preconditioning effect of diazoxide against OGD induced neuronal injury in vitro. 
Although diazoxide was able to protect neurons from injury in their experiments 
and although 5-HD reversed this effect the authors were not convinced that 
mKATP channels were involved (Kis et al., 2003): Their reasoning is based on 
their observations that the two additionally tested non-selective KATP channel 
openers cromakalim and nicorandil did not produce any protection in their 
experiments at all. Furthermore they found that glibenclamide, which is a KATP 
channel inhibitor that acts on both pKATP and mKATP channels, was ineffective in 
reversing diazoxide’s effect. Since they also provide evidence that diazoxide 
might involve other pathways to induce preconditioning such as reactive oxygen 
species and protein kinases, and since there is evidence from other groups that 5-
HD might prefer other targets as well (Hanley et al., 2002a; Lim et al., 2002; Das 
et al., 2003; Dzeja et al., 2003; Hanley et al., 2003), they question the role of 
mKATP channels in their model of pharmacological preconditioning. Therefore 
as explained above, results implying mKATP channel involvement in neuronal 
preconditioning should be viewed with some caution.  
Nevertheless, the data of the present study demonstrating Kir6.2/SUR1 type pKATP 
channel dependent preconditioning of diazoxide are in agreement with the 
literature since for instance Dabrowski and colleagues demonstrated high affinity 
activation of Kir6.2/SUR1 by diazoxide (Dabrowski et al., 2003). 
Another interesting aspect of the present study becomes obvious when the 
preconditioning concentration-response relationships of xenon and diazoxide are 
compared to the efficacy with which both were able to activate pKATP channels in 
the heterologous HEK293 cell expression system: One MAC of xenon was as 
sufficient a concentration to precondition neuronal glial cell co-cultures as it was 
to open pKATP channels in HEK293 cells. Furthermore channel opening with one 
MAC of xenon was equally efficient to diazoxide when the latter was given at its 
preconditioning concentration of 0.01mM. Finally, since the preconditioning 
doses of the two compounds xenon (1 MAC) and diazoxide (0.01mM) increase K+ 
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currents by 50% it can also be postulated that this level of KATP channel activity is 
enough to produce preconditioning.  
Therefore the present study provides a clear link between the newly established 
property of xenon as a pKATP channel opener and xenon induced neuronal 
preconditioning. Moreover, both effects of xenon are achieved at anaesthetic or 
even sub-anaesthetic concentrations and thus can be accomplished with clinically 
safe doses.  
 
Although the present study provides some mechanistic and functional data as 
regards to the involvement of pKATP channels in pharmacological, especially 
anaesthetic neuronal preconditioning some important problems are still elusive: 
For example the exact location of KATP channels in the preconditioning 
pathway(s) and therefore the question whether they represent triggers or effectors 
of protection remain as uncertain as the involved signalling cascades.  
However, from the data presented here it seems feasible to hypothesise that KATP 
channels are triggers of preconditioning. This is deduced from the observations of 
the HEK293 cell experiments where xenon displays a short lasting effect, i.e. 
KATP channels close as soon as xenon is removed from the bath solution. In 
contrast, the preconditioning experiments of the present study show a lasting 
effect of xenon. These data taken together would suggest the presence of a 
signalling step between channel opening (trigger) and cellular protection 
(effector). 
With the involvement of pKATP channels it seems that xenon mimics ischaemic 
preconditioning whereas sevoflurane might act on a different target (Figure 8.1). 
Whether this target is downstream from the activation of KATP channels, or 
involves an entirely independent pathway for preconditioning is unclear at 
present.  
Nevertheless, sevoflurane’s ability to precondition neuronal glial cell co-cultures 
against OGD-induced damage is supported by studies, which report neuronal 
protection induced by pre-treatment with nearly all modern volatile anaesthetics 
(for reviews see Clarkson (Clarkson, 2007) and Wang (Wang et al., 2008b)). 
Halothane and isoflurane preconditioning for example was shown to reduce injury 
in a rat model of focal brain ischaemia in vivo (Kapinya et al., 2002). A similar 
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observation was made in neuronal cultures in vitro: Less damage was found when 
neurons were exposed to sevoflurane preemptively (Kapinya et al., 2002; Kaneko 
et al., 2005). Furthermore, the potency of desflurane, halothane, isoflurane and 
sevoflurane to induce preconditioning was found to be linear correlated to the 
anaesthesia inducing potencies of those volatiles in rat cerebellar slices (Wang et 
al., 2007a). 
Additionally, sevoflurane was shown to have preconditioning effects both in vitro 
and in vivo. Luo and colleagues for instance could demonstrate that sevoflurane 
pre-treatment protected neurons in a rat model of neonatal asphyxia. The same 
authors also reported sevoflurane preconditioning in primary neuronal as well as 
neuronal glial cell co-cultures (Luo et al., 2008). These results were in accordance 
with data provided by Payne as well as Wang and colleagues who showed 
reduced hippocampal injury by sevoflurane application against hypoxia-ischaemia 
both in vivo and in vitro (Payne et al., 2005; Wang et al., 2007b). However, the 
role of KATP channels in volatile -especially sevoflurane- induced neuronal 
preconditioning remained unclear until the present study. 
Although reports by Kehl and colleagues as well as Wang and colleagues 
suggested an mKATP channel dependent mechanism, these authors did not 
exclude an involvement of pKATP channels (Kehl et al., 2004; Wang et al., 2006). 
The results of Kehl and Wang suggesting KATP channel involvement in 
sevoflurane preconditioning are in contrast not only to the results of the present 
study but also to findings of other groups with different inhalational anaesthetics. 
Zheng and colleagues for example were not able to reverse the effect of isoflurane 
preconditioning in cerebellar brain slices with KATP channel inhibitors (Zheng and 
Zuo, 2003). Additionally, Marinovic and colleagues found that preconditioning of 
cardiomyocytes with isoflurane did not involve plasmalemmal KATP channels 
(Marinovic et al., 2006).  
 
Based on the results of the present study an involvement of KATP channels in 
volatile anaesthetic induced preconditioning seems highly unlikely, with the 
precise mechanisms conveyed by these agents still speculative. 
Several recent reviews have discussed potential mediators and pathways of 
volatile anaesthetics preconditioning (De Hert, 2004; Tanaka et al., 2004; 
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Clarkson, 2007; Wang et al., 2008b). These signalling cascades can be broadly 
divided into cell membrane based and intracellular mechanisms. Amongst the 
membrane-based receptors that have been shown to be involved in protection are 
adenosine A1 and A3, glutamate as well as GABA receptors. Especially the 
interaction of anaesthetics with glutamatergic pathways have been investigated 
thoroughly, since glutamate represents the main excitatory amino acid of the body 
and is also involved in excitotoxicity (see introduction 5.5.3). For example 
halothane and isoflurane have recently been found to inhibit N-methyl-d-aspartate 
(NMDA) receptors likely via an interaction with the receptor’s glycine binding 
site (Ogata et al., 2006; Dickinson et al., 2007). Also sevoflurane has been shown 
to reduce glutamate neurotransmission (Stucke et al., 2005). Intracellular 
mediators frequently associated with anaesthetics-induced protection are 
immediate early genes like c-fos, inducible nitric oxide synthase (iNOS) and its 
product nitric oxide (NO), reactive oxygen species (ROS) and protein kinases 
such as MAPK, PKC, ERK (Wang et al., 2008b). 
Whether these mediators also contributed to sevoflurane preconditioning has not 
been addressed in present study and remains therefore unclear. Also uncertain 
remain the cellular end-effectors of such preconditioning signalling cascades. 
However, in the following section a brief account on possible effectors is given 
when the KATP channel dependence of xenon preconditioning is put into context. 
 
Although xenon preconditioning had been shown before in neurons and hearts 
(Ma et al., 2006; Luo et al., 2008; Weber et al., 2008) the obvious absolute 
dependence on plasmalemmal KATP channel opening in this study - as 
demonstrated by the complete reversal of the xenon effect by tolbutamide - was 
somehow surprising. Since xenon had previously been shown to be a N-methyl-d-
aspartate (NMDA) receptor antagonist (Franks et al., 1998; Dickinson et al., 
2007) and a two-pore K+ channel opener (Gruss et al., 2004) one could have 
expected an involvement of these mechanisms as well. Partial instead of full 
antagonism of xenon’s preconditioning effect with the pKATP channel blocker 
would have been therefore the most likely scenario. However, the present results 
are not unprecedented: In a clinical trial gavastinel, a NMDA receptor antagonist 
that like xenon inhibits the receptor via blocking of the glycine binding site 
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(Dickinson et al., 2007), had been shown ineffective in the treatment of acute 
ischaemic stroke in man (Sacco et al., 2001). 
Whilst this study established xenon as an opener of plasmalemmal KATP channels 
and showed that one functional consequence of this property is neuroprotection, 
some questions remain unsolved: If pKATP channels are the trigger for xenon 
induced neuroprotection which are the downstream effectors responsible for the 
lasting effect? In the following part potential mechanisms are discussed and a 
concept introduced that could explain the seemingly divergent results of volatile 
anaesthetics and xenon-induced preconditioning. 
In general KATP channels - derived from their intrinsic characteristics - can 
facilitate three different principles to trigger protection: The first principle is 
deduced from the attribute of K+ channels to modulate neuronal membrane 
potentials and consequently cellular activity. The second principle is based on the 
hallmark feature of KATP channels, their regulation by ATP. As the third and final 
principle it can be hypothesised that the ion flow that is associated with K+ 
channel opening might be of significance for regulation of cellular osmolarity and 
hence volume. 
Once activated, KATP channels as members of the inward rectifier family of K+ 
channels contribute to the stabilisation of the cell’s resting membrane potential. 
They therefore are a counter-regulatory method that is set up to resist neuronal 
depolarisation and subsequently energy consuming excitation (Nichols et al., 
1996; Ashcroft and Trapp, 2001). Since they are directly regulated by nucleotides, 
their opening mechanism is a function of the cell’s metabolic state (Ashcroft and 
Trapp, 2001; Zhuo et al., 2005). At present it is hypothesised that although widely 
distributed in the CNS, pKATP channels come only into action once the cell has 
come under metabolic stress such as hypoxic-ischaemia or hypoglycaemia to help 
reduce neuronal activity and hence preserve energy (Wang et al., 2005; Zhuo et 
al., 2005). However, this principle can be assumed to be part of a quick adaptive 
mechanism probably designed to allow cells to respond rapidly to changes in their 
environment and substrate supply. Whether this principle participates also in 
ongoing protection remains to be determined as well as whether its implication, 
namely a potentially continuous down regulation of neuronal function, would be 
beneficial for the organism. 
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Therefore it is more likely that other mechanisms contribute to ongoing 
neuroprotection triggered by pKATP channel opening. As has been demonstrated in 
this study xenon opens pKATP channels most likely via interference with the 
capability of ATP to bind to the channels pore forming Kir6.2 subunit. This in turn 
might lead to a temporary increase of the ATP concentration in the submembrane 
compartment.  
Although a study by Gribble and colleagues found no gradient between the bulk 
cytosolic and submembrane ATP concentrations (Gribble et al., 2000) more recent 
publications support the hypothesis of energy compartmentalisation at least in 
cardiomyocytes (Selivanov et al., 2004; Zingman et al., 2007). Therefore the 
localised increase in ATP concentration might then either act as an intracellular 
second messenger or it might be released via connexin 43 hemichannels, which 
are present in neuronal cell membranes (Kang et al., 2008; Lin et al., 2008). Once 
in the extracellular space ATP could be metabolised to adenosine that 
subsequently mediates neuroprotection via binding to adenosine-A1 receptors 
(Heurteaux et al., 1995; Ballanyi, 2004). This ‘extracellular ATP’ hypothesis 
nicely explains the propagation of a protective impulse to neighbouring cells and 
seems to shift the focus away from KATP channels towards adenosine-A1 receptors 
and possibly other not yet undetermined cascades. However, given the fact that 
adenosine receptors not only stimulate G-protein coupled K+ channels but also 
activate pKATP channels (Heurteaux et al., 1995), the central question of how 
pKATP channels mediate preconditioning remains unsolved. 
 
The just discussed two potential protective mechanisms appear not very likely to 
be the underlying major principle of pKATP channel triggered preconditioning. 
Hence the question remains whether there is a pathway that is capable of 
facilitating a mechanism that relies more on the specific properties of K+ channels.  
Loss of cell volume, or cell shrinkage, is a hallmark feature of programmed cell 
death (apoptosis). However, there is now an increasing body of evidence to 
suggest that cell volume reduction is not only an early morphological 
characteristic of apoptosis but also a triggering event for cell death pathways 
(Burg et al., 2006; Bortner and Cidlowski, 2007). Indeed it has not only been 
shown that experimental apoptotic stimuli induce early cell shrinkage but also that 
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cell shrinkage alone was able to induce apoptosis (Bortner and Cidlowski, 2007). 
Consequently this initial loss of cell volume at the beginning of an apoptotic 
process has been termed apoptotic volume decrease (AVD). AVD is an interesting 
concept when neuroprotection is discussed in the context of pKATP channel 
opening because it has been shown that the underlying process of AVD is the 
efflux of monovalent ions, especially K+, out of the cell with subsequent reduction 
of the intracellular K+ concentration. Therefore it has been postulated that 
physiological intracellular potassium concentrations are important not only for the 
cell’s ionic and electrical homeostasis but also to suppress apoptotic mechanisms 
(Montague et al., 1999). There is indeed evidence that shows that cellular loss of 
potassium and hyperpolarisation due to K+ channel opening induces a loss of cell 
volume and subsequently apoptosis (Burg et al., 2006; Bortner and Cidlowski, 
2007). 
Various K+ channels have been linked to this process but there are also reports of 
a critical involvement of pKATP channels: Yu and colleagues for instance found 
that mouse neocortical neurons when exposed to an apoptotic stimulus like 
staurosporine showed early hyperpolarisation that was at least partially based on 
an ATP-sensitive K+ current. A potential KATP channel involvement was further 
supported by their finding that sustained application of the KATP channel opener 
cromakalim also induced apoptosis (Yu et al., 1997). 
 
Potassium efflux mediated AVD as a trigger for apoptosis seems not to be an 
exclusive phenomenon of toxin induced cell death. Instead there is indirect 
evidence to suggest that similar mechanisms are also involved in hypoxic-
ischaemia induced events. For instance Fujimura and colleagues demonstrated 
increased transmembrane potassium flow and hyperpolarisation in rat 
hippocampal neurons after exposure to hypoxia (Fujimura et al., 1997). They and 
others also provide support for a critical role of KATP channels in this process 
(Trapp and Ballanyi, 1995; Fujimura et al., 1997; Ballanyi, 2004).  
How then is xenon-induced preconditioning linked to KATP channel-triggered cell 
volume loss (AVD) and apoptosis?  
If for biological systems the general rule is accepted that every mechanism is 
balanced to some extend by a counter-mechanism then one could assume the same 
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to be true for cellular death pathways. That means every stimulus that triggers 
apoptosis will ultimately also lead to the activation of protective anti-apoptotic 
pathways (Bortner and Cidlowski, 2007). As has been discussed above (see 
introduction 5.7) this forms the foundation for the concept of preconditioning. 
Preconditioning therefore is the exposure of cells to a minimal damaging stimulus 
that results in the induction of mechanisms that produce resistance against a 
second stronger insult (Murry et al., 1986). Based on this it could be hypothesised 
that the xenon induced K+ efflux leads to a minor reduction of intracellular K+ 
with subsequent cell shrinkage and induction of pro-apoptotic as well as in 
response to that anti-apoptotic pathways. Since the xenon effect on the KATP 
current is only mild, the same can be assumed for the induction of pro-apoptotic 
mechanisms. Therefore the protective pathways might be able to outweigh the 
damaging cascades thus shifting the ratio of damage to protection towards the 
latter. 
How would this assumption fit with the KATP channel independent 
preconditioning of volatile anaesthetics? A first idea comes from the already 
discussed article from Wang and colleagues who found that pre-emptive 
application of sevoflurane protected neurones in hippocampal slices against 
hypoxic injury. They further identified hypoxic hyperpolarisations as part of the 
protective mechanism (Wang et al., 2007b). Since an involvement of pKATP 
channels in sevoflurane preconditioning was unlikely, the observed 
hyperpolarisation could have been the result of an activation of other K+ channels 
by sevoflurane. This notion is supported by studies reporting opening of mainly 
two-pore K+ (K2P) channels through the volatile anaesthetics halothane, isoflurane 
and sevoflurane (Sirois et al., 2000; Gruss et al., 2004; Huneke et al., 2004; 
Putzke et al., 2007). This is the more important since Bortner and colleagues 
suggested potassium leak channels such as K2P channels to play a central role in 
neuronal AVD and hence apoptotic pathways (Bortner and Cidlowski, 2007). 
Therefore similar to what was said about the possible mechanism of xenon 
preconditioning volatile anaesthetics might also protect via potassium efflux 
induced cellular shrinkage. But other than xenon volatiles most likely trigger this 
through potassium channels other than KATP (see Figure 8.1). However, whether 
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and to what extent these mechanism participate in anaesthetic preconditioning 
needs to be determined by future research.  
 
 
 
Figure 8.1: Suggested mechanisms of inhalational anaesthetics induced 
preconditioning 
A) Xenon exerts neuronal preconditioning via a mechanism that critically 
involves plasmalemmal KATP channels (Kir6.2/SUR1). 
B) Sevoflurane also preconditions neurons. This preconditioning effect does not 
involve KATP channels but might be mediated via other types K+ channels.  
‘In’ denotes the inside of the cell, ‘out’ the outside. 
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8.3 Physiological Significance of KATP Channel Inhibition 
 
This study provides evidence that halogenated anaesthetics inhibit plasmalemmal 
KATP channels. This should have very little effect under physiological 
circumstances in most tissues since KATP channels are closed under conditions 
where ATP is abundant. They would only open during conditions of metabolic 
stress, for instance in the course of thrombembolic stroke where hypoxia is 
present (see chapter 5.5). However, even under normal circumstances pancreatic 
β-cells use this channel characteristic to regulate the body’s glucose homeostasis. 
At decreased blood glucose and hence low pancreatic ATP concentrations KATP 
channel open to hyperpolarize the membrane potential of the β-cell. Elevated 
glucose and ATP concentrations on the contrary lead to channel closure, which 
is followed by β-cell depolarisation and subsequent activation of voltage 
dependent Ca2+ channels. The increased intracellular Ca2+ concentration is then 
causing insulin release (Trapp and Ashcroft, 1997; Ashcroft and Gribble, 1999; 
Ashcroft, 2005). Consequently, KATP channel inhibition as a side-effect of drug 
therapy could potentially lead to unwanted hyperinsulinemia and hypoglycaemia 
that might even become critical if unnoticed - for example during the course of a 
general anaesthetic. Although scarce, there is indeed some evidence in the 
literature hinting towards a blood glucose lowering effect of volatile 
anaesthetics. For instance a recent case report described the occurrence of 
unexpected hypoglycaemia in a previously fit and well male patient during 
maxillary-facial surgery (Ackland et al., 2007). Moreover in a prospective trial 
including 154 patients Huang and colleagues intended to investigate the 
influence of glucose-free intravenous solutions on blood sugar levels during 
neurosurgery. They found in both adult and paediatric patients no evidence of 
hyperglycaemia but in about 25% of adult patients hypoglycaemia after 
prolonged eight to nine hours of surgery. In contrast, no hypoglycaemia was 
detected in children indicating a potential age difference (Huang et al., 2000). 
However, Loepke and colleagues found decreased blood sugar levels in neonatal 
mice anaesthetized with isoflurane (Loepke et al., 2006). 
Additionally, KATP channel openers are or could be used in the near future in a 
variety of diseases such as heart disease, peripheral vascular disease, asthma, 
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bladder dysfunction or epilepsy (Jahangir and Terzic, 2005). Co-administration of 
drugs, which might antagonise KATP channel opening could potentially have 
disastrous consequences especially for patients where K+ channel openers are 
given as anti-arrhythmics or anti-anginal medications (Reimann et al., 2001; 
Gribble and Reimann, 2003b). Despite the fact that the halogenated volatile 
anaesthetics tested here had inhibitory effects on KATP currents even at low 
concentrations, at present there are not sufficient data to allow a critical evaluation 
of potential interactions between those anaesthetics and KATP channel openers. 
Furthermore, since it so far remains unclear whether these drugs interact with the 
potassium channel (Kir) subunit or the sulphonylurea receptor (SUR) as well as 
whether specific channel compositions are preferred (e.g. neuronal versus 
cardiac), more research is warranted on this potentially important topic. Since this 
study was concerned with the identification of pathways potentially involved in 
xenon preconditioning and since KATP channel opening rather than closure is the 
basic principle of pKATP channel mediated protection it seemed unlikely that 
preconditioning via volatile anaesthetics is mediated via pKATP channels. 
Therefore pathways involving these compounds were not further investigated in 
this study. 
 
 
8.4 Physiological Consequence of KATP Channel Activation 
 
One concern of the clinician intending to use KATP channel opening drugs for the 
prevention of stroke might be a potential interference with drugs used in the 
treatment of non-insulin dependent (type 2) diabetes mellitus. It could therefore be 
suggested that KATP channel opener antagonize the insulin releasing effect of 
sulphonylurea receptor antagonists like tolbutamide. This might be especially 
relevant in the perioperative period since diabetic patients per se carry an 
increased risk for the development of stroke after surgery (see also introduction 
chapters 5.3 and 5.4) (Bolognesi et al., 2008). They therefore represent a 
population likely benefiting from neuroprotective preconditioning strategies. 
Elevated blood glucose levels might offset this favourable effect of K+ channel 
openers since perioperative hyperglycaemia has been shown to be significantly 
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associated with adverse outcomes after coronary bypass grafting (McAlister et al., 
2003) as well as during intensive care treatment (van den Berghe et al., 2001). 
However, the findings of the present study do not support this notion because 
tolbutamide prevented the xenon induced opening of pKATP channels (Figure 
7.11). These results argue on the contrary that treatment of type 2 diabetes 
mellitus might diminish the KATP channel dependent organ protective effects 
afforded by xenon. This concept is reminiscent of the interference of 
sulphonylurea drugs with the anti-anginal KATP channel opener nicorandil. A 
study by Reimann and colleagues demonstrated that the effect of nicorandil on 
cardiac and smooth muscle type pKATP channels was reversed by the action of the 
commonly used antidiabetic glibenclamide (Reimann et al., 2001).  
 
Whilst the potential antagonism of KATP channel opening drugs by sulphonylureas 
is a valid worry for peripheral tissues, so far there is no evidence to support 
concerns about a similar interference in the central nervous system. To the 
contrary at present there is only data showing that tolbutamide does not easily 
partition into the brain (Takanaga et al., 1998; Murakami et al., 2000). Therefore 
xenon seems to be a viable choice as a neuroprotectant even for diabetic patients 
treated with tolbutamide.  
Similarly to KATP channel inhibitors most KATP channel openers seem not to cross 
the blood-brain barrier under physiological conditions (Jahangir and Terzic, 
2005). Nevertheless, studies have reported neuroprotective effects of these drugs 
in vivo. For instance, systemic application of diazoxide reduced infarct volume 
elicited by temporary occlusion of the middle cerebral artery in rats (Mayanagi et 
al., 2007). Similar results were obtained from a global ischaemia model in dogs: 
Intravenous administration of diazoxide improved neurological function and 
diminished histopathologically assessed brain injury (Shake et al., 2001). 
However, although the authors of these studies attributed the beneficial effects of 
diazoxide to a direct action on neurons, it is also possible that the observed 
outcome is secondary to an increased cerebral blood flow due to the vasodilatory 
effect of these drugs. This hypothesis is supported by a study reporting KATP 
channel opening in vascular smooth muscle cells in response to KATP channel 
activators such as diazoxide and pinacidil (Meisheri et al., 1990). Moreover, 
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experiments in human volunteers showed endothelial dysfunction - defined as 
reduced vasodilation in response to acetycholine - after 20 minutes of ischaemia-
reperfusion. Ischaemic preconditioning as well as diazoxide were able to prevent 
this dysfunction whilst co-application of the KATP channel inhibitor glibenclamide 
restored it (Broadhead et al., 2004). 
Likewise, xenon has been shown to stimulate cerebral blood flow and to dilate 
pial vessels (Gur et al., 1985; Junck et al., 1985; Hartmann et al., 1991; Fukuda et 
al., 2001). Additionally, the results of the present study indicate that xenon is able 
to precondition neuronal tissue directly via interaction with plasmalemmal KATP 
channels. However, if taken together with the studies mentioned above, which 
established xenon as a cerebral vasodilator, the present findings might be 
extrapolated to the hypothesis that xenon has no, or a reduced, tissue specificity. 
Therefore xenon might not only open neuronal but also other subtypes of 
plasmalemmal KATP channels such as the vascular smooth muscle type 
Kir6.1/SUR2B channel. Since SUR confers relative tissue specificity to the 
channel and since xenon induced KATP channel opening without involving SUR1, 
this hypothesis is supported by the finding of the present study. 
 
 
8.5 Possible Clinical Implications for the Use of Xenon as Preconditioner 
 
Two recent studies have re-emphasised the risk of stroke and hence its clinical 
importance in the perioperative period – both for cardiac and non-cardiac surgical 
patients (Bateman et al., 2009; Li et al., 2009). Because of this clinical importance 
and because of the also remaining limited therapeutic options (see 5.6) clinicians 
now increasingly seek to either minimize the incidence of perioperative stroke by 
controlling contributing factors or to alleviate its effects on each individual patient 
(Caplan, 2009). 
Based on current experimental evidence part of such a risk management strategy 
could be the pre-emptive administration of neuroprotecive drugs comparable to 
what has been shown to be effective in hearts (Landoni et al., 2009). However, the 
situation in the brain is slightly more complicated than that in cardiomyocytes: In 
hearts protection develops early (‘early phase’) after exposure to the 
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preconditioning stimulus. This is probably not the case in neuronal tissue. Here a 
preconditioner needs 24 hours to develop its effect (‘late phase’) (Kato et al., 
1991; Barone et al., 1998), hence intraoperatively administered drugs are unlikely 
to protect brains on the day of surgery. Translated into the clinical situation with 
the use anaesthetics as preconditioners, this would require for patients to receive 
an anaesthetic twice during the course of a little bit more than a day – once as part 
of a preconditioning strategy and 24 hours later during surgery. 
Possible concerns about such a clinical preconditioning paradigm might include 
logistic issues, the appropriate ‘delivery’ environment and unwanted drug effects 
on potentially seriously ill patients. Whilst rigorous planning and meticulous 
patient recruitment might solve the first aspect, the second appears less important 
given the fact that the delivery of an anaesthetic in a safe environment with 
trained doctors and nurses constitutes a standard treatment in every modern 
hospital. Preconditioning could therefore be expected to easily enrich the 
therapeutic spectrum of many trusts. However, the final concern about unwanted 
drug actions especially on the cardio-vascular system needs some additional 
considerations. In this context the potential for an acute cardiac decompensation 
during preconditioning should be as much limited as possible. This might be 
achieved through the choice of drug used for preconditioning. Although largely 
equipotent in their neuropotective effects, the currently available anaesthetic 
preconditioners display a considerable variability in their cardio-suppressive 
properties. At present the compound that comes closest to the ideal of being 
haemodynamically inert is xenon (Derwall et al., 2009). Therefore xenon might 
become the ‘first-choice’ neuronal preconditioning agent in critically ill patients 
or in patients with the highest risk of cardiac decompensation. This notion is 
based not only on its favourable side-effect profile but also supported by an 
increasing body of evidence in support for its preconditioning efficacy, including 
this study (Ma et al., 2006; Luo et al., 2008; Bantel et al., 2009).  
However, to make xenon preconditioning applicable for use in clinical practice its 
best concentration as well as optimal exposure time and application-to-surgery 
interval in humans or higher mammals needs to be determined first. But based on 
the current evidence xenon might be worth the effort. 
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9. CONCLUSIONS 
 
In summary, this study has established xenon as a novel plasmalemmal KATP 
channel opener and it has also demonstrated for the first time that xenon induced 
neuronal preconditioning is critically dependent on pKATP channel opening. 
This study further provides insights into the mechanism of xenon-induced K+-
channel opening in demonstrating an interaction of xenon with the Kir6.2 pore 
forming rather than the channel’s regulatory SUR1 subunit. The channel opening 
effect of xenon was also shown to be critically dependent on the presence of ATP. 
Additional data even suggest a specific interference of xenon with ATP at the 
Kir6.2 ATP binding site, which might follow the pattern of competitive 
antagonism. Therefore the results presented here support the idea that xenon 
opens neuronal plasmalemmal KATP channels by diminishing the block ATP 
normally confers to the channel. 
This study also investigated the effects of the volatile anaesthetics halothane, 
isoflurane and sevoflurane on neuronal pKATP channels and found all of them to 
inhibit Kir6.2/SUR1. The inability of volatile anaesthetics to open pKATP channels 
was confirmed in preconditioning experiments. Here sevoflurane, in contrast to 
xenon, preconditioned in a KATP channel-independent manner. Thus the data 
provided by the present study suggest two distinct pathways for inhalational 
anaesthetic induced preconditioning, one pKATP channel-dependent, and the other 
pKATP channel-independent. 
Further studies are needed to gain more insight into the mechanism of xenon-
induced KATP channel opening and also to reveal the differences in the protection 
afforded by the two preconditioning pathways. However, given xenon’s 
favourable safety profile the results presented here might open new doors for the 
development of neuroprotective strategies especially in the peri-operative period. 
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